Clustering	O
of	O
missense	O
mutations	O
in	O
the	B-DRUG
ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
gene	O
in	O
a	O
sporadic	B-D_ASE
T	I-D_ASE
-	I-D_ASE
cell	I-D_ASE
leukaemia	I-D_ASE
.	O

Ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
(	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
)	O
is	O
a	O
recessive	B-D_ASE
multi	I-D_ASE
-	I-D_ASE
system	I-D_ASE
disorder	I-D_ASE
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	O
11q22	O
-	O
q23	O
(	O
ref	O
.	O
3	O
)	O
.	B-DRUG

The	O
risk	O
of	O
cancer	B-D_ASE
,	O
especially	O
lymphoid	B-D_ASE
neoplasias	I-D_ASE
,	O
is	O
substantially	O
elevated	O
in	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
patients	O
and	O
has	O
long	O
been	O
associated	O
with	O
chromosomal	O
instability	B-DRUG
.	O

By	O
analysing	O
tumour	B-D_ASE
DNA	O
from	O
patients	O
with	O
sporadic	B-D_ASE
T	I-D_ASE
-	I-D_ASE
cell	I-D_ASE
prolymphocytic	I-D_ASE
leukaemia	I-D_ASE
(	O
T	B-D_ASE
-	I-D_ASE
PLL	I-D_ASE
)	O
,	O
a	O
rare	O
clonal	B-D_ASE
malignancy	I-D_ASE
with	O
similarities	O
to	O
a	O
mature	B-D_ASE
T	I-D_ASE
-	I-D_ASE
cell	I-D_ASE
leukaemia	I-D_ASE
seen	O
in	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
,	O
we	B-DRUG
demonstrate	O
a	O
high	O
frequency	O
of	O
ATM	B-DRUG
mutations	I-DRUG
in	B-DRUG
T	B-D_ASE
-	I-D_ASE
PLL	I-D_ASE
.	O

In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
in	O
this	O
leukaemia	B-D_ASE
were	O
missense	O
mutations	O
.	O

These	O
clustered	O
in	O
the	O
region	O
corresponding	O
to	O
the	O
kinase	O
domain	O
,	O
which	O
is	O
highly	O
conserved	O
in	O
ATM	O
-	O
related	O
proteins	O
in	O
mouse	O
,	O
yeast	O
and	O
Drosophila	O
.	O

The	O
resulting	O
amino	O
-	O
acid	O
substitutions	O
are	O
predicted	B-DRUG
to	I-DRUG
interfere	O
with	O
ATP	O
binding	B-DRUG
or	I-DRUG
substrate	I-DRUG
recognition	I-DRUG
.	O

Two	O
of	O
seventeen	O
mutated	O
T	B-D_ASE
-	I-D_ASE
PLL	I-D_ASE
samples	O
had	O
a	O
previously	O
reported	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
allele	O
.	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
,	O
suggesting	B-DRUG
that	O
this	O
tumour	B-D_ASE
suppressor	O
is	O
not	O
frequently	O
altered	O
in	O
this	O
leukaemia	B-D_ASE
.	O

Occasional	O
missense	O
mutations	O
in	O
ATM	O
were	O
also	O
found	B-DRUG
in	O
tumour	B-D_ASE
DNA	O
from	O
patients	O
with	O
B	B-D_ASE
-	I-D_ASE
cell	I-D_ASE
non	I-D_ASE
-	I-D_ASE
Hodgkins	I-D_ASE
lymphomas	I-D_ASE
(	O
B	B-D_ASE
-	I-D_ASE
NHL	I-D_ASE
)	O
and	O
a	O
B	B-D_ASE
-	I-D_ASE
NHL	I-D_ASE
cell	O
line	O
.	O

The	O
evidence	O
of	O
a	O
significant	O
proportion	O
of	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
and	B-DRUG
a	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
of	O
ATM	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	B-D_ASE
establishes	O
somatic	O
inactivation	O
of	O
this	O
gene	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B-D_ASE
T	I-D_ASE
-	I-D_ASE
PLL	I-D_ASE
and	O
suggests	O
that	O
ATM	O
acts	O
as	O
a	O
tumour	B-D_ASE
suppressor	O
.	O

As	O
constitutional	O
DNA	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
T	B-D_ASE
-	I-D_ASE
PLL	I-D_ASE
will	O
require	O
further	O
investigation	O
.	O
.	B-DRUG

Myotonic	B-D_ASE
dystrophy	I-D_ASE
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	B-DRUG
Ca2	O
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
.	O

Myotonic	B-D_ASE
dystrophy	I-D_ASE
(	O
DM	B-D_ASE
)	B-DRUG
,	O
the	O
most	B-DRUG
prevalent	O
muscular	B-D_ASE
disorder	I-D_ASE
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B-D_ASE
protein	O
kinase	O
;	O
DMPK	O
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O

To	O
obtain	O
clues	B-DRUG
to	O
the	O
normal	O
biological	O
role	O
of	O
DMPK	O
in	O
cellular	O
ion	B-DRUG
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	O
+	B-DRUG
transients	O
,	O
and	B-DRUG
the	O
content	O
of	B-DRUG
ATP	B-DRUG
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	B-DRUG
of	O
wild	O
-	O
type	O
and	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
knockout	O
mice	O
.	O

In	O
vitro	O
-	B-DRUG
differentiated	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
l	O
-	O
type	O
Ca2	O
+	O
and	O
Na	O
+	O
channels	O
.	O

The	O
mutant	B-DRUG
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	O
+	O
responses	O
upon	O
triggering	O
by	O
acetylcholine	O
or	O
high	O
external	O
K	O
+	O
.	O

In	O
addition	O
,	B-DRUG
we	O
observed	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
+	O
through	O
the	O
l	O
-	O
type	O
Ca2	O
+	O
channel	O
.	O

Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	O
+	O
/	O
K	B-DRUG
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
-	O
ATPase	O
are	O
affected	O
by	O
DMPK	O
absence	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
contraction	B-DRUG
coupling	O
in	O
skeletal	O
muscle	O
.	B-DRUG
.	O

Constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B-D_ASE
retinoblastoma	I-D_ASE
.	O

In	B-DRUG
most	O
patients	O
with	O
isolated	O
unilateral	B-D_ASE
retinoblastoma	I-D_ASE
,	O
tumor	B-D_ASE
development	O
is	O
initiated	O
by	O
somatic	O
inactivation	O
of	O
both	O
alleles	O
of	O
the	B-DRUG
RB1	O
gene	O
.	O

However	O
,	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	B-D_ASE
predisposition	O
to	B-DRUG
their	O
offspring	O
.	O

To	O
determine	O
the	O
frequency	O
and	O
nature	O
of	O
constitutional	O
RB1	O
-	O
gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B-D_ASE
retinoblastoma	I-D_ASE
,	B-DRUG
we	O
analyzed	O
DNA	O
from	O
peripheral	O
blood	O
and	O
from	B-DRUG
tumor	B-D_ASE
tissue	O
.	O

The	O
analysis	O
of	O
tumors	B-D_ASE
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
of	O
constitutional	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
intragenic	O
loci	O
.	O

Three	O
of	O
13	O
uninformative	O
patients	O
had	O
constitutional	O
deletions	O
.	O

For	O
39	O
randomly	O
selected	O
tumors	B-D_ASE
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequencing	O
,	O
and	O
Southern	O
blot	O
analysis	O
were	O
used	O
to	O
identify	O
mutations	O
.	O

Mutations	O
were	O
detected	O
in	O
21	O
(	O
91	O
%	O
)	O
of	O
23	B-DRUG
tumors	B-D_ASE
with	O
LOH	O
.	O

In	O
6	O
(	O
38	O
%	B-DRUG
)	O
of	O
16	O
tumors	B-D_ASE
without	O
LOH	O
,	O
one	O
mutation	O
was	O
detected	O
,	O
and	O
in	O
9	O
(	O
56	O
%	O
)	O
of	O
the	O
tumors	B-D_ASE
without	O
LOH	O
,	O
both	O
mutations	O
were	O
found	O
.	B-DRUG

Thus	O
,	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
in	O
tumors	B-D_ASE
of	O
36	O
patients	O
.	O

Thirty	O
-	O
nine	B-DRUG
of	O
the	O
mutations	O
-	O
including	O
34	O
small	O
mutations	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
and	O
hypermethylation	O
in	O
3	O
tumors	O
-	O
were	O
not	O
detected	O
in	O
the	O
corresponding	B-DRUG
peripheral	B-DRUG
blood	O
DNA	O
.	O

In	O
6	O
(	O
17	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutation	O
was	O
detected	B-DRUG
in	O
constitutional	O
DNA	O
,	O
and	O
1	O
of	O
these	O
mutations	O
is	B-DRUG
known	O
to	O
be	O
associated	O
with	O
reduced	O
expressivity	O
.	O

The	O
presence	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
associated	O
with	O
an	O
early	O
age	O
at	O
treatment	O
.	O

In	O
1	O
patient	O
,	O
somatic	O
mosaicism	B-DRUG
was	O
demonstrated	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
RNA	O
from	O
peripheral	O
blood	O
.	O

In	O
2	O
patients	O
without	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
patients	B-DRUG
showed	O
multifocal	O
tumors	B-D_ASE
and	O
the	B-DRUG
other	O
later	O
developed	O
bilateral	B-D_ASE
retinoblastoma	I-D_ASE
.	O

In	O
conclusion	O
,	O
our	B-DRUG
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B-D_ASE
depend	O
on	O
the	O
nature	O
of	O
the	O
first	O
mutation	O
,	O
its	O
time	O
in	O
development	O
,	O
and	O
the	O
number	O
and	O
types	O
of	O
cells	O
that	O
are	O
affected	O
.	O
.	O

Hereditary	B-D_ASE
deficiency	I-D_ASE
of	I-D_ASE
the	I-D_ASE
fifth	I-D_ASE
component	I-D_ASE
of	I-D_ASE
complement	I-D_ASE
in	B-DRUG
man	O
.	O

I	O
.	O

Clinical	B-DRUG
,	B-DRUG
immunochemical	O
,	O
and	O
family	O
studies	O
.	O

The	B-DRUG
first	O
recognized	O
human	O
kindred	O
with	O
hereditary	B-D_ASE
deficiency	I-D_ASE
of	I-D_ASE
the	I-D_ASE
fifth	I-D_ASE
component	I-D_ASE
of	I-D_ASE
complement	I-D_ASE
(	O
C5	B-DRUG
)	O
is	O
described	O
.	O

The	O
proband	O
,	O
a	O
20	O
-	O
year	O
-	O
old	O
black	O
female	O
with	O
systemic	B-D_ASE
lupus	I-D_ASE
erythematosus	I-D_ASE
since	O
age	O
11	O
,	O
lacked	O
serum	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remission	O
.	O

C5	O
was	O
undetectable	O
in	B-DRUG
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
hemolytic	O
assays	O
.	O

Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
of	O
lupus	O
,	O
but	B-DRUG
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
C3	O
levels	O
fell	O
during	O
exacerbations	O
.	O

A	O
younger	O
half	B-DRUG
-	O
sister	O
,	O
who	O
had	O
no	O
underlying	O
disease	O
,	B-DRUG
was	O
also	O
found	O
to	O
lack	O
immunochemically	O
detectable	O
C5	O
.	O

By	O
hemolytic	O
assay	O
,	B-DRUG
she	O
exhibited	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
concentrations	O
of	O
other	B-DRUG
complement	O
components	O
.	O

C5	O
levels	O
of	O
other	O
family	O
members	O
were	O
either	O
normal	O
or	O
approximately	O
half	O
-	O
normal	O
,	O
consistent	O
with	O
autosomal	O
codominant	O
inheritance	O
of	O
the	O
gene	O
determining	O
C5	B-D_ASE
deficiency	I-D_ASE
.	O

Normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5	B-D_ASE
-	I-D_ASE
deficient	I-D_ASE
(	O
C5D	B-D_ASE
)	O
sera	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
C5	O
.	O

In	O
specific	O
C5	O
titrations	O
,	O
however	O
,	B-DRUG
it	B-DRUG
was	O
noted	O
that	O
when	O
limited	O
amounts	O
of	O
C5	O
were	O
assayed	B-DRUG
in	O
the	O
presence	B-DRUG
of	O
low	B-DRUG
dilutions	O
of	O
either	O
C5D	B-D_ASE
serum	O
,	O
curving	O
rather	O
than	O
linear	O
dose	O
-	O
response	O
plots	B-DRUG
were	O
consistently	O
obtained	O
,	O
suggesting	O
some	O
inhibitory	O
effect	O
.	O

Further	O
studies	O
suggested	O
that	O
low	O
dilutions	O
of	O
C5D	B-D_ASE
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
at	O
some	O
step	O
in	O
the	O
hemolytic	O
assay	O
of	O
C5	O
,	O
rather	O
than	O
a	O
true	O
C5	O
inhibitor	O
or	O
inactivator	O
.	O

Of	O
clinical	O
interest	O
are	B-DRUG
(	O
a	O
)	O
the	O
documentation	B-DRUG
of	O
membranous	O
glomerulonephritis	B-D_ASE
,	O
vasculitis	B-D_ASE
,	O
and	O
arthritis	B-D_ASE
in	O
an	O
individual	O
lacking	O
C5	O
(	B-DRUG
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
remarkable	O
propensity	O
to	O
bacterial	B-D_ASE
infections	I-D_ASE
in	O
the	O
proband	O
,	O
even	B-DRUG
during	O
periods	O
of	O
low	O
-	O
dose	O
or	O
alternate	O
-	O
day	O
corticosteroid	O
therapy	O
.	O

Other	O
observations	O
indicate	O
that	O
the	O
C5D	B-D_ASE
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
to	O
mount	O
a	O
neutrophilic	O
leukocytosis	O
during	B-DRUG
pyogenic	B-D_ASE
infection	I-D_ASE
.	B-DRUG
.	O

Susceptibility	O
to	O
ankylosing	B-D_ASE
spondylitis	I-D_ASE
in	O
twins	O
:	O
the	O
role	O
of	O
genes	O
,	O
HLA	O
,	O
and	O
the	O
environment	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	B-DRUG
in	O
susceptibility	O
to	O
ankylosing	B-D_ASE
spondylitis	I-D_ASE
(	O
AS	B-D_ASE
)	O
.	O

METHODS	O
Twins	O
with	O
AS	B-D_ASE
were	O
identified	O
from	O
the	O
Royal	O
National	B-DRUG
Hospital	O
for	O
Rheumatic	B-D_ASE
Diseases	I-D_ASE
database	O
.	O

Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses	B-DRUG
,	O
and	O
disease	B-DRUG
severity	O
was	O
assessed	O
using	O
a	O
combination	O
of	O
validated	O
scoring	O
systems	O
.	O

HLA	O
typing	O
for	O
HLA	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
-	O
DR1	B-DRUG
was	O
performed	O
by	O
polymerase	B-DRUG
chain	O
reaction	O
with	O
sequence	O
-	O
specific	B-DRUG
primers	O
,	O
and	O
zygosity	O
was	O
assessed	O
using	O
microsatellite	O
markers	B-DRUG
.	O

Genetic	O
and	B-DRUG
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx	O
,	B-DRUG
using	O
data	O
from	O
this	O
and	O
previous	O
studies	O
of	O
twins	O
with	O
AS	B-D_ASE
.	O

RESULTS	O
Six	O
of	O
8	B-DRUG
monozygotic	O
(	O
MZ	O
)	O
twin	O
pairs	O
were	O
disease	O
concordant	O
,	O
compared	O
with	O
4	O
of	O
15	O
B27	O
-	O
positive	O
dizygotic	O
(	O
DZ	O
)	O
twin	O
pairs	O
(	O
27	O
%	O
)	O
and	O
4	O
of	O
32	O
DZ	O
twin	O
pairs	O
overall	O
(	O
12	O
.	O
5	O
%	O
)	O
.	O

Nonsignificant	O
increases	O
in	O
similarity	O
with	O
regard	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
severity	O
scores	B-DRUG
assessed	O
were	O
noted	O
in	O
disease	O
-	O
concordant	O
MZ	O
twins	O
compared	O
with	O
concordant	O
DZ	O
twins	O
.	O

HLA	B-DRUG
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
rate	O
of	B-DRUG
disease	O
concordance	O
was	O
significantly	O
increased	O
among	O
DZ	O
twin	O
pairs	O
in	O
which	O
the	O
co	O
-	O
twin	O
was	O
positive	O
for	O
both	O
B27	O
and	O
DR1	O
.	O

Additive	O
genetic	O
effects	B-DRUG
were	B-DRUG
estimated	O
to	O
contribute	O
97	O
%	O
of	O
the	O
population	O
variance	O
.	O

CONCLUSION	O
Susceptibility	O
to	O
AS	B-D_ASE
is	O
largely	O
genetically	O
determined	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	B-DRUG
is	O
probably	O
ubiquitous	O
.	O

HLA	O
-	O
B27	O
accounts	O
for	O
a	O
minority	O
of	O
the	O
overall	O
genetic	O
susceptibility	O
to	O
AS	B-D_ASE
.	O

Cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	B-DRUG
proteins	O
in	O
discrete	O
nuclear	O
domains	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
predispose	O
women	O
to	O
early	O
-	O
onset	O
breast	B-D_ASE
and	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
by	O
compromising	O
the	B-DRUG
genes	B-DRUG
presumptive	O
function	O
as	O
a	O
tumor	B-D_ASE
suppressor	O
.	O

Although	O
the	O
biochemical	O
properties	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood	O
,	O
their	O
expression	O
pattern	O
and	O
subcellular	B-DRUG
localization	O
suggest	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
regulation	O
.	O

When	O
resting	O
cells	O
are	O
induced	O
to	O
proliferate	O
,	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BRCA1	O
increase	O
in	O
late	O
G1	O
and	O
reach	O
a	O
maximum	O
during	O
S	O
phase	O
.	O

Moreover	O
,	B-DRUG
in	O
S	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
accumulate	O
into	O
discrete	O
subnuclear	O
foci	O
termed	O
"	O
BRCA1	O
nuclear	O
dots	O
.	O

"	O
BRCA1	O
associates	O
in	O
vivo	B-DRUG
with	O
a	O
structurally	O
related	O
protein	B-DRUG
termed	O
BARD1	O
.	O

Here	O
we	O
show	O
that	O
the	O
steady	B-DRUG
-	O
state	B-DRUG
levels	O
of	O
BARD1	O
,	O
unlike	O
those	O
of	O
BRCA1	O
,	O
remain	O
relatively	O
constant	O
during	O
cell	O
cycle	O
progression	O
.	O

However	O
,	O
immunostaining	O
revealed	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
dots	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
but	O
not	O
during	O
the	O
G1	O
phase	O
.	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
the	O
nuclear	O
fractions	O
of	O
both	B-DRUG
G1	O
-	O
and	O
S	O
-	O
phase	O
cells	O
.	O

Therefore	O
,	O
progression	O
to	O
S	O
phase	O
is	O
accompanied	O
by	O
the	O
aggregation	O
of	O
nuclear	O
BARD1	O
polypeptides	O
into	B-DRUG
BRCA1	O
nuclear	O
dots	O
.	O

This	O
cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	B-DRUG
indicates	O
a	O
role	O
for	O
BARD1	O
in	B-DRUG
BRCA1	O
-	O
mediated	O
tumor	B-D_ASE
suppression	O
.	O

Ethnic	O
differences	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
hereditary	B-D_ASE
hemochromatosis	I-D_ASE
(	O
HH	B-D_ASE
)	O
is	O
likely	O
to	O
be	O
caused	O
by	O
homozygosity	B-DRUG
for	O
a	O
Cys282Tyr	O
mutation	O
in	B-DRUG
the	I-DRUG
HFE	O
gene	O
located	B-DRUG
4	O
.	O

5	O
Mb	O
telomeric	O
to	O
HLA	O
-	O
A	O
.	O

Population	O
studies	O
of	O
this	O
polymorphism	O
are	O
facilitated	O
by	O
the	O
fact	B-DRUG
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
site	O
.	O

We	O
have	O
studied	O
the	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
in	O
different	O
ethnic	O
groups	O
.	O

In	O
agreement	O
with	O
previous	O
observations	O
the	O
Tyr	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
absent	O
in	O
Asiatic	O
(	O
Indian	O
,	O
Chinese	O
)	O
populations	O
.	O

The	B-DRUG
highest	O
allele	O
frequency	O
(	O
7	O
.	O
5	O
%	O
)	O
was	O
found	O
in	O
Swedes	O
.	O

Saamis	O
(	O
2	O
%	O
)	O
and	B-DRUG
Mordvinians	O
(	O
1	O
.	O
8	O
%	O
)	O
had	O
significantly	O
lower	O
frequencies	O
of	O
the	O
Tyr	O
allele	O
.	O

Comparisons	O
with	O
allele	O
frequencies	O
based	O
on	O
prevalence	O
estimates	O
of	O
HH	B-D_ASE
showed	O
some	O
disagreements	O
with	O
the	O
RFLP	O
data	O
,	O
particularly	O
in	O
Finns	O
.	O

The	B-DRUG
newly	O
described	O
HFE	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	O
HH	B-D_ASE
as	O
well	O
as	O
studies	O
of	O
the	O
relationship	O
between	B-DRUG
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
cancer	B-D_ASE

Autosomal	B-D_ASE
dominant	I-D_ASE
neurohypophyseal	I-D_ASE
diabetes	I-D_ASE
insipidus	I-D_ASE
associated	O
with	O
a	O
missense	B-DRUG
mutation	O
encoding	O
Gly23	O
-	O
-	O
>	O
Val	O
in	O
neurophysin	O
II	B-DRUG
.	O

Autosomal	B-D_ASE
dominant	I-D_ASE
neurohypophyseal	I-D_ASE
diabetes	I-D_ASE
insipidus	I-D_ASE
(	O
ADNDI	B-D_ASE
)	O
is	O
an	O
inherited	B-D_ASE
disease	I-D_ASE
caused	O
by	O
progressive	O
degeneration	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
leading	O
to	O
decreased	O
ability	O
to	O
produce	O
the	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
.	O

Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B-D_ASE
insipidus	I-D_ASE
at	O
1	O
-	O
6	O
yr	O
of	O
age	O
.	O

The	O
genetic	O
locus	O
of	O
the	O
disease	O
is	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
NPII	O
)	O
gene	O
,	O
and	O
mutations	O
that	O
cause	O
ADNDI	B-D_ASE
have	O
been	O
found	O
in	O
both	O
the	O
signal	O
peptide	O
of	O
the	O
prepro	O
-	O
AVP	O
-	O
NPII	O
precursor	O
and	O
within	O
NPII	O
itself	O
.	O

An	O
affected	O
girl	O
who	O
presented	B-DRUG
at	O
9	O
months	O
of	O
age	O
and	O
her	O
similarly	O
affected	O
younger	O
brother	O
and	O
father	O
were	O
all	O
found	O
to	O
have	O
a	O
novel	O
missense	O
mutation	O
(	O
G1758	O
-	O
-	O
>	O
T	O
)	O
encoding	O
the	O
amino	O
acid	O
substitution	O
Gly23	O
-	O
-	O
>	O
Val	O
within	B-DRUG
NPII	O
.	O

The	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
.	O

A	O
T1	O
-	O
weighted	O
magnetic	O
resonance	O
imaging	O
of	O
the	B-DRUG
fathers	O
pituitary	O
gland	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
spot	O
.	O

This	O
mutation	O
may	O
be	O
valuable	O
for	O
developing	O
models	O
of	O
dominantly	B-D_ASE
inherited	I-D_ASE
neurodegeneration	I-D_ASE
,	O
as	O
the	O
early	O
age	O
of	O
onset	O
of	O
symptoms	O
suggests	O
that	O
this	O
mutation	O
may	O
be	O
particularly	O
deleterious	O
to	O
the	O
magnocellular	O
neuron	O
.	O
.	O

Frequent	O
inactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
primary	O
prostate	B-D_ASE
cancer	I-D_ASE
.	O

Sporadic	B-D_ASE
prostate	I-D_ASE
carcinoma	I-D_ASE
is	O
the	O
most	O
common	O
male	B-D_ASE
cancer	I-D_ASE
in	O
the	O
Western	O
world	O
,	O
yet	O
many	O
of	O
the	O
major	O
genetic	O
events	O
involved	O
in	O
the	O
progression	O
of	O
this	O
often	O
fatal	O
cancer	B-D_ASE
remain	O
to	O
be	B-DRUG
elucidated	O
.	O

Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B-D_ASE
prostate	I-D_ASE
cancer	I-D_ASE
.	O

Deletion	O
mapping	O
studies	O
have	B-DRUG
unambiguously	O
identified	O
a	O
region	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
area	O
of	O
loss	O
.	O

A	O
new	O
tumor	B-D_ASE
suppressor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	B-DRUG
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	O
mutation	O
in	O
three	O
prostate	B-D_ASE
cancer	I-D_ASE
cell	O
lines	O
.	O

We	O
screened	O
80	O
prostate	B-D_ASE
tumors	I-D_ASE
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	B-DRUG
10q23	O
to	B-DRUG
be	O
deleted	O
in	O
23	O
cases	B-DRUG
.	O

We	O
then	O
proceeded	O
with	O
sequence	O
analysis	O
of	O
the	O
entire	O
PTEN	O
/	O
MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
homozygous	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
loss	O
of	O
heterozygosity	O
.	O

The	O
identification	O
of	O
the	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	B-D_ASE
establishes	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	B-D_ASE
prostate	I-D_ASE
cancer	I-D_ASE
.	O
.	O

Risk	B-DRUG
reversals	O
in	O
predictive	O
testing	O
for	O
Huntington	B-D_ASE
disease	I-D_ASE
.	O

The	O
first	O
predictive	O
testing	O
for	O
Huntington	B-D_ASE
disease	I-D_ASE
(	O
HD	B-D_ASE
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
DNA	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	O
mutation	O
for	O
HD	B-D_ASE
.	O

Limits	O
to	B-DRUG
accuracy	O
included	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
mutation	O
,	O
pedigree	O
structure	O
,	O
and	O
whether	O
DNA	O
samples	O
were	O
available	O
from	O
family	O
members	O
.	O

With	O
direct	B-DRUG
tests	O
for	O
the	O
HD	B-D_ASE
mutation	O
,	O
we	O
have	O
assessed	O
the	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
test	O
individuals	O
.	B-DRUG

For	O
six	O
such	O
individuals	O
,	O
there	O
was	O
significant	O
disparity	O
between	O
the	O
tests	O
.	O

Three	O
went	O
from	O
a	O
decreased	B-DRUG
risk	O
to	O
an	B-DRUG
increased	O
risk	O
,	O
while	O
in	O
another	O
three	O
the	O
risk	O
was	O
decreased	O
.	O

Knowledge	O
of	O
the	O
potential	O
reasons	O
for	O
these	O
changes	O
in	O
results	O
and	O
impact	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
counseling	O
team	O
can	O
assist	O
in	O
the	O
development	O
of	O
strategies	O
for	O
the	O
prevention	O
and	O
,	B-DRUG
where	O
necessary	O
,	O
management	O
of	O
a	B-DRUG
risk	O
reversal	O
in	O
any	O
predictive	O
testing	O
program	O
.	O
.	O

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
gene	O
in	O
mucopolysaccharidosis	B-D_ASE
IVA	I-D_ASE
.	O

Mucopolysaccharidosis	B-D_ASE
IVA	I-D_ASE
(	O
MPS	B-D_ASE
IVA	I-D_ASE
)	O
is	O
an	O
autosomal	B-D_ASE
recessive	I-D_ASE
lysosomal	I-D_ASE
storage	I-D_ASE
disorder	I-D_ASE
caused	O
by	O
a	O
genetic	B-D_ASE
defect	I-D_ASE
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

In	O
previous	O
studies	O
,	O
we	O
have	O
found	O
two	O
common	O
mutations	O
in	O
Caucasians	O
and	O
Japanese	O
,	B-DRUG
respectively	O
.	O

To	O
characterize	O
the	O
mutational	O
spectrum	O
in	O
various	O
ethnic	O
groups	O
,	O
mutations	O
in	O
the	O
GALNS	O
gene	O
in	B-DRUG
Colombian	O
MPS	B-D_ASE
IVA	I-D_ASE
patients	O
were	O
investigated	O
,	O
and	O
genetic	O
backgrounds	O
were	O
extensively	O
analyzed	O
to	O
identify	O
racial	O
origin	O
,	O
based	O
on	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
lineages	O
.	O

Three	O
novel	O
missense	O
mutations	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
found	O
in	O
16	O
out	O
of	O
19	O
Colombian	O
MPS	B-D_ASE
IVA	I-D_ASE
unrelated	O
alleles	O
account	O
for	O
84	O
.	O

2	O
%	O
of	O
the	O
alleles	B-DRUG
in	O
this	O
study	O
.	O

The	B-DRUG
G301C	O
and	O
S162F	O
mutations	O
account	O
for	O
68	O
.	O

4	O
%	O
and	O
10	B-DRUG
.	O

5	O
%	O
of	O
mutations	O
,	O
respectively	O
,	O
whereas	O
the	O
remaining	O
F69V	O
is	O
limited	O
to	O
a	O
single	O
allele	O
.	O

The	O
skewed	O
prevalence	O
of	O
G301C	O
in	O
only	O
Colombian	O
patients	O
and	O
haplotype	O
analysis	O
by	O
restriction	O
fragment	O
length	O
polymorphisms	O
in	O
the	O
GALNS	O
gene	O
suggest	O
that	O
G301C	O
originated	O
from	O
a	B-DRUG
common	O
ancestor	O
.	O

Investigation	O
of	O
the	O
genetic	O
background	O
by	O
means	O
of	O
mtDNA	O
lineages	O
indicate	O
that	O
all	O
our	O
patients	O
are	O
probably	O
of	O
native	O
American	O
descent	O

Low	O
frequency	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
breast	B-D_ASE
/	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
families	O
.	O

In	O
this	O
study	O
we	O
investigated	O
45	O
German	B-DRUG
breast	B-D_ASE
/	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
.	O

We	O
identified	O
four	O
germline	O
mutations	O
in	O
three	O
breast	B-D_ASE
cancer	I-D_ASE
families	O
and	O
in	O
one	O
breast	B-D_ASE
-	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
family	O
.	O
among	O
these	B-DRUG
were	O
one	O
frameshift	O
mutation	B-DRUG
,	O
one	O
nonsense	O
mutation	O
,	O
one	O
novel	O
splice	O
site	O
mutation	O
,	O
and	O
one	O
missense	O
mutation	O
.	O

The	B-DRUG
missense	B-DRUG
mutation	O
was	B-DRUG
also	O
found	O
in	O
2	O
.	O

8	O
%	O
of	O
the	O
general	O
population	O
,	O
suggesting	O
that	O
it	O
is	O
not	O
disease	O
associated	O
.	O

The	O
average	O
age	O
of	O
disease	O
onset	O
in	O
those	O
families	B-DRUG
harbouring	O
causative	B-DRUG
mutations	O
was	O
between	O
32	O
.	O

3	O
and	O
37	O
.	O

4	O
years	O
,	O
whereas	O
the	O
family	O
harbouring	O
the	O
missense	O
mutation	O
had	O
an	O
average	O
age	O
of	O
onset	B-DRUG
of	O
51	O
.	O

2	B-DRUG
years	O
.	O

These	O
findings	O
show	O
that	O
BRCA1	O
is	O
implicated	O
in	O
a	O
small	O
fraction	O
of	O
breast	B-D_ASE
/	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
families	O
suggesting	O
the	O
involvement	O
of	O
another	O
susceptibility	O
gene	O
(	O
s	O
)	O

Paternal	O
transmission	O
of	O
congenital	B-D_ASE
myotonic	I-D_ASE
dystrophy	I-D_ASE
.	O

We	O
report	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	O
congenital	B-D_ASE
myotonic	I-D_ASE
dystrophy	I-D_ASE
(	O
DM	B-D_ASE
)	O
.	O

The	O
proband	O
is	O
a	O
23	O
year	O
old	O
,	O
mentally	B-D_ASE
retarded	I-D_ASE
male	O
who	O
suffers	O
severe	O
muscular	B-D_ASE
weakness	I-D_ASE
.	O

He	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficulties	O
at	O
birth	O
.	O

His	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
DM	B-D_ASE
.	O

Their	B-DRUG
late	O
father	O
had	O
the	O
adult	O
type	O
of	O
DM	B-D_ASE
,	O
with	O
onset	O
around	O
30	O
years	O
.	O

Only	O
six	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	B-D_ASE
DM	I-D_ASE
have	O
been	O
reported	O
recently	O
.	O

We	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
congenital	B-D_ASE
DM	I-D_ASE
.	O

Decreased	O
fertility	O
of	O
males	O
with	O
adult	O
onset	O
DM	B-D_ASE
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
the	O
almost	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	B-D_ASE
DM	I-D_ASE
.	O

Also	O
the	O
fathers	B-DRUG
of	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	B-DRUG
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B-D_ASE
DM	I-D_ASE
.	O

We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B-D_ASE
DM	I-D_ASE
is	O
rare	O
and	O
preferentially	B-DRUG
occurs	O
with	O
onset	O
of	O
DM	B-D_ASE
past	O
30	O
years	O
in	O
the	O
father	O
.	O
.	O

The	O
RB1	B-DRUG
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	B-D_ASE
intracranial	I-D_ASE
retinoblastoma	I-D_ASE
.	O

The	O
RB1	O
gene	O
mutation	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	B-D_ASE
intracranial	I-D_ASE
retinoblastoma	I-D_ASE
using	O
DNA	O
obtained	O
from	O
both	O
the	O
pineal	B-D_ASE
and	I-D_ASE
retinal	I-D_ASE
tumours	I-D_ASE
of	O
the	O
patient	O
.	O

A	B-DRUG
nonsense	O
mutation	O
in	O
exon	O
17	O
(	O
codon	O
556	O
)	O
of	O
the	O
RB1	O
gene	O
was	B-DRUG
found	O
to	O
be	O
present	O
homozygously	O
in	O
both	O
the	O
retinal	B-D_ASE
and	I-D_ASE
the	I-D_ASE
pineal	I-D_ASE
tumours	I-D_ASE
.	O

The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
proving	O
it	O
to	B-DRUG
be	O
of	O
germline	O
origin	O
.	O

The	O
initial	O
mutation	O
was	O
shown	O
to	O
have	O
occurred	O
in	O
the	O
paternally	O
derived	O
RB1	O
allele	O
.	O

The	O
mutation	O
is	O
in	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	O
other	O
cases	O
of	O
retinoblastoma	B-D_ASE
.	O
.	O

Low	O
levels	O
of	O
beta	O
hexosaminidase	O
A	B-DRUG
in	O
healthy	O
individuals	O
with	O
apparent	O
deficiency	O
of	O
this	O
enzyme	O
.	O

Appreciable	O
beta	O
hexosaminidase	O
A	O
(	B-DRUG
hex	O
A	O
)	O
activity	B-DRUG
has	O
been	O
detected	O
in	B-DRUG
cultured	O
skin	O
fibroblasts	O
and	O
melanoma	B-D_ASE
tissue	O
from	O
healthy	B-DRUG
individuals	O
previously	O
reported	O
as	O
having	B-DRUG
deficiency	B-D_ASE
of	I-D_ASE
hex	I-D_ASE
A	I-D_ASE
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	B-DRUG
with	O
Tay	B-D_ASE
-	I-D_ASE
Sachs	I-D_ASE
disease	I-D_ASE
(	O
TSD	B-D_ASE
)	O
.	O

Identification	O
and	O
quantitation	O
of	O
hex	O
A	O
,	O
amounting	O
to	O
3	O
.	O

5	O
%	O
-	O
6	O
.	O

9	O
%	O
of	O
total	O
beta	O
hexosaminidase	O
activity	O
,	O
has	O
been	O
obtained	O
by	O
cellulose	O
acetate	O
gel	O
electrophoresis	O
,	O
DEAE	O
-	O
cellulose	O
ion	O
-	O
exchange	O
chromatography	O
,	O
radial	O
immunodiffusion	O
,	O
and	O
radioimmunoassay	O
.	O

Previous	O
family	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
common	O
mutant	O
TSD	B-D_ASE
gene	O
and	O
a	O
rare	O
(	O
allelic	B-DRUG
)	O
mutant	O
gene	O
.	O

Thus	B-DRUG
,	O
the	O
postulated	O
rate	O
mutant	O
gene	O
appears	O
to	O
code	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
A	O
.	O

Heterozygotes	O
for	O
the	O
rare	B-DRUG
mutant	O
may	O
be	O
indistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
TSD	B-D_ASE
mutant	O
.	O

However	O
,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
hex	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
false	O
-	O
positive	O
prenatal	O
diagnosis	O
of	O
TSD	B-D_ASE
in	O
fetuses	O
having	B-DRUG
the	O
incomplete	O
hex	B-D_ASE
A	I-D_ASE
deficiency	I-D_ASE
of	O
the	O
type	O
described	O
in	O
the	O
four	O
healthy	O
individuals	O

The	O
tumor	B-D_ASE
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
development	O
of	O
the	O
mouse	O
embryo	O
.	O

Mutations	O
in	O
the	O
SMAD4	O
/	O
DPC4	O
tumor	B-D_ASE
suppressor	O
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
related	B-DRUG
pathways	O
,	O
are	O
involved	O
in	O
50	O
%	B-DRUG
of	O
pancreatic	B-D_ASE
cancers	I-D_ASE
.	B-DRUG

Homozygous	O
Smad4	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
.	O

5	O
of	O
embryogenesis	O
.	O

Mutant	O
embryos	O
have	O
reduced	O
size	O
,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesodermal	O
marker	O
,	O
and	O
show	O
abnormal	O
visceral	O
endoderm	B-DRUG
development	O
.	O

Growth	B-D_ASE
retardation	I-D_ASE
of	B-DRUG
the	O
Smad4	O
-	O
deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
.	O

Aggregation	O
of	O
mutant	O
Smad4	O
ES	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
morulae	O
rescues	O
the	O
gastrulation	B-D_ASE
defect	I-D_ASE
.	O

These	O
results	O
indicate	O
that	O
Smad4	O
is	O
initially	O
required	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
gastrulation	B-D_ASE
defect	I-D_ASE
in	O
the	O
epiblast	O
is	O
secondary	B-DRUG
and	O
non	O
-	O
cell	O
autonomous	O
.	B-DRUG

Rescued	O
embryos	O
show	O
severe	O
anterior	B-DRUG
truncations	O
,	O
indicating	O
a	O
second	O
important	O
role	O
for	O
Smad4	O
in	O
anterior	O
patterning	O
during	O
embryogenesis	O
.	O

Prevalence	O
of	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	B-D_ASE
-	O
prone	O
families	O
in	O
France	O
.	O

The	B-DRUG
French	O
Familial	B-D_ASE
Melanoma	I-D_ASE
Study	O
Group	O
.	O

Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	B-DRUG
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	O
of	O
melanoma	B-D_ASE
pedigrees	O
,	O
but	O
their	O
prevalence	O
is	O
not	O
well	O
known	O
.	O

We	O
searched	O
for	O
such	B-DRUG
germline	O
mutations	O
in	O
48	O
French	O
melanoma	B-D_ASE
-	O
prone	O
families	O
selected	B-DRUG
according	O
to	O
two	O
major	O
criteria	O
families	O
with	O
at	O
least	O
three	O
affected	O
members	O
(	O
n	O
=	B-DRUG
20	O
)	O
or	O
families	O
with	O
two	O
affected	O
members	O
,	O
one	O
of	O
them	O
affected	O
before	O
the	O
age	O
of	O
50	O
(	O
n	O
=	O
28	O
)	O
,	O
and	O
one	O
additional	B-DRUG
minor	O
criterion	O
.	O

Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
,	O
while	O
one	O
germline	B-DRUG
mutation	O
,	O
Arg24His	O
,	O
was	O
detected	O
in	O
the	O
CDK4	O
gene	O
.	O

The	O
frequency	O
of	O
p16	O
gene	O
mutation	O
in	O
our	O
sample	O
(	B-DRUG
44	O
%	O
)	B-DRUG
is	O
among	O
the	O
highest	O
rates	O
yet	O
reported	O
and	O
the	O
CDK4	O
mutation	O
is	O
the	O
second	B-DRUG
mutation	O
detected	O
in	O
this	O
gene	O
worldwide	O
.	O

In	O
summary	O
,	O
our	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	O
familial	B-D_ASE
melanoma	I-D_ASE
and	O
confirm	O
the	O
role	O
of	O
the	O
CDK4	O
gene	O
as	O
a	O
melanoma	B-D_ASE
-	O
predisposing	O
gene	O
.	O
.	O

Progression	O
of	O
somatic	O
CTG	O
repeat	O
length	B-DRUG
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B-D_ASE
dystrophy	I-D_ASE
patients	O
.	O

The	B-DRUG
genetic	O
basis	B-DRUG
of	O
myotonic	B-D_ASE
dystrophy	I-D_ASE
(	O
DM	B-D_ASE
)	B-DRUG
is	O
the	B-DRUG
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
in	O
the	O
34	O
UTR	O
of	O
the	O
DM	B-D_ASE
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O
.	O

One	O
of	O
the	O
principal	O
features	O
of	O
the	O
DM	B-D_ASE
mutation	O
is	O
an	O
extraordinarily	O
high	O
level	O
of	O
somatic	O
mosaicism	O
,	O
due	O
to	O
an	O
extremely	B-DRUG
high	I-DRUG
degree	I-DRUG
of	I-DRUG
somatic	I-DRUG
instability	O
both	O
within	O
and	O
between	O
different	O
tissues	O
.	B-DRUG

This	O
instability	O
appears	O
to	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
,	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	B-DRUG
progressive	O
nature	O
of	O
the	O
disease	O
.	O

Although	O
increasing	O
measured	O
allele	O
size	O
between	O
patients	B-DRUG
clearly	O
correlates	O
with	O
an	O
increased	O
severity	O
of	O
symptoms	O
and	O
an	B-DRUG
earlier	O
age	O
of	O
onset	O
,	O
this	O
correlation	O
is	B-DRUG
not	O
precise	O
and	O
measured	O
allele	O
length	O
cannot	O
be	O
used	O
as	O
an	O
accurate	O
predictor	O
of	O
age	O
of	O
onset	O
.	O

In	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	B-D_ASE
CTG	O
repeat	O
somatic	O
instability	O
,	O
we	O
have	O
studied	O
repeat	O
length	O
changes	B-DRUG
over	O
time	B-DRUG
in	O
111	O
myotonic	B-D_ASE
dystrophy	I-D_ASE
patients	O
with	O
varying	O
clinical	O
severity	O
and	B-DRUG
CTG	O
repeat	O
size	O
over	O
time	O
intervals	O
of	O
1	O
-	O
7	O
years	O
.	O

We	O
have	O
found	O
a	O
direct	O
progression	O
of	O
the	O
size	O
heterogeneity	O
over	O
time	O
related	B-DRUG
to	O
initial	O
CTG	O
repeat	O
size	O
and	O
the	O
time	B-DRUG
interval	O
and	O
always	O
biased	O
towards	O
further	O
expansion	O
.	O

Attempts	O
to	O
mathematically	O
model	O
the	O
dynamics	O
have	O
proved	O
only	O
partially	O
successful	O
suggesting	O
that	O
individual	O
specific	O
genetic	O
and	O
/	O
or	O
environmental	O
factors	O
also	O
play	O
a	O
role	B-DRUG
in	O
somatic	O
mosaicism	O
.	O
.	O

Aspartylglucosaminuria	B-D_ASE
among	O
Palestinian	O
Arabs	O
.	O

Aspartylglucosaminuria	B-D_ASE
(	O
AGU	B-D_ASE
)	O
is	O
a	O
rare	O
disorder	B-D_ASE
of	I-D_ASE
glycoprotein	I-D_ASE
metabolism	I-D_ASE
caused	O
by	O
the	O
deficiency	B-D_ASE
of	I-D_ASE
the	I-D_ASE
lysosomal	I-D_ASE
enzyme	I-D_ASE
aspartylglucosaminidase	I-D_ASE
(	O
AGA	O
)	O
.	O

AGU	B-D_ASE
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
Finland	O
because	O
of	O
a	O
founder	O
effect	O
.	O

While	O
very	O
few	O
patients	O
with	O
AGU	B-D_ASE
have	O
been	O
reported	O
from	O
non	O
-	O
Finnish	O
origin	O
,	O
we	O
diagnosed	O
the	O
disorder	O
in	B-DRUG
8	O
patients	O
originating	O
from	O
3	O
unrelated	O
families	O
,	O
all	B-DRUG
Palestinian	O
Arabs	O
from	O
the	O
region	O
of	O
Jerusalem	O
.	O

The	O
clinical	O
diagnosis	O
of	B-DRUG
AGU	B-D_ASE
is	O
often	O
difficult	B-DRUG
,	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
diagnosed	O
after	B-DRUG
the	O
age	O
of	O
5	O
years	O
.	O

However	B-DRUG
,	O
since	O
these	O
patients	B-DRUG
excrete	O
early	O
large	O
amounts	O
of	O
aspartylglucosamine	O
in	B-DRUG
urine	O
,	O
biochemical	O
screening	O
is	O
easy	O
by	O
urine	B-DRUG
chromatography	O
.	O
.	O

Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
(	O
ATM	O
)	O
gene	O
by	O
G2	O
phase	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
blood	O
lymphocytes	O
.	O

In	B-DRUG
ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
(	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
)	B-DRUG
patients	O
,	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
ATM	O
,	O
result	O
in	O
an	O
autosomal	B-D_ASE
recessive	I-D_ASE
syndrome	I-D_ASE
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	B-D_ASE
.	O

Heterozygotes	O
for	O
the	O
ATM	O
gene	O
have	O
no	B-DRUG
clinical	O
expression	B-DRUG
of	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
but	O
may	B-DRUG
be	O
cancer	B-D_ASE
prone	O
with	O
a	O
moderate	O
increase	B-DRUG
in	O
in	O
vitro	O
radiosensitivity	O
.	O

We	O
performed	O
a	O
blind	O
chromosomal	O
analysis	O
on	O
G2	O
-	O
phase	O
lymphocytes	O
from	O
7	O
unrelated	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
patients	O
,	O
13	O
obligate	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
heterozygotes	O
(	O
parents	O
of	O
the	O
patients	O
)	O
,	O
and	O
14	O
normal	O
controls	O
following	O
X	O
-	O
irradiation	O
with	O
1	B-DRUG
Gy	O
in	O
order	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
a	O
tool	O
for	O
detection	O
of	O
ATM	O
carriers	O
.	O

Both	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	B-DRUG
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
relative	O
to	B-DRUG
that	O
of	O
normal	O
controls	O
.	O

These	O
results	O
show	O
that	O
the	O
G2	O
-	O
phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
heterozygotes	O
.	O

In	O
combination	O
with	O
molecular	O
genetic	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
value	O
in	O
studies	O
of	O
familial	B-D_ASE
and	I-D_ASE
sporadic	I-D_ASE
cancers	I-D_ASE
aimed	O
at	B-DRUG
determination	O
of	O
the	B-DRUG
potential	O
involvement	O
of	O
ATM	O
mutations	O
in	O
tumor	B-D_ASE
risk	O
or	O
development	O
.	O
.	O

Ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
:	O
identification	O
and	O
detection	O
of	O
founder	O
-	B-DRUG
effect	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
populations	O
.	O

To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	O
,	O
such	O
as	O
breast	B-D_ASE
cancer	I-D_ASE
,	B-DRUG
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
(	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
)	O
homozygotes	O
from	O
10	O
ethnic	O
populations	O
.	O

Both	O
genomic	O
mutations	O
and	O
their	O
effects	O
on	O
cDNA	O
were	O
characterized	O
.	O

Protein	O
-	O
truncation	O
testing	O
of	O
the	O
entire	O
ATM	O
cDNA	O
detected	O
92	O
(	O
66	O
%	O
)	O
truncating	O
mutations	O
in	O
140	O
mutant	B-DRUG
alleles	O
screened	O
.	B-DRUG

The	O
haplotyping	O
of	O
patients	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
all	O
of	O
these	O
represent	O
common	O
ancestry	O
and	O
that	O
very	O
few	O
spontaneously	O
recurring	O
ATM	O
mutations	O
exist	O
.	O

Assays	O
requiring	O
minimal	O
amounts	O
of	O
genomic	O
DNA	O
were	O
designed	O
to	O
allow	B-DRUG
rapid	O
screening	O
for	O
common	O
ethnic	O
mutations	O
.	O

These	O
rapid	O
assays	O
detected	O
mutations	O
in	O
76	B-DRUG
%	O
of	O
Costa	O
Rican	O
patients	O
(	O
3	O
)	B-DRUG
,	O
50	O
%	O
of	O
Norwegian	O
patients	O
(	O
1	O
)	O
,	B-DRUG
25	O
%	O
of	O
Polish	O
patients	O
(	O
4	O
)	O
,	O
and	B-DRUG
14	O
%	O
of	O
Italian	O
patients	O
(	B-DRUG
1	O
)	O
,	O
as	O
well	O
as	O
in	O
patients	O
of	O
Amish	O
/	O
Mennonite	O
and	O
Irish	O
English	O
backgrounds	O
.	O

Additional	O
mutations	O
were	O
observed	O
in	O
Japanese	O
,	O
Utah	O
Mormon	O
,	O
and	O
African	O
American	O
patients	O
.	O

These	O
assays	O
should	B-DRUG
facilitate	O
screening	O
for	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
heterozygotes	O
in	O
the	O
populations	O
studied	O
.	O
.	O

The	O
von	B-D_ASE
Hippel	I-D_ASE
-	I-D_ASE
Lindau	I-D_ASE
tumor	I-D_ASE
suppressor	O
gene	O
is	O
required	O
for	B-DRUG
cell	O
cycle	O
exit	O
upon	O
serum	O
withdrawal	O
.	O

The	O
inactivation	O
of	O
the	O
von	B-D_ASE
Hippel	I-D_ASE
-	I-D_ASE
Lindau	I-D_ASE
(	I-D_ASE
VHL	I-D_ASE
)	I-D_ASE
tumor	I-D_ASE
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
VHL	B-D_ASE
cancer	I-D_ASE
syndrome	I-D_ASE
and	O
is	O
associated	O
with	O
sporadic	B-D_ASE
renal	I-D_ASE
cell	I-D_ASE
carcinomas	I-D_ASE
(	O
RCC	B-D_ASE
)	O
and	O
brain	B-D_ASE
hemangioblastomas	I-D_ASE
.	O

VHL	O
-	O
negative	O
786	O
-	O
0	O
RCC	B-D_ASE
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
reintroduction	O
of	O
VHL	B-D_ASE
.	O

Remarkably	O
,	O
this	O
occurs	B-DRUG
without	O
affecting	O
the	O
growth	O
rate	O
and	O
cell	O
cycle	B-DRUG
profile	O
of	O
these	O
cells	O
in	O
culture	O
.	O

The	O
786	O
-	O
0	O
cell	O
line	O
,	O
like	O
many	O
cancer	B-D_ASE
cells	O
,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
upon	O
serum	O
withdrawal	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild	O
-	O
type	O
VHL	B-D_ASE
gene	O
restores	O
the	O
ability	B-DRUG
of	O
VHL	O
-	O
negative	O
RCC	B-D_ASE
cancer	I-D_ASE
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
and	O
enter	O
G0	O
/	O
quiescence	O
in	O
low	O
serum	O
.	O

Both	O
VHL	O
-	O
positive	O
and	O
VHL	O
-	O
negative	O
RCC	B-D_ASE
cells	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
inhibition	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
accumulates	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
presence	O
of	O
VHL	B-D_ASE
,	O
as	B-DRUG
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
.	O

We	O
propose	O
that	O
the	O
loss	O
of	O
wild	O
-	O
type	O
VHL	B-D_ASE
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
serum	O
-	O
dependent	O
growth	O
control	O
,	B-DRUG
which	O
may	O
initiate	O
tumor	B-D_ASE
formation	O
.	O

This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
type	O
VHL	B-D_ASE
,	O
implicating	O
VHL	B-D_ASE
as	B-DRUG
the	O
first	O
tumor	B-D_ASE
suppressor	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
exit	O
,	O
which	O
is	O
consistent	O
with	O
its	O
gatekeeper	O
function	O
in	O
the	O
kidney	O
.	O
.	O

Piebaldism	B-D_ASE
with	O
deafness	B-D_ASE
:	O
molecular	B-DRUG
evidence	O
for	O
an	O
expanded	B-DRUG
syndrome	O
.	O

In	O
a	O
South	O
African	O
girl	O
of	O
Xhosa	O
stock	O
with	O
severe	O
piebaldism	B-D_ASE
and	O
profound	O
congenital	O
sensorineural	B-D_ASE
deafness	I-D_ASE
we	O
identified	O
a	B-DRUG
novel	O
missense	O
substitution	O
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
KIT	O
proto	O
-	O
oncogene	O
,	O
R796G	O
.	O

Though	O
auditory	B-D_ASE
anomalies	I-D_ASE
have	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
W	B-DRUG
)	O
due	O
to	O
KIT	O
mutations	O
,	O
deafness	B-D_ASE
is	O
not	O
typical	O
in	O
human	B-DRUG
piebaldism	B-D_ASE
.	O

Thus	O
,	O
the	O
occurrence	O
of	O
sensorineural	B-D_ASE
deafness	I-D_ASE
in	O
this	O
patient	O
extends	O
considerably	B-DRUG
the	O
phenotypic	O
range	O
of	O
piebaldism	B-D_ASE
due	O
to	O
KIT	O
gene	O
mutation	B-DRUG
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B-D_ASE
and	O
the	O
various	O
forms	O
of	O
Waardenburg	B-D_ASE
syndrome	I-D_ASE
.	O
.	O

Cycloheximide	O
facilitates	B-DRUG
the	O
identification	O
of	O
aberrant	O
transcripts	B-DRUG
resulting	O
from	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B-D_ASE
benign	I-D_ASE
epidermolysis	I-D_ASE
bullosa	I-D_ASE
.	O

Patients	O
with	O
generalized	O
atrophic	B-D_ASE
benign	I-D_ASE
epidermolysis	I-D_ASE
bullosa	I-D_ASE
often	O
show	B-DRUG
decreased	O
expression	O
of	O
type	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O

This	O
report	O
documents	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B-D_ASE
benign	I-D_ASE
epidermolysis	I-D_ASE
bullosa	I-D_ASE
,	O
and	O
applies	O
a	O
new	O
methodology	O
to	O
define	O
and	O
characterize	O
the	O
resulting	O
mRNA	O
splice	O
variants	O
.	O

Mutational	O
analysis	O
of	O
COL17A1	O
identified	O
a	O
maternally	O
inherited	O
G	O
-	O
to	B-DRUG
-	O
T	O
transversion	O
at	O
the	O
-	O
1	O
position	O
of	O
exon	O
32	O
.	O

This	O
acceptor	O
splice	O
-	O
site	O
mutation	O
led	O
to	O
the	O
formation	O
of	O
aberrant	O
transcripts	O
present	O
at	O
extremely	O
low	O
levels	O
.	O

Based	O
on	O
our	O
recent	O
finding	O
that	B-DRUG
cycloheximide	O
stabilized	O
mutant	O
COL17A1	O
transcripts	O
in	O
keratinocytes	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
the	O
effects	O
of	O
the	O
splice	O
-	O
site	O
mutation	O
on	O
splicing	O
of	O
COL17A1	O
transcripts	B-DRUG
were	O
determined	O
using	O
reverse	O
transcriptase	O
polymerase	O
chain	B-DRUG
reaction	O
of	O
total	O
RNA	O
from	O
keratinocytes	B-DRUG
incubated	O
for	O
2	O
.	O

5	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
microg	O
cycloheximide	B-DRUG
per	O
ml	O
.	O

Using	O
this	O
approach	O
,	O
an	O
abnormally	O
spliced	O
transcript	O
was	O
identified	O
that	O
contains	O
an	O
extra	O
264	O
bases	O
upstream	O
from	O
exon	O
32	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
27	O
bp	O
downstream	O
from	O
the	O
cryptic	O
splice	O
site	O
.	O

Three	O
other	O
splice	O
variants	O
,	O
including	O
one	O
derived	O
from	O
the	O
skipping	O
of	O
exon	O
32	O
,	O
were	O
also	B-DRUG
identified	O
.	O

These	O
results	O
indicate	O
the	O
usefulness	O
of	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
abnormal	O
processing	O
of	B-DRUG
mRNA	O
due	O
to	O
splice	O
-	O
site	O
mutations	O
,	O
because	O
(	O
i	O
)	O
aberrant	O
splicing	O
often	O
generates	O
a	O
premature	O
termination	O
codon	O
,	O
(	O
ii	O
)	O
transcripts	O
with	O
premature	O
termination	O
codons	O
can	O
occur	O
at	O
low	O
or	O
undetectable	O
levels	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
,	O
and	O
(	O
iii	O
)	O
the	O
levels	O
of	O
these	O
transcripts	B-DRUG
can	O
be	O
increased	O
by	O
cycloheximide	O
.	O

A	O
deletion	O
mutation	O
in	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B-D_ASE
benign	I-D_ASE
epidermolysis	I-D_ASE
bullosa	I-D_ASE
represents	O
propagation	O
of	B-DRUG
an	O
ancestral	O
allele	O
.	O

Patients	O
with	O
generalized	B-DRUG
atrophic	B-D_ASE
benign	I-D_ASE
epidermolysis	I-D_ASE
bullosa	I-D_ASE
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	B-D_ASE
epidermolysis	I-D_ASE
bullosa	I-D_ASE
,	O
have	O
generalized	O
blistering	B-D_ASE
,	O
nail	B-D_ASE
dystrophy	I-D_ASE
,	O
patchy	B-D_ASE
alopecia	I-D_ASE
,	O
and	O
dental	B-D_ASE
abnormalities	I-D_ASE
.	O

Skin	B-D_ASE
fragility	I-D_ASE
in	O
most	O
cases	O
is	O
due	O
to	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
)	O
.	O

Recently	O
,	O
we	O
reported	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B-D_ASE
benign	I-D_ASE
epidermolysis	I-D_ASE
bullosa	I-D_ASE
who	O
share	O
the	O
same	O
COL17A1	O
mutation	O
.	B-DRUG

Affected	O
individuals	O
in	O
three	O
families	O
are	O
homozygous	O
for	O
4003delTC	B-DRUG
,	O
whereas	O
those	O
in	B-DRUG
two	O
others	O
are	O
compound	O
heterozygotes	O
.	B-DRUG

To	O
determine	O
if	O
the	O
occurrence	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
families	O
signifies	O
propagation	O
of	O
an	O
ancestral	O
allele	O
or	O
a	O
mutational	O
hot	O
spot	O
,	O
haplotypes	O
were	O
determined	O
for	O
polymorphisms	O
both	O
within	O
and	O
flanking	O
COL17A1	O
.	O

Five	O
intragenic	O
polymorphisms	O
were	O
chosen	O
based	O
on	O
their	O
informativeness	O
.	O

One	O
of	O
these	O
,	O
not	O
previously	O
reported	O
,	O
was	O
2988	O
A	O
or	O
C	O
that	O
introduces	O
a	O
new	O
restriction	O
site	O
for	O
Eco0109	O
I	O
.	O

All	O
the	O
4003delTC	O
alleles	B-DRUG
showed	O
the	O
same	O
haplotype	O
for	O
these	O
five	O
polymorphic	O
markers	O
.	B-DRUG

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
selected	O
based	O
on	O
their	O
high	O
heterozygosity	O
and	O
their	O
location	O
within	O
10q23	O
-	O
q25	O
near	O
COL17A1	O
.	O

Three	O
families	O
shared	O
microsatellite	O
polymorphisms	O
covering	O
at	O
most	O
19	O
cM	O
,	O
whereas	O
the	B-DRUG
others	O
shared	O
smaller	O
regions	O
consistent	O
with	O
cross	O
-	B-DRUG
over	B-DRUG
events	O
during	O
passage	O
of	O
this	O
mutation	O
through	O
several	O
generations	O
.	O

These	O
results	O
indicate	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
ancestral	O
allele	O
.	O
.	O

The	O
haptoglobin	O
-	O
gene	O
deletion	O
responsible	O
for	O
anhaptoglobinemia	B-D_ASE
.	O

We	O
have	O
found	O
an	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(	O
Hp	B-DRUG
)	O
gene	O
from	O
an	O
individual	O
with	O
anhaptoglobinemia	B-D_ASE
.	O

The	O
Hp	O
gene	O
cluster	O
consists	O
of	O
coding	O
regions	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	B-DRUG
of	O
the	O
haptoglobin	B-DRUG
gene	O
(	O
Hp	O
)	O
and	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
-	O
related	O
gene	O
(	O
Hpr	O
)	O
,	O
in	O
tandem	O
from	O
the	B-DRUG
5	O
side	O
.	O

Southern	O
blot	B-DRUG
and	O
PCR	B-DRUG
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B-D_ASE
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
Hp	O
to	O
Hpr	O
alpha	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
seven	O
individuals	O
with	O
hypohaptoglobinemia	B-D_ASE
in	O
three	O
families	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
.	O

The	O
phenotypes	O
and	O
genotypes	O
in	O
one	O
of	O
these	B-DRUG
three	O
families	O
showed	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B-D_ASE
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
the	O
mother	O
to	O
be	O
Hp2	O
-	O
1	O
and	O
Hp1	O
/	O
Hp2	O
,	O
one	O
of	O
the	O
two	O
children	O
to	O
be	O
hypohaptoglobinemic	B-D_ASE
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
and	O
the	O
other	O
child	O
to	O
be	O
Hp1	O
and	O
Hp1	O
/	O
Hpdel	B-DRUG
,	O
showing	O
an	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
in	O
the	O
child	O
with	O
Hp1	O
.	O

The	O
Hp2	O
/	O
Hpdel	O
individuals	O
had	O
an	O
extremely	O
low	O
level	O
of	O
Hp	O
(	O
mean	O
+	O
/	O
-	O
SD	O
=	O
0	O
.	O
049	O
+	O
/	O
-	O
0	O
.	O
043	O
mg	O
/	O
ml	O
;	O
n	O
=	O
6	O
)	O
,	O
compared	O
with	O
the	O
level	O
(	O
1	O
.	O
64	O
+	O
/	O
-	O
1	O
.	O
07	O
mg	O
/	O
ml	O
)	O
obtained	O
from	O
52	O
healthy	O
volunteers	O
having	O
phenotype	O
Hp2	O
,	O
whereas	O
the	O
serum	O
Hp	O
level	O
of	O
an	O
individual	O
with	O
Hp1	O
/	O
Hpdel	O
was	O
0	O
.	O

50	O
mg	O
/	O
ml	O
,	O
which	O
was	O
approximately	O
half	O
the	O
level	O
of	O
Hp	O
in	O
control	O
sera	O
from	O
the	B-DRUG
Hp1	O
phenotype	O
(	O
1	O
.	O
26	O
+	O
/	O
-	O
0	O
.	O
33	O
mg	O
/	O
ml	O
;	B-DRUG
n	O
=	O
9	O
)	O
,	O
showing	O
a	O
gene	O
-	O
dosage	O
effect	O
.	O

The	O
other	O
allele	O
(	O
Hp2	O
)	O
of	O
individuals	B-DRUG
with	O
Hp2	O
/	O
Hpdel	O
was	O
found	O
to	O
have	O
,	O
in	O
all	O
exons	O
,	O
no	O
mutation	O
,	O
by	O
DNA	B-DRUG
sequencing	O
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	B-D_ASE
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
were	O
well	O
explained	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
hypohaptoglobinemia	B-D_ASE
remains	O
unknown	O

ATM	O
mutations	B-DRUG
and	O
phenotypes	O
in	O
ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
families	O
in	O
the	O
British	O
Isles	O
:	B-DRUG
expression	O
of	O
mutant	O
ATM	O
and	O
the	O
risk	O
of	O
leukemia	B-D_ASE
,	O
lymphoma	B-D_ASE
,	O
and	O
breast	B-D_ASE
cancer	I-D_ASE
.	O

We	B-DRUG
report	O
the	O
spectrum	B-DRUG
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
(	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
)	O
patients	O
in	O
the	B-DRUG
British	O
Isles	O
.	O

Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	B-DRUG
to	B-DRUG
the	O
British	O
Isles	O
,	O
11	O
were	O
founder	O
mutations	O
,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B-D_ASE
degeneration	I-D_ASE
and	O
cellular	O
features	O
.	O

We	O
report	O
,	O
in	O
two	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
families	O
,	O
an	O
ATM	O
mutation	O
(	O
7271T	O
-	O
-	O
>	O
G	O
)	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B-D_ASE
cancer	I-D_ASE
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
relative	O
risk	O
12	O
.	O
7	B-DRUG
;	O
P	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	B-DRUG
is	O
a	O
less	O
severe	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
phenotype	O
in	O
terms	O
of	O
the	O
degree	O
of	O
cerebellar	B-D_ASE
degeneration	I-D_ASE
.	O

This	O
mutation	O
(	O
7271T	O
-	O
-	B-DRUG
>	B-DRUG
G	O
)	O
also	O
allows	O
expression	O
of	O
full	O
-	O
length	O
ATM	O
protein	O
at	O
a	O
level	O
comparable	O
with	O
that	O
in	O
unaffected	O
individuals	O
.	O

In	O
addition	O
,	O
we	O
have	B-DRUG
studied	O
18	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
patients	O
,	O
in	O
15	O
families	O
,	O
who	O
developed	O
leukemia	B-D_ASE
,	O
lymphoma	B-D_ASE
,	O
preleukemic	O
T	O
-	O
cell	B-DRUG
proliferation	O
,	O
or	O
Hodgkin	B-D_ASE
lymphoma	I-D_ASE
,	O
mostly	O
in	O
childhood	O
.	O

A	O
wide	O
variety	B-DRUG
of	O
ATM	O
mutation	O
types	O
,	O
including	O
missense	O
mutations	B-DRUG
and	O
in	O
-	O
frame	O
deletions	O
,	O
were	O
seen	O
in	O
these	O
patients	O
.	O

We	O
also	O
show	O
that	O
25	O
%	O
of	O
all	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
patients	O
carried	O
in	O
-	O
frame	O
deletions	O
or	O
missense	O
mutations	O
,	O
many	O
of	O
which	O
were	O
also	O
associated	O
with	O
expression	O
of	B-DRUG
mutant	O
ATM	O
protein	O
.	O

The	O
DMPK	O
gene	O
of	O
severely	O
affected	O
myotonic	B-D_ASE
dystrophy	I-D_ASE
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
expanded	O
CTG	O
repeat	O
.	O

Using	O
methylation	O
-	B-DRUG
sensitive	O
restriction	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	B-DRUG
pattern	O
on	O
the	B-DRUG
5	O
side	O
of	B-DRUG
the	O
CTG	O
repeat	O
in	O
the	O
DMPK	O
gene	O
of	B-DRUG
normal	O
individuals	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	B-D_ASE
dystrophy	I-D_ASE
,	O
showing	B-DRUG
expansions	O
of	O
the	O
repetitive	O
sequence	O
.	O

The	O
gene	O
segment	O
analyzed	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
carrying	O
exons	O
11	O
-	O
15	O
.	O

There	O
is	O
constitutive	O
methylation	O
in	O
intron	O
12	O
at	O
restriction	O
sites	B-DRUG
of	O
SacII	O
and	O
HhaI	O
,	B-DRUG
localized	O
1	O
,	O
159	O
-	O
1	O
,	O
232	O
bp	O
upstream	O
of	B-DRUG
the	O
CTG	O
repeat	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
HhaI	O
,	O
and	O
HpaII	O
in	O
this	O
region	O
are	B-DRUG
unmethylated	O
,	O
in	O
normal	O
individuals	O
and	O
most	O
of	O
the	O
patients	O
.	O

In	O
a	O
number	O
of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
however	O
,	O
complete	O
methylation	O
of	O
these	O
restriction	O
sites	O
was	O
found	O
in	O
the	O
mutated	O
allele	O
.	O

In	O
most	O
of	O
these	O
patients	O
,	O
the	O
onset	O
of	O
the	O
disease	O
was	O
congenital	O
.	O

Preliminary	O
in	B-DRUG
vivo	B-DRUG
footprinting	O
data	O
gave	O
evidence	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
normal	O
genes	O
at	O
an	O
Sp1	O
consensus	O
binding	O
site	O
upstream	B-DRUG
of	O
the	O
CTG	O
repeat	B-DRUG
and	O
for	O
a	O
significant	O
reduction	O
of	O
this	O
interaction	O
in	O
cells	O
with	O
a	O
hypermethylated	O
DMPK	O
gene	O
.	O
.	O

The	O
hemochromatosis	B-D_ASE
gene	O
product	O
complexes	B-DRUG
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
binding	O
.	O

We	O
recently	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	O
hereditary	B-D_ASE
hemochromatosis	I-D_ASE
called	O
HFE	O
.	O

The	O
gene	O
product	O
,	O
a	O
member	O
of	O
the	O
major	O
histocompatibility	O
complex	B-DRUG
class	O
I	O
-	B-DRUG
like	O
family	O
,	O
was	O
found	O
to	O
have	O
a	O
mutation	O
,	O
Cys	O
-	O
282	O
-	O
-	O
>	O
Tyr	O
(	O
C282Y	O
)	O
,	O
in	O
85	O
%	O
of	O
patient	O
chromosomes	O
.	O

This	B-DRUG
mutation	O
eliminates	B-DRUG
the	O
ability	O
of	B-DRUG
HFE	O
to	O
associate	O
with	O
beta2	O
-	O
microglobulin	O
(	O
beta2m	O
)	O
and	O
prevents	O
cell	O
-	O
surface	O
expression	O
.	O

A	O
second	O
mutation	O
that	O
has	O
no	O
effect	O
on	O
beta2m	O
association	O
,	O
H63D	O
,	O
was	O
found	O
in	O
eight	O
out	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
mutant	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
in	O
cultured	O
293	O
cells	O
overexpressing	O
wild	O
-	O
type	O
or	O
mutant	B-DRUG
HFE	O
proteins	O
that	O
both	O
the	O
wild	O
-	O
type	O
and	O
H63D	O
HFE	O
proteins	O
form	O
stable	B-DRUG
complexes	O
with	O
the	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
.	O

The	B-DRUG
C282Y	O
mutation	O
nearly	O
completely	O
prevents	B-DRUG
the	O
association	O
of	O
the	O
mutant	O
HFE	O
protein	O
with	O
the	O
TfR	O
.	O

Studies	O
on	O
cell	O
-	O
associated	O
transferrin	O
at	O
37	O
degrees	B-DRUG
C	O
suggest	O
that	O
the	O
overexpressed	O
wild	O
-	O
type	O
HFE	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	B-DRUG
TfR	O
for	O
transferrin	O
.	O

The	O
overexpressed	O
H63D	B-DRUG
protein	B-DRUG
does	O
not	O
have	O
this	O
effect	O
,	B-DRUG
providing	O
the	O
first	O
direct	B-DRUG
evidence	O
for	O
a	O
functional	O
consequence	O
of	O
the	O
H63D	O
mutation	O
.	B-DRUG

Addition	O
of	O
soluble	O
wild	O
-	O
type	O
HFE	O
/	O
beta2m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
the	O
apparent	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
steady	O
-	O
state	O
conditions	O
,	O
both	B-DRUG
in	O
293	O
cells	O
and	O
in	O
HeLa	O
cells	O
.	O

Furthermore	O
,	O
at	O
4	O
degrees	O
C	O
,	O
the	O
added	O
soluble	O
complex	O
of	O
HFE	O
/	O
beta2m	O
inhibited	O
binding	O
of	O
transferrin	O
to	O
HeLa	O
cell	B-DRUG
TfR	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Scatchard	O
plots	O
of	O
these	O
data	B-DRUG
indicate	O
that	O
the	O
added	O
heterodimer	O
substantially	O
reduced	O
the	O
affinity	O
of	O
TfR	O
for	O
transferrin	O
.	O

These	O
results	O
establish	O
a	O
molecular	O
link	O
between	O
HFE	O
and	B-DRUG
a	O
key	O
protein	O
involved	B-DRUG
in	O
iron	O
transport	O
,	O
the	O
TfR	O
,	O
and	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	B-DRUG
role	O
in	O
the	O
pathogenesis	O
of	O
hereditary	B-D_ASE
hemochromatosis	I-D_ASE
.	O
.	O

Genomic	B-DRUG
organization	O
of	B-DRUG
the	O
UBE3A	O
/	O
E6	O
-	O
AP	O
gene	O
and	O
related	O
pseudogenes	O
.	O

The	O
UBE3A	O
gene	O
encodes	O
the	O
E6	O
-	O
AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
recently	O
been	O
shown	B-DRUG
to	B-DRUG
be	O
mutated	O
in	O
Angelman	B-D_ASE
syndrome	I-D_ASE
patients	O
who	O
lack	O
15q11	O
-	O
q13	O
deletions	O
or	O
chromosome	O
15	O
paternal	O
uniparental	B-D_ASE
disomy	I-D_ASE
.	O

Previous	B-DRUG
UBE3A	O
cDNA	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
of	O
approximately	O
2	O
.	O

6	B-DRUG
kb	O
and	O
a	O
3	O
-	O
untranslated	O
region	O
(	O
UTR	B-DRUG
)	O
of	O
<	O
50	O
bp	O
,	O
whereas	O
Northern	O
analysis	O
has	O
indicated	O
mRNA	O
sizes	O
of	O
5	O
-	O
8	O
kb	O
.	O

We	O
have	O
analyzed	O
additional	O
cDNA	O
clones	O
and	O
provide	O
evidence	O
for	O
an	O
additional	O
0	O
.	O

5	O
kb	O
of	O
5	O
-	O
UTR	O
and	O
>	O
2	O
kb	O
of	O
3	O
-	O
UTR	O
.	O

We	O
have	O
established	O
the	O
genomic	O
organization	O
of	O
UBE3A	O
and	O
the	O
sequence	O
of	O
intron	O
-	O
exon	O
borders	B-DRUG
.	O

We	O
have	O
also	O
mapped	O
two	O
highly	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
,	O
to	O
chromosomes	O
2	O
and	O
21	B-DRUG
,	O
respectively	O
,	O
and	O
determined	O
their	O
genomic	O
organization	O
.	O

These	O
results	O
will	O
form	O
the	O
basis	O
for	O
studies	O
of	O
mutation	O
and	O
imprinting	O
of	O
UBE3A	O
.	B-DRUG

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B-D_ASE
disease	I-D_ASE
and	O
Bannayan	B-D_ASE
-	I-D_ASE
Zonana	I-D_ASE
syndrome	I-D_ASE
,	O
two	O
hamartoma	B-D_ASE
syndromes	I-D_ASE
with	O
germline	O
PTEN	O
mutation	O
.	O

The	O
tumour	B-D_ASE
suppressor	O
gene	B-DRUG
PTEN	O
,	O
which	O
maps	O
to	O
10q23	O
.	B-DRUG

3	O
and	O
encodes	O
a	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
was	O
shown	O
recently	O
to	O
play	O
a	O
broad	O
role	O
in	O
human	O
malignancy	B-D_ASE
.	O

Somatic	O
PTEN	O
deletions	O
and	B-DRUG
mutations	O
were	O
observed	B-DRUG
in	O
sporadic	B-D_ASE
breast	I-D_ASE
,	I-D_ASE
brain	I-D_ASE
,	I-D_ASE
prostate	I-D_ASE
and	I-D_ASE
kidney	I-D_ASE
cancer	I-D_ASE
cell	O
lines	O
and	O
in	O
several	O
primary	O
tumours	B-D_ASE
such	O
as	O
endometrial	B-D_ASE
carcinomas	I-D_ASE
,	O
malignant	B-D_ASE
melanoma	I-D_ASE
and	O
thyroid	B-D_ASE
tumours	I-D_ASE
.	O

In	O
addition	O
,	O
PTEN	O
was	O
identified	O
as	O
the	O
susceptibility	O
gene	O
for	O
two	O
hamartoma	B-D_ASE
syndromes	I-D_ASE
Cowden	B-D_ASE
disease	I-D_ASE
(	O
CD	B-D_ASE
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	B-D_ASE
-	I-D_ASE
Zonana	I-D_ASE
(	I-D_ASE
BZS	I-D_ASE
)	I-D_ASE
or	I-D_ASE
Ruvalcaba	I-D_ASE
-	I-D_ASE
Riley	I-D_ASE
-	I-D_ASE
Smith	I-D_ASE
syndrome	I-D_ASE
(	O
MIM	O
153480	O
)	O
.	O

Constitutive	O
DNA	O
from	O
37	O
CD	B-D_ASE
families	O
and	O
seven	O
BZS	B-D_ASE
families	O
was	O
screened	O
for	O
germline	O
PTEN	O
mutations	O
.	O

PTEN	O
mutations	O
were	O
identified	O
in	O
30	O
of	O
37	O
(	O
81	O
%	O
)	O
CD	B-D_ASE
families	O
,	O
including	O
missense	B-DRUG
and	O
nonsense	O
point	O
mutations	O
,	O
deletions	O
,	O
insertions	O
,	O
a	B-DRUG
deletion	O
/	O
insertion	O
and	O
splice	B-DRUG
site	O
mutations	O
.	O

These	O
mutations	O
were	O
scattered	O
over	O
the	O
entire	O
length	O
of	O
PTEN	O
,	B-DRUG
with	O
the	O
exception	O
of	O
the	O
first	O
,	O
fourth	O
and	B-DRUG
last	O
exons	O
.	O

A	O
hot	O
spot	O
for	O
PTEN	O
mutation	O
in	O
CD	B-D_ASE
was	O
identified	O
in	O
exon	O
5	O
that	O
contains	O
the	O
PTPase	O
core	B-DRUG
motif	O
,	O
with	O
13	O
of	O
30	O
(	O
43	O
%	O
)	O
CD	B-D_ASE
mutations	O
identified	O
in	O
this	O
exon	B-DRUG
.	O

Seven	O
of	O
30	O
(	O
23	O
%	O
)	O
were	O
within	O
the	O
core	O
motif	O
,	O
the	O
majority	O
(	O
five	O
of	O
seven	O
)	O
of	O
which	O
were	O
missense	O
mutations	O
,	O
possibly	O
pointing	O
to	O
the	O
functional	O
significance	O
of	O
this	O
region	O
.	O

Germline	O
PTEN	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	B-DRUG
BZS	B-D_ASE
families	O
studied	B-DRUG
.	O

Interestingly	O
,	O
none	O
of	O
these	O
mutations	O
was	O
observed	O
in	O
the	O
PTPase	O
core	O
motif	O
.	O

It	O
is	O
also	O
worthy	O
of	O
note	O
that	O
a	O
single	O
nonsense	O
point	O
mutation	O
,	O
R233X	O
,	O
was	O
observed	O
in	O
the	O
germline	O
DNA	O
from	O
two	O
unrelated	O
CD	B-D_ASE
families	B-DRUG
and	O
one	O
BZS	B-D_ASE
family	O
.	O

Genotype	O
-	O
phenotype	O
studies	O
were	B-DRUG
not	O
performed	O
on	O
this	O
small	O
group	O
of	O
BZS	B-D_ASE
families	O
.	O

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	B-D_ASE
families	O
revealed	O
two	O
possible	O
associations	B-DRUG
worthy	O
of	O
follow	O
-	O
up	O
in	O
independent	O
analyses	O
.	O

The	O
first	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
CD	B-D_ASE
families	O
with	O
breast	B-D_ASE
disease	I-D_ASE
.	O

A	O
correlation	O
was	O
observed	O
between	O
the	O
presence	O
/	O
absence	O
of	O
a	O
PTEN	O
mutation	O
and	O
the	O
type	O
of	O
breast	O
involvement	O
(	O
unaffected	O
versus	O
benign	O
versus	O
malignant	O
)	O
.	O

Specifically	O
and	O
more	O
directly	O
,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
malignant	B-D_ASE
breast	I-D_ASE
disease	I-D_ASE
.	O

Secondly	O
,	O
there	O
appeared	O
to	O
be	O
an	O
interdependent	O
association	B-DRUG
between	O
mutations	O
upstream	O
and	O
within	O
the	O
PTPase	O
core	O
motif	O
,	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	B-DRUG
mutations	O
,	O
and	O
the	O
involvement	B-DRUG
of	O
all	O
major	O
organ	O
systems	O
(	O
central	O
nervous	B-DRUG
system	O
,	B-DRUG
thyroid	O
,	O
breast	O
,	O
skin	O
and	O
gastrointestinal	B-DRUG
tract	O
)	O
.	O

However	O
,	O
these	O
observations	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
number	O
of	O
CD	B-D_ASE
families	O
.	O

Molecular	O
defects	O
leading	O
to	O
human	O
complement	B-D_ASE
component	I-D_ASE
C6	I-D_ASE
deficiency	I-D_ASE
in	O
an	O
African	O
-	O
American	O
family	O
.	O

Complement	B-D_ASE
component	I-D_ASE
C6	I-D_ASE
deficiency	I-D_ASE
(	O
C6D	B-D_ASE
)	O
was	O
diagnosed	O
in	O
a	O
16	O
-	O
year	O
-	O
old	O
African	O
-	O
American	O
male	O
with	O
meningococcal	B-D_ASE
meningitis	I-D_ASE
.	O

The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	B-D_ASE
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	B-D_ASE
or	O
other	O
neisserial	B-D_ASE
infection	I-D_ASE
.	O

By	O
using	O
exon	O
-	B-DRUG
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
as	O
a	O
screening	O
step	O
and	B-DRUG
nucleotide	O
sequencing	O
of	O
target	O
exons	O
,	O
we	O
determined	O
that	O
the	O
proband	O
was	O
a	O
compound	O
heterozygote	B-DRUG
for	O
two	O
C6	O
gene	B-DRUG
mutations	O
.	O

The	O
first	O
,	O
1195delC	O
located	O
in	O
exon	O
7	O
,	O
is	O
a	O
novel	O
mutation	O
,	O
while	O
the	O
second	O
,	O
1936delG	O
in	O
exon	O
12	O
,	O
has	O
been	B-DRUG
described	O
before	O
to	O
cause	O
C6D	B-D_ASE
in	O
an	O
unrelated	O
African	O
-	O
American	O
individual	O
.	O

Both	O
mutations	O
result	O
in	O
premature	O
termination	O
codons	O
and	O
C6	O
null	B-DRUG
alleles	O
.	O

Allele	O
-	O
specific	O
PCR	O
indicated	O
that	O
the	O
probands	O
two	B-DRUG
brothers	O
also	O
inherited	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
mother	O
and	O
the	O
1936delG	O
mutation	O
from	O
their	O
homozygous	O
father	O
.	O
.	O

PAX6	O
mutations	O
reviewed	O
.	O

Mutations	O
in	O
PAX6	O
are	O
responsible	O
for	O
human	O
aniridia	B-D_ASE
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
Peters	B-D_ASE
anomaly	I-D_ASE
,	O
with	O
congenital	B-D_ASE
cataracts	I-D_ASE
,	O
with	O
autosomal	B-D_ASE
dominant	I-D_ASE
keratitis	I-D_ASE
,	O
and	O
with	O
isolated	B-D_ASE
foveal	I-D_ASE
hypoplasia	I-D_ASE
.	O

No	O
locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B-D_ASE
,	O
and	O
PAX6	O
is	O
clearly	O
the	O
major	O
,	O
if	O
not	O
only	O
,	O
gene	O
responsible	O
.	O

Twenty	O
-	O
eight	O
percent	B-DRUG
of	O
identified	O
PAX6	O
mutations	O
are	O
C	O
-	O
T	O
changes	B-DRUG
at	O
CpG	O
dinucleotides	O
,	O
20	O
%	O
are	O
splicing	O
errors	O
,	O
and	O
more	O
than	O
30	O
%	O
are	O
deletion	B-DRUG
or	O
insertion	O
events	O
.	O

There	O
is	B-DRUG
a	O
noticeably	O
elevated	B-DRUG
level	O
of	O
mutation	O
in	B-DRUG
the	O
paired	O
domain	O
compared	O
with	O
the	O
rest	O
of	O
the	O
gene	O
.	O

Increased	O
mutation	O
in	O
the	O
homeodomain	O
is	O
accounted	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
.	O

Very	O
nearly	O
all	O
mutations	O
appear	B-DRUG
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
mutant	O
allele	O
,	O
and	O
more	O
than	O
80	O
%	O
of	O
exonic	O
substitutions	O
result	O
in	O
nonsense	O
codons	O
.	O

In	O
a	O
gene	O
with	O
such	O
extraordinarily	O
high	O
sequence	B-DRUG
conservation	O
throughout	O
evolution	O
,	O
there	O
are	B-DRUG
presumed	O
undiscovered	O
missense	O
mutations	O
,	O
these	O
are	O
hypothesized	O
to	O
exist	O
in	O
as	O
-	O
yet	O
unidentified	O
phenotypes	O
.	O
.	O

Genetic	O
heterogeneity	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
in	O
breast	B-D_ASE
cancer	I-D_ASE
families	O
.	O

The	O
Breast	B-D_ASE
Cancer	I-D_ASE
Linkage	O
Consortium	B-DRUG
.	O

The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
inherited	B-D_ASE
breast	I-D_ASE
cancer	I-D_ASE
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	B-D_ASE
cancer	I-D_ASE
,	O
collected	O
by	O
the	O
Breast	B-D_ASE
Cancer	I-D_ASE
Linkage	O
Consortium	O
.	O

Families	O
were	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
ovarian	B-D_ASE
or	I-D_ASE
other	I-D_ASE
cancers	I-D_ASE
.	O

Overall	O
,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
in	O
an	O
estimated	O
52	O
%	B-DRUG
of	O
families	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
families	O
,	O
and	O
to	O
neither	O
gene	O
in	O
16	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
6	O
%	O
-	O
28	O
%	O
)	O
,	O
suggesting	O
other	O
predisposition	O
genes	O
.	O

The	O
majority	O
(	O
81	O
%	O
)	O
of	O
the	O
breast	B-D_ASE
-	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
families	O
were	O
due	O
to	O
BRCA1	O
,	B-DRUG
with	O
most	B-DRUG
others	O
(	B-DRUG
14	O
%	O
)	O
due	O
to	O
BRCA2	O
.	O

Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B-D_ASE
and	I-D_ASE
female	I-D_ASE
breast	I-D_ASE
cancer	I-D_ASE
were	O
due	O
to	O
BRCA2	O
(	O
76	O
%	O
)	O
.	B-DRUG

The	O
largest	O
proportion	O
(	O
67	O
%	O
)	B-DRUG
of	O
families	O
due	B-DRUG
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
four	O
or	O
five	O
cases	O
of	O
female	O
breast	B-D_ASE
cancer	I-D_ASE
only	O
.	O

These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	B-DRUG
the	B-DRUG
assumed	O
penetrance	O
model	B-DRUG
for	O
BRCA1	O
or	O
by	O
including	O
or	O
excluding	O
BRCA1	O
mutation	O
data	O
.	O

Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
one	O
of	O
the	O
standard	O
screening	O
methods	O
,	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
or	O
splice	O
sites	O
in	O
an	O
estimated	O
63	O
%	O
(	O
95	B-DRUG
%	O
CI	O
51	O
%	B-DRUG
-	O
77	O
%	O
)	O
.	O

The	O
estimated	B-DRUG
sensitivity	O
was	O
identical	O
for	O
direct	O
sequencing	O
and	O
other	O
techniques	O
.	O

The	O
penetrance	O
of	O
BRCA2	O
was	B-DRUG
estimated	O
by	O
maximizing	O
the	O
LOD	O
score	O
in	O
BRCA2	O
-	O
mutation	O
families	O
,	O
over	O
all	O
possible	O
penetrance	O
functions	O
.	O

The	O
estimated	O
cumulative	O
risk	O
of	O
breast	B-D_ASE
cancer	I-D_ASE
reached	O
28	O
%	O
(	O
95	O
%	B-DRUG
CI	O
9	O
%	B-DRUG
-	O
44	B-DRUG
%	O
)	O
by	O
age	O
50	O
years	O
and	O
84	O
%	O
(	O
95	O
%	O
CI	O
43	O
%	O
-	O
95	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O

The	O
corresponding	O
ovarian	B-D_ASE
cancer	I-D_ASE
risks	O
were	O
0	O
.	O

4	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	B-DRUG
-	O
1	O
%	O
)	O
by	O
age	O
50	B-DRUG
years	O
and	O
27	O
%	B-DRUG
(	O
95	O
%	O
CI	O
0	O
%	O
-	O
47	O
%	O
)	O
by	O
age	O
70	O
years	O
.	B-DRUG

The	O
lifetime	O
risk	O
of	O
breast	B-D_ASE
cancer	I-D_ASE
appears	O
similar	O
to	O
the	O
risk	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
suggestion	O
of	O
a	O
lower	O
risk	O
in	O
BRCA2	O
carriers	O
<	O
50	O
years	O
of	O
age	O
.	O

Eye	B-D_ASE
movement	I-D_ASE
abnormalities	I-D_ASE
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	B-D_ASE
ataxia	I-D_ASE
type	I-D_ASE
I	I-D_ASE
.	O

We	O
compared	O
horizontal	O
eye	O
movements	O
(	O
visually	O
guided	O
saccades	B-DRUG
,	B-DRUG
antisaccades	B-DRUG
,	B-DRUG
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	B-D_ASE
ataxias	I-D_ASE
type	I-D_ASE
I	I-D_ASE
spinocerebellar	B-D_ASE
ataxias	I-D_ASE
1	I-D_ASE
and	I-D_ASE
2	I-D_ASE
(	O
SCA1	B-D_ASE
,	O
n	O
=	O
11	O
;	O
SCA2	B-D_ASE
,	O
n	O
=	O
10	O
)	O
and	O
SCA3	B-D_ASE
/	O
Machado	B-D_ASE
-	I-D_ASE
Joseph	I-D_ASE
disease	I-D_ASE
(	O
MJD	B-D_ASE
)	B-DRUG
(	B-DRUG
n	O
=	O
16	O
)	O
.	O

In	O
SCA1	B-D_ASE
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
resulting	B-DRUG
in	O
hypermetria	B-D_ASE
.	O

The	O
smooth	O
pursuit	O
gain	O
was	O
decreased	B-DRUG
.	O

In	O
SCA2	B-D_ASE
,	O
saccade	O
velocity	O
was	O
markedly	O
decreased	O
.	O

The	O
percentage	O
of	O
errors	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
significantly	O
correlated	O
with	O
age	O
at	O
disease	O
onset	O
.	O

In	O
addition	O
,	O
a	O
correlation	O
between	O
smooth	B-DRUG
pursuit	O
gain	O
and	O
the	O
number	O
of	O
trinucleotide	O
repeats	O
was	O
found	O
.	O

In	O
SCA3	B-D_ASE
,	O
gaze	B-D_ASE
-	I-D_ASE
evoked	I-D_ASE
nystagmus	I-D_ASE
was	O
often	O
present	O
as	O
was	O
saccade	O
hypometria	B-DRUG
and	O
smooth	O
pursuit	O
gain	O
was	O
markedly	O
decreased	O
.	O

Three	O
major	O
criteria	O
,	O
saccade	O
amplitude	O
,	O
saccade	O
velocity	O
,	O
and	O
presence	O
of	O
gaze	B-D_ASE
-	I-D_ASE
evoked	I-D_ASE
nystagmus	I-D_ASE
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
the	O
SCA1	B-D_ASE
,	O
90	O
%	O
of	O
the	O
SCA2	B-D_ASE
,	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
SCA3	B-D_ASE
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	B-D_ASE
,	O
SCA2	B-D_ASE
,	O
and	O
SCA3	B-D_ASE
at	O
early	B-DRUG
clinical	O
stages	O
of	O
the	O
diseases	O
.	O
.	B-DRUG

Genetic	O
basis	O
and	O
molecular	O
mechanism	O
for	O
idiopathic	B-D_ASE
ventricular	I-D_ASE
fibrillation	I-D_ASE
.	O

Ventricular	B-D_ASE
fibrillation	I-D_ASE
causes	O
more	O
than	O
300	O
,	O
000	O
sudden	O
deaths	O
each	O
year	O
in	O
the	O
USA	O
alone	O
.	O

In	O
approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	B-DRUG
non	O
-	B-DRUG
cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode	O
,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	B-D_ASE
ventricular	I-D_ASE
fibrillation	I-D_ASE
(	O
IVF	B-D_ASE
)	O
.	O

A	O
distinct	O
group	O
of	O
IVF	B-D_ASE
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
.	O

Because	B-DRUG
of	O
the	O
small	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
high	O
incidence	O
of	O
sudden	B-D_ASE
death	I-D_ASE
,	O
however	O
,	O
molecular	O
genetic	B-DRUG
studies	O
of	O
IVF	B-D_ASE
have	O
not	O
yet	O
been	O
done	O
.	O

Because	O
IVF	B-D_ASE
causes	O
cardiac	O
rhythm	O
disturbance	O
,	O
we	O
investigated	O
whether	O
malfunction	O
of	O
ion	B-DRUG
channels	O
could	O
cause	O
the	O
disorder	O
by	O
studying	O
mutations	O
in	O
the	O
cardiac	B-DRUG
sodium	O
channel	O
gene	O
SCN5A	O
.	O

We	O
have	O
now	O
identified	O
a	O
missense	O
mutation	O
,	O
a	O
splice	O
-	O
donor	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
SCN5A	O
in	O
three	O
IVF	B-D_ASE
families	O
.	O

We	O
show	O
that	O
sodium	O
channels	O
with	O
the	O
missense	O
mutation	O
recover	B-DRUG
from	O
inactivation	O
more	O
rapidly	O
than	O
normal	O
and	O
that	O
the	O
frameshift	O
mutation	O
causes	O
the	O
sodium	O
channel	O
to	O
be	O
non	O
-	O
functional	O
.	O

Our	O
results	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion	O
-	O
channel	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
IVF	B-D_ASE
.	O
.	O

Molecular	O
heterogeneity	B-DRUG
in	O
mucopolysaccharidosis	B-D_ASE
IVA	I-D_ASE
in	O
Australia	O
and	O
Northern	O
Ireland	O
:	O
nine	O
novel	O
mutations	O
including	O
T312S	O
,	O
a	O
common	O
allele	O
that	O
confers	O
a	O
mild	O
phenotype	O
.	O

Mucopolysaccharidosis	B-D_ASE
IVA	I-D_ASE
(	O
MPS	B-D_ASE
IVA	I-D_ASE
)	O
is	O
an	O
autosomal	B-D_ASE
recessive	I-D_ASE
lysosomal	I-D_ASE
storage	I-D_ASE
disorder	I-D_ASE
caused	O
by	O
a	O
genetic	B-D_ASE
defect	I-D_ASE
in	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

Previous	O
studies	O
of	O
patients	O
from	O
a	O
British	O
-	O
Irish	O
population	O
showed	B-DRUG
that	O
the	O
I113F	O
mutation	B-DRUG
is	O
the	O
most	O
common	O
single	O
mutation	O
among	O
MPS	B-D_ASE
IVA	I-D_ASE
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype	O
.	O

We	O
studied	O
mutations	O
in	B-DRUG
the	B-DRUG
GALNS	O
gene	O
from	O
23	O
additional	O
MPS	B-D_ASE
IVA	I-D_ASE
patients	O
(	O
15	O
from	O
Australia	O
,	O
8	O
from	O
Northern	O
Ireland	O
)	O
,	O
with	O
various	O
clinical	O
phenotypes	O
(	O
severe	O
,	B-DRUG
16	O
cases	O
;	O
intermediate	O
,	O
4	O
cases	O
;	O
mild	O
,	O
3	O
cases	O
)	O
.	O

We	O
found	O
two	O
common	O
mutations	O
that	O
together	O
accounted	O
for	O
32	O
%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
patients	O
.	O

One	O
is	B-DRUG
the	O
T312S	O
mutation	O
,	O
a	O
novel	O
mutation	O
found	O
exclusively	O
in	O
milder	O
patients	O
.	O

The	O
other	B-DRUG
is	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
a	O
severe	O
phenotype	O
.	O

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
%	O
)	O
and	O
6	O
(	O
14	O
%	O
)	O
of	O
44	O
unrelated	O
alleles	O
,	O
respectively	O
.	O

The	O
relatively	O
high	O
residual	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
an	O
explanation	O
for	O
the	O
mild	O
phenotype	O
in	O
patients	O
with	O
this	O
mutation	O
.	O

The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
mutations	O
in	O
Australia	O
corresponded	O
to	O
those	O
observed	O
in	O
Northern	O
Ireland	B-DRUG
and	O
are	O
unique	O
to	O
these	O
two	B-DRUG
populations	O
,	O
suggesting	O
that	O
both	O
mutations	B-DRUG
were	O
probably	O
introduced	O
to	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
19th	O
century	O
.	O

Haplotype	O
analysis	O
using	O
6	O
RFLPs	O
provides	O
additional	B-DRUG
data	B-DRUG
that	O
the	O
I113F	O
mutation	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

The	O
other	O
9	O
novel	B-DRUG
mutations	O
identified	O
in	O
these	O
23	O
patients	O
were	O
each	O
limited	O
to	O
a	O
single	O
family	B-DRUG
.	O

These	O
data	O
provide	O
further	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	O
MPS	B-D_ASE
IVA	I-D_ASE
in	B-DRUG
British	O
-	O
Irish	O
patients	O
and	O
provide	B-DRUG
evidence	O
for	B-DRUG
their	O
transmission	O
to	O
Australia	O
by	O
British	O
-	O
Irish	O
migrants	O
.	O
.	O

Identification	O
of	O
constitutional	O
WT1	O
mutations	B-DRUG
,	O
in	O
patients	O
with	O
isolated	O
diffuse	B-D_ASE
mesangial	I-D_ASE
sclerosis	I-D_ASE
,	O
and	O
analysis	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
by	O
use	B-DRUG
of	O
a	O
computerized	O
mutation	O
database	O
.	O

Constitutional	O
mutations	O
of	O
the	O
WT1	O
gene	O
,	O
encoding	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
involved	O
in	O
renal	O
and	O
gonadal	O
development	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys	B-D_ASE
-	I-D_ASE
Drash	I-D_ASE
syndrome	I-D_ASE
(	O
DDS	B-D_ASE
)	O
,	O
or	O
diffuse	B-D_ASE
mesangial	I-D_ASE
sclerosis	I-D_ASE
(	B-DRUG
DMS	B-D_ASE
)	O
associated	B-DRUG
with	O
pseudohermaphroditism	B-D_ASE
and	O
/	O
or	O
Wilms	B-D_ASE
tumor	I-D_ASE
(	O
WT	B-D_ASE
)	O
.	O

Most	O
mutations	O
in	O
DDS	B-D_ASE
patients	O
lie	O
in	O
exon	O
8	O
or	O
exon	O
9	B-DRUG
,	O
encoding	O
zinc	O
finger	O
2	O
or	O
zinc	O
finger	O
3	O
,	O
respectively	O
,	O
with	O
a	O
hot	O
spot	O
(	O
R394W	O
)	O
in	O
exon	O
9	O
.	O

We	O
analyzed	O
a	O
series	O
of	O
24	O
patients	O
,	O
10	B-DRUG
with	O
isolated	B-D_ASE
DMS	I-D_ASE
(	O
IDMS	B-D_ASE
)	O
,	O
10	O
with	O
DDS	B-D_ASE
,	O
and	O
4	O
with	O
urogenital	B-D_ASE
abnormalities	I-D_ASE
and	O
/	O
or	O
WT	B-D_ASE
.	O

We	O
report	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
,	O
4	O
of	O
whom	O
presented	O
with	O
IDMS	B-D_ASE
.	O

One	O
male	O
and	O
two	B-DRUG
female	O
IDMS	B-D_ASE
patients	O
with	O
WT1	O
mutations	O
underwent	O
normal	O
puberty	O
.	O

Two	O
mutations	O
associated	O
with	O
IDMS	B-D_ASE
are	O
different	O
from	O
those	O
described	O
in	O
DDS	B-D_ASE
patients	B-DRUG
.	O

No	O
WT1	O
mutations	B-DRUG
were	O
detected	O
in	O
the	O
six	O
other	O
IDMS	B-D_ASE
patients	O
,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
disease	O
.	O

We	O
analyzed	O
genotype	O
/	B-DRUG
phenotype	O
correlations	O
,	O
on	O
the	O
basis	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
mutation	O
database	O
of	O
84	O
germ	O
-	O
line	O
mutations	O
,	O
to	O
compare	O
the	O
distribution	O
and	O
type	O
of	O
mutations	O
,	O
according	O
to	O
the	O
different	O
symptoms	O
.	O

This	O
demonstrated	B-DRUG
(	O
1	O
)	O
the	O
association	O
between	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
and	O
DMS	B-D_ASE
;	O
(	O
2	O
)	B-DRUG
among	O
patients	O
with	O
DMS	B-D_ASE
,	O
a	O
higher	O
frequency	O
of	O
exon	O
8	O
mutations	O
among	O
46	O
,	O
XY	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
46	O
,	O
XY	O
patients	O
with	O
sexual	O
ambiguity	O
or	O
male	O
phenotype	O
;	O
and	B-DRUG
(	O
3	O
)	O
statistically	O
significant	O
evidence	O
that	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
preferentially	O
affect	O
amino	O
acids	O
with	O
different	O
functions	O
.	O
.	O

The	O
185delAG	O
BRCA1	O
mutation	O
originated	O
before	O
the	O
dispersion	O
of	O
Jews	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
Ashkenazim	O
.	O

The	O
185delAG	O
mutation	B-DRUG
in	B-DRUG
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	B-DRUG
Jews	O
both	O
in	O
familial	B-D_ASE
breast	I-D_ASE
and	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
and	O
in	B-DRUG
the	B-DRUG
general	O
population	O
.	O

All	O
tested	O
Ashkenazi	O
mutation	O
carriers	O
share	O
the	O
same	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
.	O

Our	O
previous	O
study	O
showed	B-DRUG
that	O
this	O
Ashkenazi	O
mutation	O
also	O
occurs	O
in	O
Iraqi	O
Jews	O
with	O
a	O
similar	O
allelic	O
pattern	O
.	O

We	O
extended	O
our	O
analysis	O
to	B-DRUG
other	O
non	O
-	O
Ashkenazi	O
subsets	O
354	O
of	O
Moroccan	O
origin	O
,	O
200	O
Yemenites	B-DRUG
and	O
150	O
Iranian	O
Jews	O
.	O

Heteroduplex	O
analysis	O
complemented	O
by	O
direct	B-DRUG
DNA	O
sequencing	O
of	O
abnormally	O
migrating	O
bands	O
were	O
employed	O
.	O

Four	O
of	O
Moroccan	O
origin	O
(	O
1	O
.	O
1	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
Iranians	O
was	O
a	O
carrier	O
of	O
the	O
185delAG	O
mutation	O
.	O

BRCA1	O
allelic	O
patterns	O
were	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non	O
-	O
Ashkenazi	B-DRUG
185delAG	O
mutation	O
carriers	O
who	O
had	O
breast	B-D_ASE
/	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
.	O

Six	O
non	O
-	O
Ashkenazi	O
individuals	O
shared	O
the	O
common	O
Ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
closely	O
related	O
pattern	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
6	O
)	O
displayed	O
a	O
distinct	O
BRCA1	O
allelic	O
pattern	O
.	O

We	B-DRUG
conclude	O
that	O
the	O
185delAG	O
BRCA1	O
mutation	O
occurs	O
in	O
some	O
non	O
-	O
Ashkenazi	O
populations	O
at	O
rates	O
comparable	O
with	O
that	O
of	O
Ashkenazim	O
.	O

The	O
majority	O
of	O
Jewish	O
185delAG	O
mutation	O
carriers	O
have	O
a	O
common	O
allelic	O
pattern	O
,	O
supporting	O
the	O
founder	O
effect	O
notion	O
,	O
but	O
dating	O
the	O
mutations	O
origin	O
to	O
an	O
earlier	O
date	O
than	O
currently	O
estimated	O
.	O

However	O
,	O
the	O
different	O
allelic	O
pattern	O
at	O
the	B-DRUG
BRCA1	O
locus	O
even	O
in	O
some	O
Jewish	O
mutation	O
carriers	O
,	O
might	O
suggest	O
that	O
the	O
mutation	O
arose	O
independently	O
.	O
.	O

Crystal	O
structure	O
of	O
the	O
hemochromatosis	B-D_ASE
protein	O
HFE	O
and	O
characterization	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor	O
.	O

HFE	O
is	O
an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B-D_ASE
-	I-D_ASE
overload	I-D_ASE
disease	I-D_ASE
hereditary	B-D_ASE
hemochromatosis	I-D_ASE
.	O

HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	B-DRUG
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
,	O
implicating	O
HFE	O
in	O
iron	O
metabolism	O
.	O

The	O
2	O
.	O

6	O
A	O
crystal	O
structure	O
of	B-DRUG
HFE	O
reveals	O
the	B-DRUG
locations	O
of	O
hemochromatosis	B-D_ASE
mutations	O
and	O
a	O
patch	O
of	O
histidines	O
that	O
could	O
be	O
involved	O
in	O
pH	O
-	O
dependent	O
interactions	O
.	O

We	O
also	O
demonstrate	O
that	O
soluble	O
TfR	O
and	O
HFE	O
bind	O
tightly	B-DRUG
at	O
the	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
,	O
but	O
not	O
at	O
the	O
acidic	O
pH	O
of	O
intracellular	O
vesicles	O
.	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	B-DRUG
1	O
)	O
differs	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
)	B-DRUG
,	O
implying	O
a	O
different	O
mode	O
of	O
binding	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
consistent	O
with	O
our	O
demonstration	O
that	O
HFE	O
,	O
transferrin	O
,	O
and	O
TfR	O
form	O
a	O
ternary	O
complex	O
.	O

Identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	B-D_ASE
disease	I-D_ASE
.	B-DRUG

Four	O
mutations	O
-	O
-	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
-	O
-	O
in	O
the	O
copper	O
-	O
transporting	O
enzyme	O
,	O
P	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
identified	B-DRUG
in	O
Korean	B-DRUG
Patients	O
with	O
Wilson	B-D_ASE
disease	I-D_ASE
.	O

Arg778Leu	O
,	O
the	O
most	O
frequently	B-DRUG
reported	O
mutation	O
of	O
this	O
enzyme	O
,	O
was	O
found	O
in	O
six	O
of	O
eight	O
unrelated	O
patients	O
studied	O
,	O
an	O
allele	O
frequency	O
of	O
37	B-DRUG
.	B-DRUG

5	O
%	O
,	O
which	O
is	O
considerably	O
higher	O
than	O
those	O
in	O
other	O
Asian	O
populations	O
.	O

The	O
novel	O
single	B-DRUG
nucleotide	O
deletion	O
,	O
2304delC	O
,	O
was	O
found	O
in	O
one	O
patient	O
.	O

Since	O
a	O
mutation	O
at	O
cDNA	O
nucleotide	O
2302	O
(	O
2302insC	O
)	O
had	B-DRUG
been	O
previously	O
described	O
,	O
this	O
region	O
of	O
the	O
ATP7B	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	O
Wilson	B-D_ASE
disease	I-D_ASE
.	O

Disruption	O
of	O
splicing	O
regulated	O
by	O
a	O
CUG	O
-	O
binding	O
protein	O
in	O
myotonic	B-D_ASE
dystrophy	I-D_ASE
.	O

Myotonic	B-D_ASE
dystrophy	I-D_ASE
(	O
DM	B-D_ASE
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	B-D_ASE
gene	O
.	O

One	O
model	O
of	O
DM	B-D_ASE
pathogenesis	O
suggests	O
that	O
RNAs	B-DRUG
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
by	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
.	O

Data	O
presented	B-DRUG
here	O
indicate	O
that	O
the	O
conserved	B-DRUG
heterogeneous	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
(	O
CUG	B-DRUG
-	O
BP	O
)	O
,	O
may	O
mediate	O
the	O
trans	O
-	O
dominant	O
effect	O
of	O
the	O
RNA	O
.	B-DRUG

CUG	O
-	O
BP	O
was	O
found	O
to	O
bind	O
to	O
the	B-DRUG
human	O
cardiac	O
troponin	O
T	O
(	O
cTNT	O
)	O
pre	O
-	O
messenger	O
RNA	O
and	O
regulate	O
its	O
alternative	O
splicing	O
.	O

Splicing	O
of	O
cTNT	O
was	O
disrupted	B-DRUG
in	O
DM	B-D_ASE
striated	O
muscle	O
and	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
repeats	O
.	O

Altered	O
expression	B-DRUG
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
may	O
contribute	O
to	O
DM	B-D_ASE
pathogenesis	O
.	O
.	B-DRUG

Identification	O
of	O
a	O
novel	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
II	O
gene	O
in	O
two	O
Spanish	B-DRUG
kindreds	O
with	O
familial	B-D_ASE
neurohypophyseal	I-D_ASE
diabetes	I-D_ASE
insipidus	I-D_ASE
.	O

Familial	B-D_ASE
neurohypophyseal	I-D_ASE
diabetes	I-D_ASE
insipidus	I-D_ASE
(	O
FNDI	B-D_ASE
)	O
is	O
an	O
autosomal	B-D_ASE
dominant	I-D_ASE
disease	I-D_ASE
caused	O
by	O
deficiency	O
in	O
the	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
-	O
NPII	O
)	O
gene	O
on	O
chromosome	O
20p13	O
.	O

In	B-DRUG
this	O
study	O
,	O
we	O
analyzed	O
two	O
families	B-DRUG
with	O
FNDI	B-D_ASE
using	B-DRUG
direct	O
automated	O
fluorescent	O
,	O
solid	O
phase	O
,	O
single	O
-	O
stranded	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
AVP	O
-	O
NPII	O
DNA	O
.	O

In	B-DRUG
one	O
of	O
the	O
families	O
,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
gene	O
,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	O
nucleotide	B-DRUG
2101	O
,	O
which	O
produces	O
a	O
stop	O
signal	O
in	O
codon	O
82	O
(	O
Glu	O
)	O
of	O
NPII	O
.	O

The	O
premature	O
termination	O
eliminates	O
part	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPII	O
,	O
including	O
a	O
cysteine	O
residue	O
in	O
position	O
85	O
,	O
which	O
could	O
be	O
involved	O
in	O
the	O
correct	O
folding	O
of	O
the	O
prohormone	O
.	O

In	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	O
position	O
-	O
1	O
of	O
the	O
signal	O
peptide	O
was	O
observed	O
in	O
all	O
affected	O
individuals	O
.	O

This	O
missense	O
mutation	O
,	O
which	O
replaces	O
Ala	O
with	O
Thr	O
,	O
is	O
frequent	O
among	O
FNDI	B-D_ASE
patients	B-DRUG
and	O
is	O
thought	O
to	O
reduce	O
the	O
efficiency	O
of	O
cleavage	O
by	O
signal	O
peptidases	O
.	O
.	O

Genetic	O
heterogeneity	O
of	O
Saethre	B-D_ASE
-	I-D_ASE
Chotzen	I-D_ASE
syndrome	I-D_ASE
,	O
due	O
to	O
TWIST	O
and	O
FGFR	O
mutations	O
.	O

Thirty	O
-	O
two	O
unrelated	O
patients	O
with	O
features	O
of	O
Saethre	B-D_ASE
-	I-D_ASE
Chotzen	I-D_ASE
syndrome	I-D_ASE
,	O
a	O
common	O
autosomal	B-D_ASE
dominant	I-D_ASE
condition	I-D_ASE
of	O
craniosynostosis	B-D_ASE
and	O
limb	B-D_ASE
anomalies	I-D_ASE
,	O
were	O
screened	O
for	O
mutations	O
in	O
TWIST	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
.	O

Nine	O
novel	O
and	B-DRUG
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
in	O
12	O
families	O
.	O

Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	B-DRUG
and	O
one	O
individual	O
was	O
found	O
to	O
have	O
an	O
FGFR2	O
VV269	B-DRUG
-	O
270	O
deletion	O
.	O

To	O
date	O
,	O
our	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	B-D_ASE
-	I-D_ASE
Chotzen	I-D_ASE
syndrome	I-D_ASE
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
mutations	O
.	O

More	O
than	O
35	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
in	B-DRUG
the	O
literature	O
.	O

The	O
most	O
common	O
phenotypic	O
features	O
,	O
present	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
TWIST	O
mutations	O
,	O
are	O
coronal	B-D_ASE
synostosis	I-D_ASE
,	O
brachycephaly	B-D_ASE
,	O
low	B-D_ASE
frontal	I-D_ASE
hairline	I-D_ASE
,	O
facial	B-D_ASE
asymmetry	I-D_ASE
,	O
ptosis	B-D_ASE
,	O
hypertelorism	B-D_ASE
,	O
broad	B-D_ASE
great	I-D_ASE
toes	I-D_ASE
,	O
and	O
clinodactyly	B-D_ASE
.	O

Significant	O
intra	O
-	O
and	O
interfamilial	O
phenotypic	O
variability	O
is	O
present	O
for	O
either	O
TWIST	O
mutations	O
or	O
FGFR	O
mutations	O
.	O

The	O
overlap	O
in	O
clinical	O
features	O
and	O
the	O
presence	O
,	B-DRUG
in	O
the	O
same	O
genes	O
,	O
of	O
mutations	O
for	O
more	O
than	O
one	O
craniosynostotic	B-D_ASE
condition	I-D_ASE
-	O
such	O
as	O
Saethre	B-D_ASE
-	I-D_ASE
Chotzen	I-D_ASE
,	I-D_ASE
Crouzon	I-D_ASE
,	I-D_ASE
and	I-D_ASE
Pfeiffer	I-D_ASE
syndromes	I-D_ASE
-	O
support	O
the	O
hypothesis	O
that	O
TWIST	O
and	O
FGFRs	O
are	O
components	O
of	O
the	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
limb	B-DRUG
development	O
in	O
humans	O
.	O
.	O

Mutation	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B-D_ASE
syndrome	I-D_ASE
patients	O
.	O

Angelman	B-D_ASE
syndrome	I-D_ASE
(	O
AS	B-D_ASE
)	O
is	O
caused	O
by	B-DRUG
chromosome	O
15q11	B-DRUG
-	O
q13	O
deletions	O
of	O
maternal	O
origin	O
,	O
by	O
paternal	O
uniparental	B-D_ASE
disomy	I-D_ASE
(	O
UPD	B-D_ASE
)	O
15	O
,	O
by	O
imprinting	O
defects	O
,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
gene	O
.	O

UBE3A	O
encodes	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
shows	O
brain	O
-	B-DRUG
specific	O
imprinting	O
.	O

Here	O
we	O
describe	O
UBE3A	O
coding	O
-	B-DRUG
region	O
mutations	O
detected	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	B-D_ASE
individuals	O
or	O
families	O
.	O

Two	O
identical	O
de	O
novo	O
5	O
-	O
bp	O
duplications	B-DRUG
in	O
exon	O
16	O
were	O
found	O
.	O

Among	B-DRUG
the	O
other	O
11	O
unique	O
mutations	O
,	O
8	O
were	O
small	O
deletions	O
or	B-DRUG
insertions	O
predicted	O
to	O
cause	O
frameshifts	O
,	O
1	O
was	O
a	O
mutation	O
to	B-DRUG
a	O
stop	O
codon	O
,	O
1	O
was	O
a	O
missense	O
mutation	O
,	O
and	O
1	O
was	O
predicted	O
to	O
cause	O
insertion	B-DRUG
of	O
an	O
isoleucine	O
in	O
the	O
hect	O
domain	O
of	O
the	O
UBE3A	O
protein	O
,	B-DRUG
which	O
functions	O
in	O
E2	O
binding	O
and	O
ubiquitin	O
transfer	O
.	O

Eight	O
of	O
the	O
cases	O
were	O
familial	O
,	O
and	O
five	O
were	O
sporadic	O
.	O

In	O
two	O
familial	O
cases	O
and	O
one	O
sporadic	O
case	O
,	O
mosaicism	O
for	O
UBE3A	O
mutations	O
was	O
detected	O
in	O
the	O
mother	O
of	O
three	O
AS	B-D_ASE
sons	O
,	O
in	O
the	O
maternal	O
grandfather	O
of	O
two	O
AS	B-D_ASE
first	O
cousins	O
,	O
and	B-DRUG
in	O
the	O
mother	O
of	O
an	O
AS	B-D_ASE
daughter	O
.	O

The	O
frequencies	B-DRUG
with	O
which	O
we	O
detected	O
mutations	O
were	O
5	O
(	O
14	O
%	O
)	O
of	O
35	O
in	O
sporadic	O
cases	O
and	O
8	O
(	O
80	O
%	O
)	O
of	O
10	O
in	O
familial	O
cases	O
.	O
.	O

The	O
hemochromatosis	B-D_ASE
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	B-DRUG
-	O
-	B-DRUG
>	B-DRUG
G	O
mutations	O
:	O
prevalence	O
in	O
non	O
-	O
Caucasian	O
populations	O
.	O

Hemochromatosis	B-D_ASE
,	O
the	B-DRUG
inherited	B-D_ASE
disorder	I-D_ASE
of	I-D_ASE
iron	I-D_ASE
metabolism	I-D_ASE
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B-D_ASE
overload	I-D_ASE
and	O
premature	B-D_ASE
death	I-D_ASE
.	O

The	O
hemochromatosis	B-D_ASE
gene	O
,	O
HFE	B-DRUG
,	O
recently	O
has	O
been	O
identified	B-DRUG
,	O
and	O
characterization	O
of	O
this	O
gene	O
has	O
shown	O
that	B-DRUG
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions	O
-	O
cDNA	O
nucleotides	O
845	O
G	O
-	O
-	O
>	O
A	O
(	O
C282Y	O
)	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
(	B-DRUG
H63D	O
)	O
.	O

Although	O
hemochromatosis	B-D_ASE
is	O
common	O
in	O
Caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
300	O
individuals	O
of	O
northern	O
European	O
origin	O
,	O
it	O
has	O
not	O
been	O
recognized	O
in	O
other	O
populations	O
.	O

The	O
present	O
study	O
used	O
PCR	O
and	O
restriction	O
-	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
frequency	O
of	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
and	O
187	O
C	O
-	O
-	O
>	O
G	O
mutations	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
non	O
-	O
Caucasian	O
populations	O
,	O
comprising	O
Australian	O
Aboriginal	O
,	O
Chinese	O
,	O
and	O
Pacific	O
Islanders	O
.	O

Results	O
showed	O
that	O
the	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	B-DRUG
was	O
present	O
in	O
these	O
populations	O
(	O
allele	O
frequency	O
0	O
.	B-DRUG
32	O
%	O
)	O
,	O
and	O
,	O
furthermore	O
,	O
it	O
was	O
always	O
seen	O
in	O
conjunction	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	B-DRUG
that	O
845	O
G	O
-	O
-	O
>	O
A	O
may	O
have	O
been	O
introduced	O
into	O
these	O
populations	O
by	O
Caucasian	O
admixture	O
.	O

187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
at	O
an	O
allele	O
frequency	O
of	O
2	O
.	O

68	O
%	O
in	O
the	O
two	O
populations	O
analyzed	O
(	O
Australian	O
Aboriginal	O
and	O
Chinese	B-DRUG
)	O
.	O

In	O
the	O
Australian	O
Aboriginal	O
samples	O
,	O
187	O
C	B-DRUG
-	O
-	O
>	O
G	O
was	O
found	O
to	O
be	O
associated	O
with	O
HLA	O
haplotypes	B-DRUG
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
it	O
was	O
introduced	O
by	O
recent	O
admixture	O
.	O

In	O
the	O
Chinese	O
samples	O
analyzed	O
,	O
187	O
C	O
-	O
-	O
>	O
G	O
was	O
present	O
in	O
association	O
with	O
a	O
wide	O
variety	O
of	O
HLA	O
haplotypes	O
,	O
showing	O
this	O
mutation	O
to	O
be	O
widespread	O
and	O
likely	O
to	B-DRUG
predate	O
the	O
more	O
genetically	O
restricted	O
845	O
G	O
-	O
-	O
>	O
A	O
mutation	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
in	O
attenuated	B-D_ASE
adenomatous	I-D_ASE
polyposis	I-D_ASE
coli	I-D_ASE
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
tumor	B-D_ASE
suppressor	O
APC	O
are	O
implicated	O
in	O
attenuated	B-D_ASE
adenomatous	I-D_ASE
polyposis	I-D_ASE
coli	I-D_ASE
(	O
AAPC	B-D_ASE
)	O
,	O
a	O
variant	O
of	O
familial	B-D_ASE
adenomatous	I-D_ASE
polyposis	I-D_ASE
(	O
FAP	B-D_ASE
)	O
.	O

AAPC	B-D_ASE
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B-D_ASE
adenomas	I-D_ASE
and	O
a	B-DRUG
later	O
onset	B-DRUG
of	O
colorectal	B-D_ASE
cancer	I-D_ASE
(	O
age	O
>	O
40	O
years	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	B-DRUG
assess	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
AAPC	B-D_ASE
families	O
.	O

By	O
protein	O
-	O
truncation	O
test	O
(	O
PTT	O
)	O
assay	O
,	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	B-D_ASE
gene	O
was	O
screened	O
in	O
affected	O
individuals	O
from	O
11	O
AAPC	B-D_ASE
kindreds	O
,	O
and	O
their	O
phenotypic	O
differences	O
were	B-DRUG
examined	O
.	O

Five	O
novel	O
germ	O
-	O
line	O
APC	B-D_ASE
mutations	O
were	O
identified	O
in	O
seven	O
kindreds	O
.	O

Mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	B-D_ASE
gene	O
(	O
1	O
)	O
at	O
the	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5	O
,	O
(	O
2	O
)	O
within	O
exon	O
9	O
,	O
and	O
(	O
3	O
)	O
at	O
the	O
3	O
distal	O
end	O
of	O
the	O
gene	O
.	O

Variability	O
in	O
the	O
number	O
of	O
colorectal	B-D_ASE
adenomas	I-D_ASE
was	O
most	O
apparent	O
in	B-DRUG
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
and	O
upper	O
-	B-DRUG
gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O
them	O
.	O

In	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3	O
,	O
the	O
average	O
number	O
of	O
adenomas	B-D_ASE
tended	O
to	O
be	O
lower	O
than	B-DRUG
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
was	O
similar	O
.	O

In	O
all	O
AAPC	B-D_ASE
kindreds	O
,	O
a	O
predominance	O
of	O
right	O
-	O
sided	O
colorectal	B-D_ASE
adenomas	I-D_ASE
and	O
rectal	B-D_ASE
polyp	I-D_ASE
sparing	O
was	O
observed	O
.	O

No	B-DRUG
desmoid	B-D_ASE
tumors	I-D_ASE
were	O
found	O
in	O
these	O
kindreds	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
in	O
AAPC	B-D_ASE
families	O
,	O
the	B-DRUG
location	O
of	O
the	O
APC	B-D_ASE
mutation	O
may	O
partially	O
predict	O
specific	O
phenotypic	B-DRUG
expression	O
.	O

This	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical	O
-	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B-D_ASE
patients	O
.	O
.	O

Wilms	B-D_ASE
'	I-D_ASE
tumor	I-D_ASE
1	B-DRUG
and	O
Dax	O
-	O
1	O
modulate	O
the	O
orphan	O
nuclear	B-DRUG
receptor	O
SF	O
-	O
1	O
in	O
sex	O
-	O
specific	O
gene	O
expression	O
.	O

Products	O
of	O
steroidogenic	O
factor	O
1	O
(	O
SF	O
-	O
1	O
)	O
and	O
Wilms	B-D_ASE
tumor	I-D_ASE
1	O
(	O
WT1	O
)	O
genes	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O
sexual	O
differentiation	O
.	O

In	O
males	O
,	O
SF	O
-	O
1	O
participates	B-DRUG
in	O
sexual	O
development	O
by	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
inhibiting	O
substance	O
(	O
MIS	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
WT1	O
-	O
KTS	O
isoforms	O
associate	O
and	O
synergize	O
with	O
SF	O
-	O
1	O
to	O
promote	O
MIS	O
expression	O
.	O

In	O
contrast	O
,	O
WT1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	B-D_ASE
pseudohermaphroditism	I-D_ASE
in	O
Denys	B-D_ASE
-	I-D_ASE
Drash	I-D_ASE
syndrome	I-D_ASE
,	O
fail	O
to	O
synergize	O
with	O
SF	O
-	O
1	O
.	O

Additionally	O
,	O
the	O
X	O
-	O
linked	O
,	O
candidate	O
dosage	O
-	O
sensitive	O
sex	O
-	O
reversal	O
gene	O
,	O
Dax	B-DRUG
-	O
1	O
,	O
antagonizes	O
synergy	O
between	O
SF	O
-	O
1	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
direct	O
interaction	B-DRUG
with	O
SF	O
-	O
1	O
.	O

We	O
propose	O
that	O
WT1	O
and	O
Dax	O
-	O
1	O
functionally	O
oppose	O
each	O
other	O
in	O
testis	O
development	O
by	O
modulating	O
SF	O
-	B-DRUG
1	O
-	O
mediated	O
transactivation	O
.	O
.	O

A	O
mouse	O
model	O
for	B-DRUG
Prader	B-D_ASE
-	I-D_ASE
Willi	I-D_ASE
syndrome	I-D_ASE
imprinting	O
-	O
centre	O
mutations	O
.	O

Imprinting	O
in	O
the	O
15q11	O
-	O
q13	O
region	O
involves	O
an	B-DRUG
imprinting	O
centre	O
(	O
IC	O
)	O
,	O
mapping	O
in	O
part	O
to	O
the	O
promoter	O
and	O
first	O
exon	O
of	O
SNRPN	O
.	O

Deletion	B-DRUG
of	O
this	O
IC	B-DRUG
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
Prader	B-D_ASE
-	I-D_ASE
Willi	I-D_ASE
syndrome	I-D_ASE
(	O
PWS	B-D_ASE
)	O
.	B-DRUG

We	O
have	B-DRUG
created	O
two	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
PWS	B-D_ASE
and	O
the	O
mechanism	O
of	O
this	O
IC	O
.	O

Mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
Snrpn	O
are	O
phenotypically	O
normal	O
,	O
suggesting	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
induce	O
PWS	B-D_ASE
.	O

Mice	O
with	B-DRUG
a	O
larger	O
deletion	O
involving	O
both	O
Snrpn	O
and	B-DRUG
the	O
putative	O
PWS	O
-	O
IC	O
lack	O
expression	O
of	O
the	O
imprinted	O
genes	O
Zfp127	O
(	O
mouse	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
manifest	O
several	O
phenotypes	O
common	O
to	O
PWS	B-D_ASE
infants	O
.	O

These	O
data	O
demonstrate	O
that	O
both	O
the	O
position	O
of	O
the	O
IC	O
and	O
its	O
role	O
in	O
the	O
coordinate	O
expression	O
of	O
genes	O
is	O
conserved	O
between	O
mouse	O
and	O
human	O
,	O
and	O
indicate	O
that	O
the	O
mouse	O
is	O
a	O
suitable	O
model	O
system	O
in	O
which	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
in	O
this	O
region	O
of	O
the	O
genome	O
.	O
.	O

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
two	O
founder	O
mutations	O
4612del165	B-DRUG
and	O
7883del5	O
.	O

The	O
ATM	O
(	O
A	O
-	O
T	O
,	O
mutated	O
)	B-DRUG
gene	O
on	O
human	O
chromosome	O
11q22	O
.	O

3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	B-DRUG
for	O
the	O
human	O
recessive	B-D_ASE
disease	I-D_ASE
ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
(	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
)	O
.	O

In	O
order	O
to	O
define	O
the	O
types	O
of	O
disease	O
-	O
causing	O
ATM	B-DRUG
mutations	O
in	B-DRUG
Japanese	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
patients	O
as	O
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
hotspots	O
,	O
reverse	O
-	O
transcribed	O
RNA	O
derived	O
from	O
ten	O
patients	O
belonging	O
to	O
eight	O
unrelated	O
Japanese	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
families	O
was	O
analyzed	O
for	O
mutations	O
by	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
method	O
.	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
lead	O
to	O
exon	O
skipping	O
or	O
premature	O
protein	O
truncation	O
were	O
also	B-DRUG
predominant	O
in	O
our	O
mutants	O
.	O

Six	O
different	O
mutations	O
were	O
identified	O
on	O
12	O
of	O
the	O
16	O
alleles	O
examined	O
.	O

Four	O
were	O
deletions	O
involving	O
a	O
loss	O
of	O
a	O
single	O
exon	O
exon	O
7	O
,	O
exon	O
16	O
,	O
exon	O
33	B-DRUG
or	O
exon	O
35	O
.	O

The	O
others	O
were	O
minute	O
deletions	B-DRUG
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O
55	O
.	B-DRUG

The	O
mutations	O
4612del165	O
and	O
7883del5	O
were	O
found	O
in	O
more	O
than	O
two	O
unrelated	O
families	B-DRUG
;	O
44	O
%	O
(	B-DRUG
7	O
of	O
16	O
)	O
of	O
the	O
mutant	O
alleles	O
had	O
one	O
of	O
the	O
two	O
mutations	O
.	O

The	O
4612del165	O
mutations	O
in	O
three	O
different	B-DRUG
families	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
T	B-DRUG
-	O
-	O
>	O
A	O
substitution	O
at	O
the	O
splice	O
donor	O
site	O
in	O
intron	O
33	O
.	O

Microsatellite	O
genotyping	O
around	O
the	O
ATM	O
locus	O
also	O
indicated	O
that	O
a	O
common	O
haplotype	O
was	O
shared	O
by	O
the	O
mutant	O
alleles	O
in	O
both	O
mutations	O
.	O

This	O
suggests	O
that	O
these	O
two	O
founder	O
mutations	O
may	O
be	O
predominant	O
among	O
Japanese	O
ATM	O
mutant	O
alleles	O
.	O

W474C	O
amino	O
acid	O
substitution	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
and	O
is	O
associated	O
with	O
subacute	O
G	B-D_ASE
(	I-D_ASE
M2	I-D_ASE
)	I-D_ASE
gangliosidosis	I-D_ASE
.	O

Mutations	O
in	O
the	O
HEXA	O
gene	O
,	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
,	O
that	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
Tay	B-D_ASE
-	I-D_ASE
Sachs	I-D_ASE
disease	I-D_ASE
(	O
TSD	B-D_ASE
)	O
,	O
the	O
fatal	O
infantile	B-D_ASE
form	I-D_ASE
of	I-D_ASE
G	I-D_ASE
(	I-D_ASE
M2	I-D_ASE
)	I-D_ASE
gangliosidosis	I-D_ASE
,	I-D_ASE
Type	I-D_ASE
1	I-D_ASE
.	O

Less	O
severe	O
,	O
subacute	O
(	O
juvenile	O
-	O
onset	O
)	O
and	O
chronic	O
(	O
adult	O
-	O
onset	O
)	O
variants	O
are	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
are	O
associated	O
with	O
residual	B-DRUG
levels	O
of	O
Hex	O
A	O
enzyme	O
activity	O
.	O

We	O
identified	O
a	B-DRUG
1422	O
G	O
-	O
-	O
>	B-DRUG
C	O
(	O
amino	O
acid	O
W474C	O
)	O
substitution	O
in	O
the	O
first	O
position	O
of	O
exon	O
13	O
of	O
HEXA	O
of	O
a	O
non	B-DRUG
-	O
Jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
G	B-D_ASE
(	I-D_ASE
M2	I-D_ASE
)	I-D_ASE
gangliosidosis	I-D_ASE
.	O

On	O
the	O
second	B-DRUG
maternally	O
inherited	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
disease	O
-	B-DRUG
causing	O
4	O
-	O
bp	O
insertion	O
,	O
+	O
TATC	O
1278	O
,	O
in	O
exon	O
11	B-DRUG
.	O

Pulse	O
-	O
chase	O
analysis	O
using	O
proband	O
fibroblasts	O
revealed	O
that	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
precursor	O
was	O
normally	O
synthesized	O
,	O
but	O
not	O
phosphorylated	B-DRUG
or	O
secreted	O
,	O
and	O
the	O
mature	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
detected	O
.	B-DRUG

When	B-DRUG
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
was	O
transiently	O
co	O
-	O
expressed	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
produce	O
Hex	O
A	O
(	O
alphabeta	O
)	O
in	O
COS	O
-	O
7	O
cells	O
,	B-DRUG
the	O
mature	O
alpha	O
-	O
subunit	B-DRUG
was	O
present	O
,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	B-DRUG
from	O
normal	O
alpha	O
-	B-DRUG
subunit	O
transfections	O
,	O
although	O
higher	B-DRUG
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
associated	B-DRUG
with	O
infantile	O
TSD	B-D_ASE
.	O

Furthermore	O
,	O
the	O
precursor	O
level	B-DRUG
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
found	O
to	O
accumulate	O
in	O
comparison	O
to	O
the	O
normal	O
alpha	O
-	O
subunit	O
precursor	O
levels	O
.	O

We	O
conclude	O
that	O
the	O
1422	O
G	O
-	O
-	O
>	O
C	O
mutation	O
is	O
the	O
cause	O
of	O
Hex	B-D_ASE
A	I-D_ASE
enzyme	I-D_ASE
deficiency	I-D_ASE
in	O
the	O
proband	O
.	O

The	O
resulting	O
W474C	O
substitution	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
base	O
substitution	O
falls	B-DRUG
at	O
the	B-DRUG
first	O
position	O
of	O
exon	O
13	O
,	O
aberrant	O
splicing	O
may	B-DRUG
also	O
contribute	O
to	B-DRUG
Hex	B-D_ASE
A	I-D_ASE
deficiency	I-D_ASE
in	O
this	O
proband	O
.	O
.	O

Two	O
frequent	B-DRUG
missense	O
mutations	O
in	O
Pendred	B-D_ASE
syndrome	I-D_ASE
.	O

Pendred	B-D_ASE
syndrome	I-D_ASE
is	O
an	O
autosomal	B-D_ASE
recessive	I-D_ASE
disorder	I-D_ASE
characterized	O
by	O
early	O
childhood	O
deafness	B-D_ASE
and	O
goiter	B-D_ASE
.	O

A	O
century	B-DRUG
after	O
its	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
Pendred	O
,	O
the	O
disease	O
gene	O
(	O
PDS	O
)	O
was	O
mapped	O
to	O
chromosome	O
7q22	O
-	O
q31	O
.	O

1	O
and	O
,	O
recently	O
,	B-DRUG
found	O
to	O
encode	O
a	O
putative	O
sulfate	O
transporter	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
PDS	B-D_ASE
gene	O
in	O
patients	O
from	O
14	O
Pendred	B-D_ASE
families	O
originating	O
from	O
seven	O
countries	O
and	B-DRUG
identified	O
all	O
mutations	O
.	O

The	O
mutations	O
include	O
three	O
single	O
base	O
deletions	O
,	O
one	O
splice	O
site	O
mutation	O
and	O
10	O
missense	O
mutations	O
.	B-DRUG

One	O
missense	O
mutation	O
(	O
L236P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
five	O
additional	O
non	O
-	O
consanguineous	O
families	O
.	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
found	B-DRUG
in	O
a	O
homozygous	O
state	O
in	O
one	O
family	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
four	O
families	O
.	O

Pendred	B-D_ASE
patients	O
in	O
three	O
non	O
-	O
consanguineous	O
families	O
were	O
shown	O
to	B-DRUG
be	O
compound	O
heterozygotes	O
for	O
L236P	O
and	O
T416P	O
.	O

In	O
total	O
,	O
one	O
or	O
both	O
of	O
these	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
the	O
14	O
families	O
analyzed	O
.	O

The	O
identification	O
of	O
two	O
frequent	O
PDS	B-D_ASE
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	B-D_ASE
syndrome	I-D_ASE
.	O

Insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
L1	O
,	O
in	O
the	B-DRUG
DMD	B-D_ASE
gene	O
results	O
in	O
X	B-D_ASE
-	I-D_ASE
linked	I-D_ASE
dilated	I-D_ASE
cardiomyopathy	I-D_ASE
.	O

X	B-D_ASE
-	I-D_ASE
linked	I-D_ASE
dilated	I-D_ASE
cardiomyopathy	I-D_ASE
(	O
XLDCM	B-D_ASE
)	O
is	O
a	O
clinical	O
phenotype	B-DRUG
of	O
dystrophinopathy	B-D_ASE
which	O
is	O
characterized	O
by	O
preferential	O
myocardial	B-D_ASE
involvement	I-D_ASE
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	B-D_ASE
myopathy	I-D_ASE
.	B-DRUG

To	O
date	O
,	O
several	O
mutations	O
in	O
the	O
Duchenne	B-D_ASE
muscular	I-D_ASE
dystrophy	I-D_ASE
gene	O
,	O
DMD	O
,	O
have	O
been	O
identified	O
in	O
patients	O
with	O
XLDCM	B-D_ASE
,	O
but	O
a	O
pathogenic	O
correlation	O
of	O
these	O
cardiospecific	O
mutations	O
in	O
DMD	O
with	O
the	O
XLDCM	B-D_ASE
phenotype	O
has	B-DRUG
remained	O
to	O
be	O
elucidated	O
.	B-DRUG

We	B-DRUG
report	O
here	O
the	O
identification	O
of	O
a	O
unique	O
de	O
novo	O
L1	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
DMD	O
in	O
three	O
XLDCM	B-D_ASE
patients	O
from	O
two	O
unrelated	O
Japanese	O
families	O
.	O

The	O
insertion	O
was	O
a	O
5	O
-	O
truncated	O
form	O
of	B-DRUG
human	O
L1	O
inversely	O
integrated	O
in	O
the	O
5	O
-	O
untranslated	O
region	O
in	O
the	B-DRUG
muscle	O
exon	O
1	O
,	O
which	O
affected	O
the	O
transcription	O
or	O
the	O
stability	O
of	O
the	O
muscle	O
form	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
that	O
of	O
the	O
brain	O
or	O
Purkinje	O
cell	O
form	O
,	O
probably	O
due	B-DRUG
to	O
its	O
unique	O
site	O
of	O
integration	O
.	O

We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	B-DRUG
L1	O
sequence	O
in	O
DMD	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	B-DRUG
of	O
Japanese	O
patients	O
with	O
XLDCM	B-D_ASE
.	O
.	O

Severe	O
early	B-DRUG
-	B-DRUG
onset	O
obesity	B-D_ASE
,	O
adrenal	B-D_ASE
insufficiency	I-D_ASE
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
humans	O
.	O

Sequential	O
cleavage	O
of	O
the	O
precursor	O
protein	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
(	B-DRUG
ACTH	O
)	O
,	O
melanocyte	O
-	O
stimulating	O
hormones	O
(	O
MSH	O
)	O
alpha	O
,	O
beta	O
and	O
gamma	O
as	O
well	O
as	O
the	O
opioid	O
-	O
receptor	O
ligand	O
beta	O
-	O
endorphin	O
.	O

While	B-DRUG
a	O
few	O
cases	O
of	O
isolated	B-DRUG
ACTH	B-D_ASE
deficiency	I-D_ASE
have	O
been	O
reported	O
(	O
OMIM	O
201400	O
)	O
,	O
an	O
inherited	O
POMC	O
defect	O
has	O
not	O
been	O
described	O
so	O
far	O
.	O

Recent	O
studies	O
in	O
animal	O
models	B-DRUG
elucidated	O
a	O
central	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin	O
-	O
4	O
-	O
receptor	B-DRUG
(	O
MC4	O
-	O
R	O
;	O
refs	O
3	O
-	O
5	O
)	O
and	B-DRUG
the	O
linkage	O
of	O
human	O
obesity	B-D_ASE
to	O
chromosome	B-DRUG
2	O
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus	O
,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
POMC	O
with	O
human	O
obesity	B-D_ASE
.	O

The	O
dual	B-DRUG
role	O
of	O
alpha	O
-	B-DRUG
MSH	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
hair	O
pigmentation	O
predicts	O
that	B-DRUG
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
in	O
POMC	O
function	O
would	O
include	O
obesity	B-D_ASE
,	B-DRUG
alteration	O
in	O
pigmentation	O
and	O
ACTH	B-D_ASE
deficiency	I-D_ASE
.	O

The	O
observation	O
of	O
these	O
symptoms	O
in	O
two	O
probands	O
prompted	O
us	O
to	O
search	O
for	O
mutations	O
within	O
their	O
POMC	O
genes	O
.	B-DRUG

Patient	O
1	O
was	O
found	O
to	O
be	O
a	B-DRUG
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	B-DRUG
(	O
G7013T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
appropriate	B-DRUG
synthesis	O
of	O
ACTH	O
and	O
alpha	O
-	O
MSH	O
.	B-DRUG

Patient	O
2	O
was	O
homozygous	O
for	B-DRUG
a	O
mutation	O
in	O
exon	O
2	O
(	O
C3804A	O
)	O
which	B-DRUG
abolishes	O
POMC	O
translation	O
.	O

These	O
findings	O
represent	O
the	O
first	O
examples	O
of	O
a	O
genetic	B-D_ASE
defect	I-D_ASE
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	B-D_ASE
endocrine	I-D_ASE
disorder	I-D_ASE
resulting	O
in	O
early	O
-	O
onset	O
obesity	B-D_ASE
,	O
adrenal	B-D_ASE
insufficiency	I-D_ASE
and	O
red	O
hair	O
pigmentation	O
.	O
.	O

A	O
European	O
multicenter	O
study	O
of	O
phenylalanine	B-D_ASE
hydroxylase	I-D_ASE
deficiency	I-D_ASE
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
general	O
system	O
for	O
genotype	O
-	O
based	O
prediction	O
of	O
metabolic	O
phenotype	O
.	O

Phenylketonuria	B-D_ASE
(	B-DRUG
PKU	B-D_ASE
)	O
and	O
mild	B-D_ASE
hyperphenylalaninemia	I-D_ASE
(	O
MHP	B-D_ASE
)	O
are	O
allelic	B-D_ASE
disorders	I-D_ASE
caused	O
by	B-DRUG
mutations	O
in	O
the	O
gene	O
encoding	B-DRUG
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
PAH	B-D_ASE
deficiency	I-D_ASE
correlate	O
with	O
PAH	O
genotypes	O
.	O

We	O
identified	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
seven	O
European	O
centers	O
.	O

On	O
the	O
basis	O
of	O
the	O
phenotypic	O
characteristics	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
105	O
of	O
the	O
mutations	O
were	O
assigned	O
to	O
one	O
of	O
four	O
arbitrary	O
phenotype	O
categories	O
.	O

We	O
proposed	O
and	B-DRUG
tested	O
a	O
simple	O
model	O
for	O
correlation	O
between	O
genotype	O
and	O
phenotypic	O
outcome	O
.	O

The	O
observed	O
phenotype	B-DRUG
matched	O
the	O
predicted	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
cases	O
,	O
and	O
in	O
only	O
5	O
of	O
184	O
patients	O
was	O
the	O
observed	B-DRUG
phenotype	O
more	O
than	O
one	O
category	O
away	O
from	O
that	O
expected	O
.	O

Among	O
the	O
seven	O
contributing	O
centers	O
,	O
the	O
proportion	O
of	O
patients	O
for	O
whom	O
the	O
observed	O
phenotype	O
did	O
not	O
match	O
the	O
predicted	O
phenotype	O
was	O
4	O
%	O
-	O
23	B-DRUG
%	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
suggesting	O
that	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
detection	O
or	O
phenotype	B-DRUG
classification	O
may	O
account	O
for	O
a	O
considerable	O
proportion	O
of	O
genotype	O
-	O
phenotype	O
inconsistencies	O
.	O

Our	O
data	O
indicate	O
that	B-DRUG
the	O
PAH	O
-	O
mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	B-D_ASE
deficiency	I-D_ASE
.	O

In	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
PAH	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B-D_ASE
in	O
newborns	O
.	O

Somatic	O
instability	O
of	O
the	O
CTG	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	O
myotonic	B-D_ASE
dystrophy	I-D_ASE
region	O
is	O
age	O
dependent	O
but	B-DRUG
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities	O
.	O

A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
the	O
3	O
-	O
untranslated	O
region	O
(	B-DRUG
UTR	O
)	O
of	O
the	O
DM	B-DRUG
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
is	O
responsible	O
for	O
causing	B-DRUG
myotonic	B-D_ASE
dystrophy	I-D_ASE
(	O
DM	B-D_ASE
)	O
.	O

Major	O
instability	O
,	B-DRUG
with	O
very	O
large	O
expansions	O
between	O
generations	O
and	O
high	O
levels	O
of	O
somatic	O
mosaicism	O
,	B-DRUG
is	O
observed	O
in	O
patients	O
.	O

There	B-DRUG
is	O
a	O
good	O
correlation	O
between	O
repeat	O
size	O
(	O
at	O
least	O
in	O
leucocytes	O
)	O
,	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

The	O
trinucleotide	B-DRUG
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	B-D_ASE
and	O
other	O
human	O
genetic	B-D_ASE
diseases	I-D_ASE
are	O
unknown	O
.	O

We	O
studied	O
somatic	O
instability	O
by	O
measuring	O
the	O
CTG	O
repeat	O
length	B-DRUG
at	O
several	O
ages	O
in	O
various	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	B-D_ASE
region	O
,	O
using	O
small	O
-	O
pool	O
PCR	O
.	O

These	O
mice	O
have	O
been	O
shown	O
to	B-DRUG
reproduce	O
the	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
the	O
55	O
CTG	B-DRUG
repeat	O
suggesting	O
that	O
surrounding	O
sequences	O
and	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	B-DRUG
instability	B-DRUG
mechanisms	O
.	O

As	O
observed	B-DRUG
in	O
some	O
of	O
the	O
tissues	O
of	O
DM	B-D_ASE
patients	O
,	O
there	O
is	O
a	O
tendency	O
for	O
repeat	O
length	B-DRUG
and	O
somatic	O
mosaicism	O
to	O
increase	O
with	O
the	O
age	O
of	O
the	O
mouse	O
.	O

Furthermore	O
,	B-DRUG
we	O
observed	O
no	O
correlation	O
between	O
the	O
somatic	O
mutation	O
rate	O
and	O
tissue	O
proliferation	O
capacity	O
.	O

The	O
somatic	O
mutation	O
rates	O
in	O
different	O
tissues	O
were	O
also	O
not	O
correlated	O
to	O
the	O
relative	O
inter	O
-	O
tissue	O
difference	O
in	O
transcriptional	O
levels	O
of	O
the	O
three	O
genes	O
(	O
DMAHP	O
,	O
DMPK	O
and	O
59	O
)	O
surrounding	O
the	O
repeat	B-DRUG
.	O
.	O

A	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B-D_ASE
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	B-D_ASE
phenotype	O
.	B-DRUG

We	O
have	O
used	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
individuals	O
from	O
a	B-DRUG
family	O
showing	O
mild	O
expression	O
of	O
the	O
retinoblastoma	B-D_ASE
phenotype	O
.	O

In	O
this	O
family	O
affected	O
individuals	O
developed	O
unilateral	B-D_ASE
tumors	I-D_ASE
and	O
,	O
as	O
a	B-DRUG
result	O
of	O
linkage	O
analysis	O
,	O
unaffected	B-DRUG
mutation	O
carriers	O
were	O
also	O
identified	O
within	O
the	O
pedigree	O
.	O

A	O
single	O
band	B-DRUG
shift	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	B-DRUG
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	B-DRUG
converting	O
a	O
cys	O
-	O
-	O
>	O
arg	O
at	O
nucleotide	O
position	O
28	O
in	O
the	O
exon	O
.	O

The	O
mutation	O
destroyed	O
an	O
NdeI	O
restriction	O
enzyme	O
site	O
.	O

Analysis	O
of	O
all	O
family	O
members	O
demonstrated	B-DRUG
that	O
the	O
missense	B-DRUG
mutation	O
co	O
-	O
segregated	O
with	O
patients	B-DRUG
with	O
tumors	B-D_ASE
or	O
who	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
had	O
been	O
predicted	O
to	O
carry	O
the	O
predisposing	O
mutation	O
.	O

These	O
observations	O
point	O
to	O
another	O
region	O
of	O
the	O
RB1	O
gene	O
where	O
mutations	O
only	B-DRUG
modify	O
the	O
function	O
of	O
the	O
gene	O
and	O
raise	O
important	O
questions	O
for	O
genetic	O
counseling	O
in	O
families	O
with	O
these	O
distinctive	O
phenotypes	O
.	O
.	O

Maternal	B-D_ASE
disomy	I-D_ASE
and	O
Prader	B-D_ASE
-	I-D_ASE
Willi	I-D_ASE
syndrome	I-D_ASE
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O
2	O
)	O
.	O

Maternal	B-D_ASE
uniparental	I-D_ASE
disomy	I-D_ASE
(	I-D_ASE
UPD	I-D_ASE
)	I-D_ASE
for	I-D_ASE
chromosome	I-D_ASE
15	I-D_ASE
is	O
responsible	O
for	O
an	O
estimated	O
30	O
%	O
of	O
cases	O
of	O
Prader	B-D_ASE
-	I-D_ASE
Willi	I-D_ASE
syndrome	I-D_ASE
(	O
PWS	B-D_ASE
)	O
.	B-DRUG

We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	B-D_ASE
disomy	I-D_ASE
15	I-D_ASE
in	O
PWS	B-D_ASE
that	O
is	O
most	O
consistent	O
with	O
adjacent	O
-	O
1	O
segregation	O
of	O
a	O
paternal	O
t	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	B-DRUG
;	O
q11	O
.	O
2	O
)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15	O
.	O

The	O
patient	O
(	O
J	B-DRUG
.	O
B	O
.	O
)	O
,	O
a	O
17	O
-	O
year	O
-	O
old	O
white	O
male	O
with	O
PWS	B-D_ASE
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary	B-DRUG
,	O
paternal	O
der	O
(	O
15	O
)	O
consisting	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
,	O
and	O
distal	O
chromosome	O
arm	O
3p	O
.	O

The	O
t	O
(	O
3	O
;	O
15	O
)	O
was	O
present	O
in	O
the	O
balanced	O
state	O
in	O
the	O
patients	O
father	O
and	O
a	O
sister	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
the	O
PWS	B-D_ASE
critical	O
region	O
resided	O
on	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	B-DRUG
deletion	O
of	O
the	O
PWS	B-D_ASE
region	O
on	O
the	O
normal	O
pair	O
of	O
15s	O
present	O
in	O
J	O
.	O

B	B-DRUG
.	O

Methylation	O
analysis	O
at	O
exon	O
alpha	O
of	O
the	O
small	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
showed	O
a	O
pattern	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J	O
.	O

B	O
.	O

Maternal	B-D_ASE
disomy	I-D_ASE
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
receptor	O
beta3	O
subunit	O
(	O
GABRB3	O
)	B-DRUG
locus	O
.	O

A	O
niece	O
(	O
B	O
.	O
B	O
.	O
)	O
with	O
45	O
chromosomes	O
and	O
the	O
derivative	O
3	O
but	O
without	O
the	O
der	O
(	O
15	O
)	O
demonstrated	O
a	O
phenotype	O
consistent	O
with	O
that	O
reported	O
for	O
haploinsufficiency	B-DRUG
of	O
distal	O
3	O
p	O
.	B-DRUG

Uniparental	B-D_ASE
disomy	I-D_ASE
associated	O
with	O
unbalanced	O
segregation	O
of	O
non	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
not	O
,	O
to	B-DRUG
our	O
knowledge	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	B-D_ASE
.	O

Furthermore	O
,	O
our	O
findings	O
are	O
best	O
interpreted	O
as	O
true	O
gamete	O
complementation	O
resulting	O
in	O
maternal	B-D_ASE
UPD	I-D_ASE
15	I-D_ASE
and	O
PWS	B-D_ASE

Schwartz	B-D_ASE
-	I-D_ASE
Jampel	I-D_ASE
syndrome	I-D_ASE
type	I-D_ASE
2	I-D_ASE
and	O
Stuve	B-D_ASE
-	I-D_ASE
Wiedemann	I-D_ASE
syndrome	I-D_ASE
:	O
a	O
case	O
for	O
"	O
lumping	O
"	O
.	O

Recent	O
studies	O
demonstrated	O
the	O
existence	O
of	O
a	O
genetically	O
distinct	O
,	O
usually	O
lethal	O
form	O
of	O
the	O
Schwartz	B-D_ASE
-	I-D_ASE
Jampel	I-D_ASE
syndrome	I-D_ASE
(	O
SJS	B-D_ASE
)	O
of	O
myotonia	B-D_ASE
and	O
skeletal	B-D_ASE
dysplasia	I-D_ASE
,	O
which	O
we	O
called	O
SJS	B-D_ASE
type	I-D_ASE
2	I-D_ASE
.	O

This	O
disorder	O
is	O
reminiscent	O
of	O
another	O
rare	O
condition	O
,	O
the	O
Stuve	B-D_ASE
-	I-D_ASE
Wiedemann	I-D_ASE
syndrome	I-D_ASE
(	O
SWS	B-D_ASE
)	O
,	O
which	O
comprises	O
campomelia	B-D_ASE
at	O
birth	O
with	O
skeletal	B-D_ASE
dysplasia	I-D_ASE
,	O
contractures	B-D_ASE
,	O
and	O
early	B-D_ASE
death	I-D_ASE
.	O

To	O
test	O
for	O
possible	B-DRUG
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	B-DRUG
patients	O
,	O
one	O
with	O
SJS	B-D_ASE
type	I-D_ASE
2	I-D_ASE
at	O
age	O
10	O
years	O
and	B-DRUG
another	O
with	O
SWS	B-D_ASE
at	O
age	O
7	O
years	B-DRUG
.	O

Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	B-D_ASE
or	O
SWS	B-D_ASE
presented	O
a	O
combination	O
of	O
a	O
severe	O
,	O
prenatal	O
-	O
onset	B-DRUG
neuromuscular	B-D_ASE
disorder	I-D_ASE
(	O
with	O
congenital	B-D_ASE
joint	I-D_ASE
contractures	I-D_ASE
,	O
respiratory	O
and	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	B-D_ASE
,	O
and	B-DRUG
frequent	O
death	O
in	O
infancy	O
)	O
with	O
a	O
distinct	O
campomelic	B-D_ASE
-	I-D_ASE
metaphyseal	I-D_ASE
skeletal	I-D_ASE
dysplasia	I-D_ASE
.	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
disorders	O
appear	O
to	O
be	O
a	O
single	O
entity	O
.	O

The	O
follow	O
-	O
up	O
observation	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
progressive	O
bone	B-D_ASE
dysplasia	I-D_ASE
in	O
the	O
two	O
patients	O
(	O
one	O
with	O
SJS	B-D_ASE
type	I-D_ASE
2	I-D_ASE
,	O
one	O
with	O
SWS	B-D_ASE
)	O
surviving	O
beyond	O
infancy	O
adds	O
to	O
the	O
evidence	O
in	O
favor	O
of	O
identity	O
.	O

The	O
hypothesis	O
that	O
SWS	B-D_ASE
and	O
SJS	B-D_ASE
type	I-D_ASE
2	I-D_ASE
are	O
the	B-DRUG
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
.	O
.	O

A	O
mouse	O
model	O
of	O
severe	O
von	B-D_ASE
Willebrand	I-D_ASE
disease	I-D_ASE
:	O
defects	O
in	O
hemostasis	O
and	O
thrombosis	B-D_ASE
.	O

von	B-D_ASE
Willebrand	I-D_ASE
factor	I-D_ASE
(	I-D_ASE
vWf	I-D_ASE
)	I-D_ASE
deficiency	I-D_ASE
causes	O
severe	O
von	B-D_ASE
Willebrand	I-D_ASE
disease	I-D_ASE
in	O
humans	O
.	O

We	O
generated	O
a	O
mouse	B-DRUG
model	O
for	O
this	O
disease	O
by	O
using	O
gene	O
targeting	O
.	O

vWf	B-D_ASE
-	I-D_ASE
deficient	I-D_ASE
mice	O
appeared	O
normal	O
at	O
birth	O
;	O
they	O
were	O
viable	O
and	O
fertile	B-DRUG
.	O

Neither	O
vWf	O
nor	O
vWf	O
propolypeptide	O
(	O
von	B-D_ASE
Willebrand	I-D_ASE
antigen	O
II	O
)	O
were	O
detectable	O
in	B-DRUG
plasma	O
,	O
platelets	O
,	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O
mice	O
.	O

The	O
mutant	O
mice	O
exhibited	B-DRUG
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
approximately	O
10	O
%	O
of	O
neonates	O
.	O

As	O
in	O
the	O
human	O
disease	O
,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
mice	O
was	B-DRUG
reduced	O
strongly	O
as	O
a	O
result	O
of	O
the	O
lack	O
of	O
protection	O
provided	O
by	O
vWf	O
.	O

Defective	O
thrombosis	B-D_ASE
in	O
mutant	O
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O
of	O
vascular	B-D_ASE
injury	I-D_ASE
.	O

In	O
this	O
model	O
,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
chloride	O
and	O
the	O
accumulation	O
of	O
fluorescently	O
labeled	O
platelets	O
was	O
observed	O
by	O
intravital	O
microscopy	O
.	O

We	O
conclude	O
that	O
these	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B-D_ASE
Willebrand	I-D_ASE
disease	I-D_ASE
and	O
will	O
be	O
very	B-DRUG
useful	O
for	O
investigating	O
the	O
role	B-DRUG
of	O
vWf	O
in	O
normal	O
physiology	O
and	O
in	O
disease	O
models	O
.	O
.	B-DRUG

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	B-DRUG
hereditary	B-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
.	O

Hereditary	B-D_ASE
Ovarian	I-D_ASE
Cancer	I-D_ASE
Clinical	O
Study	O
Group	O
.	O

BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
ovarian	B-D_ASE
cancer	I-D_ASE
.	O

Oral	O
contraceptives	O
protect	O
against	O
ovarian	B-D_ASE
cancer	I-D_ASE
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	B-DRUG
protect	O
against	O
hereditary	B-D_ASE
forms	I-D_ASE
of	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
.	O

METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	B-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
)	O
or	O
BRCA2	O
(	O
28	O
women	O
)	B-DRUG
.	O

The	O
control	O
women	O
were	O
enrolled	O
regardless	O
of	O
whether	O
or	O
not	O
they	B-DRUG
had	O
either	O
mutation	O
.	O

Lifetime	O
histories	O
of	O
oral	O
-	O
contraceptive	O
use	O
were	O
obtained	O
by	O
interview	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
and	O
control	O
women	B-DRUG
,	O
after	O
adjustment	O
for	O
year	O
of	O
birth	O
and	O
parity	O
.	O

RESULTS	O
The	B-DRUG
adjusted	O
odds	O
ratio	O
for	O
ovarian	B-D_ASE
cancer	I-D_ASE
associated	O
with	O
any	O
past	O
use	O
of	O
oral	O
contraceptives	O
was	O
0	O
.	O

5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	B-DRUG
0	O
.	O
8	O
)	O
.	O

The	O
risk	O
decreased	O
with	O
increasing	O
duration	O
of	O
use	O
(	O
P	O
for	O
trend	O
,	O
<	O
0	O
.	O
001	O
)	O
;	O
use	O
for	O
six	O
or	O
more	O
years	O
was	O
associated	O
with	B-DRUG
a	O
60	O
percent	O
reduction	O
in	O
risk	O
.	O

Oral	O
-	O
contraceptive	O
use	O
protected	O
against	O
ovarian	B-D_ASE
cancer	I-D_ASE
both	O
for	O
carriers	O
of	O
the	O
BRCA1	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
5	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
9	O
)	O
and	O
for	O
carriers	O
of	O
the	O
BRCA2	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	B-DRUG
.	O
4	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
2	O
to	O
1	O
.	O
1	O
)	O
.	O

CONCLUSIONS	O
Oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B-D_ASE
cancer	I-D_ASE
in	O
women	O
with	O
pathogenic	O
mutations	O
in	O
the	B-DRUG
BRCA1	O
or	O
BRCA2	O
gene	O

A	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B-D_ASE
with	O
a	O
codon	O
291	O
deletion	O
:	O
a	B-DRUG
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
and	O
genetic	O
report	O
.	O

We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B-D_ASE
(	O
ALD	B-D_ASE
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(	O
delGAG	O
291	O
)	O
in	O
the	O
ALD	B-D_ASE
gene	O
.	O

A	O
variety	O
of	O
phenotypes	O
were	O
observed	O
within	O
this	O
family	O
.	O

While	O
the	O
proband	O
(	O
patient	O
1	O
)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
intermediate	O
type	O
of	B-DRUG
adult	O
cerebral	O
and	O
cerebello	O
-	O
brain	O
stem	O
forms	O
,	O
his	O
younger	O
brother	O
(	O
patient	O
2	O
)	O
and	O
nephew	O
(	O
patient	O
3	O
)	O
had	O
a	O
childhood	O
ALD	B-D_ASE
type	B-DRUG
.	O

Another	O
nephew	O
(	O
patient	O
4	O
)	O
of	O
patient	O
1	O
was	O
classified	O
as	O
having	O
an	O
adolescent	O
form	O
.	O

The	O
tau	O
level	O
in	O
the	B-DRUG
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
in	O
patient	O
1	O
was	O
as	O
high	O
as	O
that	O
of	O
patients	O
with	O
Alzheimers	B-D_ASE
disease	I-D_ASE
(	O
AD	B-D_ASE
)	O
.	O

His	B-DRUG
brain	O
magnetic	B-DRUG
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
abnormalities	B-D_ASE
in	I-D_ASE
the	I-D_ASE
bilateral	I-D_ASE
cerebellar	I-D_ASE
hemispheres	I-D_ASE
and	O
brain	O
stem	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter	B-DRUG
,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

In	B-DRUG
patients	O
2	O
and	O
3	O
,	O
the	O
autopsy	O
findings	O
showed	O
massive	B-DRUG
demyelination	B-D_ASE
of	I-D_ASE
the	I-D_ASE
cerebral	I-D_ASE
white	I-D_ASE
matter	I-D_ASE
with	O
sparing	O
of	B-DRUG
the	O
U	O
-	O
fibers	O
,	O
compatible	O
with	O
the	O
findings	O
of	B-DRUG
childhood	O
ALD	B-D_ASE
.	O

Oleic	O
and	O
erucic	B-DRUG
acids	O
(	O
Lorenzos	O
Oil	O
)	O
were	O
administered	O
to	O
patients	O
1	O
and	O
4	O
,	O
but	O
sufficient	O
effectiveness	O
was	O
not	O
obtained	O
.	O

The	O
findings	O
in	O
this	O
family	O
suggest	O
that	O
delGAG291	O
is	B-DRUG
part	B-DRUG
of	O
the	O
cause	O
of	O
Japanese	O
ALD	B-D_ASE
with	O
phenotypic	O
variations	O
.	O

Moreover	O
,	O
although	O
the	O
scale	O
of	B-DRUG
the	O
study	O
is	O
limited	O
,	O
there	O
is	B-DRUG
a	O
possibility	O
that	O
PET	O
can	O
detect	O
an	O
insidious	B-D_ASE
lesion	I-D_ASE
which	O
is	O
undetectable	O
by	O
computed	O
tomogram	O
(	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
that	O
the	O
higher	O
level	O
of	O
tau	O
reflects	O
the	O
process	O
of	O
neuronal	B-D_ASE
degeneration	I-D_ASE
in	O
ALD	B-D_ASE
.	O

Lorenzos	O
Oil	O
should	O
be	O
given	O
in	O
the	O
early	O
stage	O
.	O
.	O

Nonsense	O
mutation	O
in	O
exon	O
4	B-DRUG
of	O
human	O
complement	O
C9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	B-D_ASE
C9	I-D_ASE
deficiency	I-D_ASE
.	O

Deficiency	B-D_ASE
of	I-D_ASE
the	I-D_ASE
ninth	I-D_ASE
component	I-D_ASE
of	I-D_ASE
human	I-D_ASE
complement	I-D_ASE
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B-D_ASE
deficiency	I-D_ASE
in	O
Japan	O
but	O
is	O
rare	B-DRUG
in	O
other	O
countries	O
.	O

We	O
studied	O
the	O
molecular	O
basis	O
of	O
C9	B-D_ASE
deficiency	I-D_ASE
in	B-DRUG
four	O
Japanese	O
C9	B-D_ASE
-	I-D_ASE
deficient	I-D_ASE
patients	O
who	O
had	O
suffered	O
from	O
meningococcal	B-D_ASE
meningitis	I-D_ASE
.	O

Direct	O
sequencing	O
of	O
amplified	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
CGA	O
-	O
-	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
four	O
C9	B-D_ASE
-	I-D_ASE
deficient	I-D_ASE
individuals	O
.	O

An	B-DRUG
allele	O
-	O
specific	O
polymerase	B-DRUG
chain	O
reaction	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	B-DRUG
normal	O
and	O
mutant	O
alleles	O
indicated	O
that	O
all	O
the	O
four	O
patients	O
were	O
homozygous	O
for	O
the	O
mutation	O
in	O
exon	O
4	O
and	O
that	O
the	B-DRUG
parents	O
of	O
patient	O
2	O
were	O
heterozygous	O
.	O

The	O
common	O
mutation	O
at	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
Japanese	O
C9	B-D_ASE
deficiency	I-D_ASE
.	O
.	O

BRCA1	O
required	O
for	B-DRUG
transcription	B-DRUG
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
.	O

The	O
breast	B-D_ASE
and	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
susceptibility	B-DRUG
gene	O
BRCA1	O
encodes	O
a	O
zinc	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O

Association	B-DRUG
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
repair	O
protein	O
Rad51	O
and	O
changes	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
localization	O
of	O
the	O
protein	O
after	O
exposure	O
to	O
DNA	O
-	O
damaging	O
agents	O
are	O
consistent	B-DRUG
with	O
a	O
role	O
for	O
BRCA1	O
in	B-DRUG
DNA	O
repair	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
mouse	O
embryonic	O
stem	O
cells	B-DRUG
deficient	B-D_ASE
in	I-D_ASE
BRCA1	I-D_ASE
are	O
defective	O
in	O
the	O
ability	O
to	O
carry	O
out	O
transcription	O
-	O
coupled	B-DRUG
repair	O
of	O
oxidative	O
DNA	O
damage	O
,	O
and	O
are	O
hypersensitive	B-DRUG
to	O
ionizing	O
radiation	O
and	O
hydrogen	O
peroxide	O
.	O

These	O
results	O
suggest	O
that	O
BRCA1	O
participates	O
,	O
directly	O
or	O
indirectly	O
,	O
in	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	B-DRUG
.	O
.	O

Truncation	O
mutations	O
in	B-DRUG
the	O
transactivation	O
region	O
of	O
PAX6	O
result	O
in	O
dominant	O
-	O
negative	O
mutants	O
.	O

PAX6	O
is	O
a	O
transcription	O
factor	O
with	O
two	O
DNA	O
-	O
binding	O
domains	B-DRUG
(	O
paired	O
box	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-	O
rich	O
transactivation	O
domain	O
.	O

PAX6	O
regulates	O
eye	O
development	O
in	O
animals	O
ranging	O
from	O
jellyfish	O
to	O
Drosophila	B-DRUG
to	O
humans	O
.	O

Heterozygous	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
aniridia	B-D_ASE
,	O
Peters	B-D_ASE
anomaly	I-D_ASE
,	O
autosomal	B-D_ASE
dominant	I-D_ASE
keratitis	I-D_ASE
,	O
and	O
familial	B-D_ASE
foveal	I-D_ASE
dysplasia	I-D_ASE
.	O

It	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
PAX6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	B-D_ASE
is	O
caused	O
due	O
to	O
genetic	O
haploinsufficiency	O
.	O

However	O
,	O
several	O
truncation	B-DRUG
mutations	O
have	O
been	O
found	O
to	O
occur	O
in	O
the	O
C	O
-	O
terminal	B-DRUG
half	O
of	O
PAX6	O
in	B-DRUG
patients	O
with	O
Aniridia	B-D_ASE
resulting	O
in	O
mutant	O
proteins	O
that	O
retain	O
the	B-DRUG
DNA	O
-	O
binding	O
domains	O
but	O
have	O
lost	O
most	O
of	O
the	O
transactivation	O
domain	O
.	B-DRUG

It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	B-DRUG
behave	O
as	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
as	O
predicted	O
by	O
haploinsufficiency	O
.	O

Contrary	O
to	O
this	O
theory	O
,	O
our	O
data	O
showed	O
that	O
these	O
mutants	O
are	O
dominant	O
-	O
negative	O
in	O
transient	O
transfection	O
assays	O
when	O
they	O
are	O
coexpressed	B-DRUG
with	O
wild	O
-	O
type	O
PAX6	O
.	O

We	O
found	O
that	O
the	O
dominant	O
-	O
negative	O
effects	O
result	O
from	O
the	O
enhanced	O
DNA	O
binding	O
ability	O
of	O
these	O
mutants	O
.	O

Kinetic	O
studies	O
of	O
binding	O
and	O
dissociation	O
revealed	O
that	O
various	O
truncation	B-DRUG
mutants	O
have	O
3	O
-	O
5	O
-	O
fold	O
higher	O
affinity	O
to	O
various	O
DNA	O
-	O
binding	O
sites	O
when	B-DRUG
compared	O
with	O
the	O
wild	O
-	O
type	O
PAX6	O
.	O

These	O
results	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	B-DRUG
of	O
mutant	O
PAX6	O
in	O
causing	O
aniridia	B-D_ASE
.	O
.	O

Reversal	O
of	O
severe	O
hypertrophic	B-D_ASE
cardiomyopathy	I-D_ASE
and	O
excellent	O
neuropsychologic	O
outcome	O
in	O
very	B-D_ASE
-	I-D_ASE
long	I-D_ASE
-	I-D_ASE
chain	I-D_ASE
acyl	I-D_ASE
-	I-D_ASE
coenzyme	I-D_ASE
A	I-D_ASE
dehydrogenase	I-D_ASE
deficiency	I-D_ASE
.	O

Very	B-D_ASE
-	I-D_ASE
long	I-D_ASE
-	I-D_ASE
chain	I-D_ASE
acyl	I-D_ASE
-	I-D_ASE
coenzyme	I-D_ASE
A	I-D_ASE
dehydrogenase	I-D_ASE
(	I-D_ASE
VLCAD	I-D_ASE
)	I-D_ASE
deficiency	I-D_ASE
is	O
a	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
.	O

We	O
describe	O
the	O
outcome	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
with	O
VLCAD	B-D_ASE
deficiency	I-D_ASE
who	O
was	O
first	O
seen	O
at	O
5	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B-D_ASE
cardiomyopathy	I-D_ASE
,	O
hepatomegaly	B-D_ASE
,	O
encephalopathy	B-D_ASE
,	O
and	O
hypotonia	B-D_ASE
.	O

Biochemical	O
studies	O
indicated	O
VLCAD	B-D_ASE
deficiency	I-D_ASE
caused	O
by	O
a	O
stable	O
yet	O
inactive	O
enzyme	O
.	O

Molecular	O
genetic	B-DRUG
analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
1668	O
ACAG	O
1669	O
splice	O
site	O
mutation	O
.	O

After	O
initial	O
treatment	O
with	O
intravenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
thrived	O
on	O
a	O
low	O
-	O
fat	O
diet	O
supplemented	O
with	O
medium	O
-	O
chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	B-DRUG
of	O
fasting	O
.	B-DRUG

Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	B-DRUG
1	O
year	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
superior	O
range	O
for	O
age	O
.	O

Clinical	O
recognition	O
of	O
VLCAD	B-D_ASE
deficiency	I-D_ASE
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
cardiomyopathy	B-D_ASE
in	O
children	O
.	O
.	O

Cloning	O
of	O
a	O
novel	O
member	O
of	O
the	O
low	B-DRUG
-	O
density	O
lipoprotein	O
receptor	O
family	O
.	O

A	O
gene	O
encoding	O
a	O
novel	O
transmembrane	B-DRUG
protein	O
was	O
identified	O
by	O
DNA	O
sequence	O
analysis	O
within	O
the	O
insulin	B-D_ASE
-	I-D_ASE
dependent	I-D_ASE
diabetes	I-D_ASE
mellitus	I-D_ASE
(	O
IDDM	B-D_ASE
)	O
locus	O
IDDM4	O
on	O
chromosome	O
11q13	O
.	O

Based	O
on	O
its	O
chromosomal	O
position	B-DRUG
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	O
diabetes	B-D_ASE
.	O

The	O
gene	O
,	O
termed	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
related	O
protein	O
5	O
(	O
LRP5	O
)	O
,	O
encodes	O
a	O
protein	O
of	O
1615	O
amino	O
acids	O
that	O
contains	O
conserved	O
modules	O
which	O
are	O
characteristic	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
receptor	O
family	O
.	O

These	O
modules	O
include	O
a	O
putative	O
signal	B-DRUG
peptide	O
for	O
protein	O
export	O
,	O
four	B-DRUG
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
repeats	O
with	O
associated	O
spacer	O
domains	O
,	O
three	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
repeats	O
,	O
a	B-DRUG
single	O
transmembrane	B-DRUG
spanning	O
domain	O
,	O
and	O
a	O
cytoplasmic	O
domain	O
.	O

The	O
encoded	O
protein	O
has	O
a	O
unique	O
organization	O
of	O
EGF	O
and	O
LDLR	O
repeats	O
;	O
therefore	O
,	O
LRP5	O
likely	O
represents	O
a	O
new	O
category	O
of	O
the	O
LDLR	B-DRUG
family	O
.	O

Both	O
human	O
and	O
mouse	O
LRP5	O
cDNAs	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
mature	O
proteins	O
are	O
95	O
%	O
identical	O
,	O
indicating	O
a	O
high	O
degree	O
of	O
evolutionary	O
conservation	O
.	O
.	O

The	O
APC	B-D_ASE
variants	O
I1307K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	B-D_ASE
tumors	I-D_ASE
,	O
but	O
not	O
always	O
with	O
a	O
family	O
history	O
.	O

Classical	O
familial	B-D_ASE
adenomatous	I-D_ASE
polyposis	I-D_ASE
(	O
FAP	B-D_ASE
)	B-DRUG
is	O
a	O
high	O
-	O
penetrance	O
autosomal	B-D_ASE
dominant	I-D_ASE
disease	I-D_ASE
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	B-D_ASE
adenomas	I-D_ASE
and	I-D_ASE
carcinoma	I-D_ASE
and	O
that	O
results	O
from	O
truncating	O
mutations	O
in	O
the	O
APC	B-D_ASE
gene	O
.	O

A	O
variant	O
of	O
FAP	B-D_ASE
is	O
attenuated	B-D_ASE
adenomatous	I-D_ASE
polyposis	I-D_ASE
coli	I-D_ASE
,	O
which	O
results	O
from	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
5	O
and	B-DRUG
3	O
regions	O
of	O
the	O
APC	B-D_ASE
gene	O
.	O

Attenuated	B-D_ASE
adenomatous	I-D_ASE
polyposis	I-D_ASE
coli	I-D_ASE
patients	O
have	O
"	O
multiple	O
"	O
colorectal	B-D_ASE
adenomas	I-D_ASE
(	O
typically	O
fewer	O
than	B-DRUG
100	O
)	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B-D_ASE
.	O

Another	O
group	O
of	O
patients	B-DRUG
with	O
multiple	O
adenomas	B-D_ASE
has	O
no	B-DRUG
mutations	O
in	O
the	O
APC	B-D_ASE
gene	O
,	B-DRUG
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	O
a	O
locus	O
,	O
or	O
loci	O
,	O
elsewhere	O
in	O
the	O
genome	O
.	O

Recently	O
,	O
however	O
,	O
a	O
missense	O
variant	O
of	O
APC	B-D_ASE
(	O
I1307K	O
)	O
was	O
described	O
that	B-DRUG
confers	O
an	O
increased	O
risk	O
of	O
colorectal	B-D_ASE
tumors	I-D_ASE
,	O
including	O
multiple	O
adenomas	B-D_ASE
,	O
in	O
Ashkenazim	O
.	O

We	O
have	O
studied	O
a	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B-D_ASE
adenomas	I-D_ASE
and	I-D_ASE
/	I-D_ASE
or	I-D_ASE
carcinoma	I-D_ASE
and	O
analyzed	O
codons	O
1263	O
-	B-DRUG
1377	O
(	O
exon	O
15G	O
)	O
of	O
the	O
APC	B-D_ASE
gene	O
for	B-DRUG
germ	O
-	O
line	O
variants	O
.	O

Three	O
patients	O
with	O
the	O
I1307K	O
allele	O
were	O
detected	O
,	O
each	O
of	O
Ashkenazi	O
descent	O
.	O

Four	O
patients	O
had	O
a	O
germ	O
-	O
line	O
E1317Q	B-DRUG
missense	O
variant	O
of	O
APC	O
that	O
was	B-DRUG
not	O
present	O
in	O
controls	O
;	O
one	O
of	O
these	O
individuals	O
had	O
an	O
unusually	O
large	O
number	O
of	O
metaplastic	B-D_ASE
polyps	I-D_ASE
of	I-D_ASE
the	I-D_ASE
colorectum	I-D_ASE
.	O

There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ	O
-	O
line	O
variants	O
of	O
the	O
APC	B-D_ASE
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	O
multiple	O
colorectal	B-D_ASE
adenomas	I-D_ASE
and	I-D_ASE
carcinoma	I-D_ASE
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	B-DRUG
classical	O
FAP	B-D_ASE
,	O
and	O
possibly	O
with	O
importance	O
for	B-DRUG
colorectal	B-D_ASE
cancer	I-D_ASE
risk	O
in	O
the	O
general	O
population	O
.	B-DRUG
.	O

Genomic	O
structure	O
of	B-DRUG
the	O
human	O
congenital	B-D_ASE
chloride	I-D_ASE
diarrhea	I-D_ASE
(	O
CLD	B-D_ASE
)	O
gene	O
.	O

Congenital	B-D_ASE
chloride	I-D_ASE
diarrhea	I-D_ASE
(	O
CLD	B-D_ASE
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
transporter	O
.	O

We	O
report	O
here	O
the	O
complete	O
genomic	O
organization	O
of	O
the	O
human	O
CLD	B-D_ASE
gene	O
which	O
spans	O
approximately	O
39kb	O
,	O
and	O
comprises	O
21	B-DRUG
exons	O
.	O

All	O
exon	O
/	O
intron	O
boundaries	O
conform	O
to	O
the	O
GT	O
/	O
AG	O
rule	O
.	O

An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
shows	O
a	O
putative	B-DRUG
TATA	O
box	O
and	O
predicts	O
multiple	O
transcription	O
factor	O
binding	O
sites	O
.	O

The	O
genomic	O
structure	O
was	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
including	O
multiple	O
large	O
-	O
insert	O
libaries	O
and	O
genomic	B-DRUG
DNA	O
from	O
Finnish	O
CLD	B-D_ASE
patients	O
and	O
controls	O
.	O

Exon	O
-	O
specific	O
primers	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
screening	B-DRUG
studies	O
of	O
patients	O
with	O
the	O
disease	O
.	O

Genomic	O
sequencing	O
of	B-DRUG
a	O
BAC	B-DRUG
clone	O
H	O
_	O
RG364P16	O
revealed	O
the	O
presence	O
of	O
another	O
,	O
highly	B-DRUG
homologous	O
gene	O
3	O
of	O
the	O
CLD	B-D_ASE
gene	O
,	O
with	O
a	O
similar	O
genomic	O
structure	O
,	O
recently	O
identified	O
as	O
the	O
Pendred	B-D_ASE
syndrome	I-D_ASE
gene	O
(	O
PDS	B-D_ASE
)	O
.	O
.	O

The	O
APCI1307K	O
allele	O
and	O
cancer	B-D_ASE
risk	O
in	O
a	O
community	O
-	O
based	O
study	O
of	O
Ashkenazi	O
Jews	O
.	O

Mutations	O
in	O
APC	O
are	O
classically	O
associated	O
with	O
familial	B-D_ASE
adenomatous	I-D_ASE
polyposis	I-D_ASE
(	O
FAP	B-D_ASE
)	O
,	O
a	O
highly	O
penetrant	O
autosomal	B-D_ASE
dominant	I-D_ASE
disorder	I-D_ASE
characterized	O
by	O
multiple	O
intestinal	O
polyps	B-D_ASE
and	O
,	O
without	O
surgical	O
intervention	O
,	O
the	O
development	O
of	O
colorectal	B-D_ASE
cancer	I-D_ASE
(	O
CRC	B-D_ASE
)	O
.	O

APC	B-D_ASE
is	O
a	O
tumour	O
-	O
suppressor	O
gene	O
,	B-DRUG
and	O
somatic	O
loss	O
occurs	O
in	O
tumours	B-D_ASE
.	O

The	O
germline	O
T	O
-	O
to	O
-	O
A	O
transversion	O
responsible	O
for	O
the	B-DRUG
APC	B-DRUG
I1307K	B-DRUG
allele	O
converts	O
the	O
wild	O
-	O
type	O
sequence	O
to	O
a	O
homopolymer	O
tract	O
(	B-DRUG
A8	O
)	O
that	O
is	O
genetically	B-DRUG
unstable	B-DRUG
and	O
prone	O
to	O
somatic	O
mutation	O
.	O

The	O
I1307K	O
allele	O
was	O
found	O
in	O
6	O
.	B-DRUG

1	O
%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
of	O
Ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	B-DRUG
CRC	B-D_ASE
(	O
ref	O
.	O
2	O
)	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
I1307K	O
in	O
cancer	B-D_ASE
,	O
we	O
genotyped	O
5	O
,	O
081	O
Ashkenazi	O
volunteers	O
in	O
a	O
community	O
survey	O
.	O

Risk	O
of	B-DRUG
developing	O
colorectal	B-D_ASE
,	I-D_ASE
breast	I-D_ASE
and	I-D_ASE
other	I-D_ASE
cancers	I-D_ASE
were	O
compared	O
between	O
genotyped	O
I1307K	O
carriers	O
and	O
non	O
-	O
carriers	O
and	O
their	O
first	O
-	B-DRUG
degree	O
relatives	O
.	O

Sperm	B-DRUG
DNA	O
analysis	O
in	O
a	O
Friedreich	B-D_ASE
ataxia	I-D_ASE
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	B-D_ASE
gene	O
.	O

Friedreich	B-D_ASE
ataxia	I-D_ASE
is	O
usually	O
caused	B-DRUG
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
FRDA	B-D_ASE
gene	O
.	O

Occasionally	O
,	O
a	O
fully	O
expanded	O
allele	O
has	O
been	O
found	O
to	O
arise	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
triplet	O
repeats	O
.	O

We	O
have	O
examined	O
the	O
sperm	O
DNA	O
of	O
a	O
premutation	O
carrier	O
.	B-DRUG

This	O
mans	O
leucocyte	O
DNA	O
showed	O
one	O
normal	O
allele	O
and	O
one	O
allele	O
of	O
approximately	O
100	O
repeats	O
.	O

His	O
sperm	O
showed	O
an	O
expanded	O
allele	B-DRUG
in	O
a	O
tight	O
range	O
centering	O
on	O
a	O
size	O
of	O
approximately	O
320	O
trinucleotide	O
repeats	O
.	O

His	O
affected	O
son	O
has	O
repeat	O
sizes	O
of	O
1040	O
and	O
540	O
.	O

These	O
data	O
suggest	O
that	O
expansion	O
occurs	O
in	O
two	O
stages	O
,	O
the	O
first	O
during	O
meiosis	O
followed	O
by	O
a	O
second	O
mitotic	O
expansion	O
.	O

We	O
also	O
show	O
that	O
in	O
all	O
informative	O
carrier	O
father	O
to	O
affected	O
child	B-DRUG
transmissions	O
,	O
with	O
the	O
notable	O
exception	O
of	O
the	O
premutation	O
carrier	O
,	O
the	O
expansion	O
size	O
decreases	O
.	O
.	O

The	O
R496H	O
mutation	O
of	O
arylsulfatase	O
A	O
does	O
not	B-DRUG
cause	O
metachromatic	B-D_ASE
leukodystrophy	I-D_ASE
.	B-DRUG

Deficiency	B-D_ASE
of	I-D_ASE
arylsulfatase	I-D_ASE
A	I-D_ASE
(	O
ARSA	B-DRUG
)	O
enzyme	O
activity	O
causes	O
metachromatic	B-D_ASE
leukodystrophy	I-D_ASE
(	O
MLD	B-D_ASE
)	O
.	O

A	O
number	O
of	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	B-D_ASE
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	B-DRUG
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	B-D_ASE
(	O
Draghia	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	B-DRUG

We	O
have	O
investigated	O
the	B-DRUG
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
African	O
American	O
population	O
(	O
f	O
=	O
0	O
.	O
09	B-DRUG
,	O
n	O
=	O
61	B-DRUG
subjects	O
)	O
.	B-DRUG

The	O
ARSA	O
enzyme	O
activity	O
in	O
subjects	O
with	O
and	O
without	O
the	O
R496H	O
mutation	O
was	O
determined	O
and	O
found	O
to	O
be	O
normal	O
.	O

It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
ARSA	O
and	O
is	O
not	O
a	O
cause	O
of	O
MLD	B-D_ASE

Down	O
-	B-DRUG
regulation	O
of	B-DRUG
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B-D_ASE
cell	I-D_ASE
carcinoma	I-D_ASE
cell	O
lines	O
by	O
wild	O
-	O
type	O
von	B-D_ASE
Hippel	I-D_ASE
-	I-D_ASE
Lindau	I-D_ASE
transgenes	B-DRUG
.	O

To	O
discover	O
genes	O
involved	O
in	O
von	B-D_ASE
Hippel	I-D_ASE
-	I-D_ASE
Lindau	I-D_ASE
(	O
VHL	B-D_ASE
)	O
-	O
mediated	O
carcinogenesis	O
,	O
we	O
used	O
renal	B-D_ASE
cell	I-D_ASE
carcinoma	I-D_ASE
cell	O
lines	O
stably	O
transfected	O
with	B-DRUG
wild	O
-	O
type	O
VHL	O
-	O
expressing	O
transgenes	O
.	B-DRUG

Large	O
-	O
scale	O
RNA	O
differential	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
several	O
differentially	O
expressed	O
genes	O
,	O
including	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene	O
,	O
termed	O
CA12	O
.	O

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
pass	O
transmembrane	B-DRUG
CA	O
possessing	O
an	O
apparently	O
intact	O
catalytic	O
domain	O
in	O
the	O
extracellular	O
CA	O
module	B-DRUG
.	O

Reintroduced	O
wild	O
-	O
type	O
VHL	B-D_ASE
strongly	B-DRUG
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	B-D_ASE
cell	I-D_ASE
carcinoma	I-D_ASE
cell	O
lines	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
CA9	O
,	O
encoding	O
another	O
transmembrane	O
CA	O
with	O
an	O
intact	O
catalytic	O
domain	O
.	O

Although	O
both	O
domains	O
of	O
the	O
VHL	B-D_ASE
protein	O
contribute	O
to	O
regulation	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
alone	O
could	O
effectively	O
regulate	O
CA9	O
expression	O
.	O

We	O
mapped	O
CA12	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
15q22	O
and	O
17q21	O
.	O

2	O
respectively	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
human	O
cancers	B-D_ASE
.	O

Additional	O
experiments	O
are	O
needed	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
in	O
the	O
extracellular	B-DRUG
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B-D_ASE
cell	O
growth	B-DRUG
.	O

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B-D_ASE
mellitus	I-D_ASE
and	O
optic	B-D_ASE
atrophy	I-D_ASE
(	O
Wolfram	B-D_ASE
syndrome	I-D_ASE
)	O
.	O

Wolfram	B-D_ASE
syndrome	I-D_ASE
(	O
WFS	B-D_ASE
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	B-D_ASE
recessive	I-D_ASE
neurodegenerative	I-D_ASE
disorder	I-D_ASE
defined	O
by	O
young	O
-	O
onset	O
non	O
-	O
immune	O
insulin	B-D_ASE
-	I-D_ASE
dependent	I-D_ASE
diabetes	I-D_ASE
mellitus	I-D_ASE
and	O
progressive	O
optic	B-D_ASE
atrophy	I-D_ASE
.	O

Linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
confirmed	O
in	O
five	O
families	O
.	O

On	O
the	B-DRUG
basis	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
associated	O
haplotypes	O
,	O
the	O
WFS	B-D_ASE
gene	O
was	O
localized	O
to	O
a	B-DRUG
BAC	O
/	O
P1	B-DRUG
contig	O
of	B-DRUG
less	O
than	B-DRUG
250	O
kb	O
.	O

Mutations	O
in	O
a	O
novel	O
gene	O
(	O
WFS1	O
)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	B-D_ASE
families	O
,	O
and	O
these	O
mutations	O
were	O
associated	O
with	B-DRUG
the	O
disease	O
phenotype	O
.	O

WFS1	O
appears	O
to	O
function	B-DRUG
in	O
survival	O
of	O
islet	O
beta	O
-	O
cells	O
and	O
neurons	O
.	O
.	O

Stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	B-D_ASE
suppressor	O
genes	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
.	O

BRCA1	O
and	O
BRCA2	O
account	O
for	O
most	O
cases	O
of	O
familial	O
,	O
early	O
onset	O
breast	B-D_ASE
and	I-D_ASE
/	I-D_ASE
or	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
and	O
encode	O
products	O
that	O
each	O
interact	O
with	O
hRAD51	O
.	O

Results	O
presented	O
here	O
show	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
complex	O
and	O
colocalize	O
in	O
subnuclear	O
foci	O
in	O
somatic	O
cells	O
and	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes	O
.	O

Like	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
replication	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
cells	O
to	O
hydroxyurea	O
or	O
UV	O
irradiation	O
.	O

Thus	O
,	O
BRCA1	O
and	O
BRCA2	O
participate	O
,	O
together	O
,	O
in	O
a	O
pathway	O
(	O
s	O
)	O
associated	O
with	O
the	B-DRUG
activation	O
of	O
double	O
-	O
strand	O
break	O
repair	O
and	O
/	O
or	O
homologous	O
recombination	O
.	O

Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	B-D_ASE
breast	I-D_ASE
and	I-D_ASE
/	I-D_ASE
or	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
.	O
.	O

A	O
novel	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	B-DRUG
CYP27	O
)	O
:	O
its	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
and	O
enzyme	O
activity	O
.	O

A	O
novel	O
C	O
to	B-DRUG
A	O
mutation	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
gene	O
(	O
CYP27	O
)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
CYP27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B-D_ASE
xanthomatosis	I-D_ASE
(	O
CTX	B-D_ASE
)	O
.	O

The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
responsible	O
for	O
deficiency	O
in	O
the	O
sterol	O
27	O
-	O
hydroxylase	O
activity	O
,	O
as	O
confirmed	O
by	O
expression	O
of	O
mutant	O
cDNA	O
into	O
COS	O
-	O
1	O
cells	O
.	O

Quantitative	O
analysis	O
showed	O
that	O
the	O
expression	O
of	O
CYP27	O
gene	O
mRNA	O
in	O
the	O
patient	O
represented	O
52	O
.	O

5	O
%	O
of	O
the	O
normal	O
level	O
.	O

As	O
the	O
mutation	O
occurred	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
(	O
-	O
2	O
position	O
of	O
exon	O
6	O
-	B-DRUG
intron	O
6	O
splice	O
site	O
)	O
of	O
the	O
gene	O
,	O
we	O
hypothesized	O
that	O
the	O
mutation	O
may	O
partially	O
affect	O
the	O
normal	O
splicing	O
efficiency	O
in	O
exon	O
6	O
and	O
cause	O
alternative	O
splicing	O
elsewhere	O
,	O
which	O
resulted	O
in	O
decreased	O
transcript	O
in	O
the	O
patient	O
.	O

Transfection	O
of	O
constructed	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutation	O
,	O
into	O
COS	O
-	O
1	O
cells	O
confirmed	O
that	B-DRUG
the	O
mutant	O
minigene	O
was	O
responsible	O
for	O
a	O
mRNA	B-DRUG
species	O
alternatively	O
spliced	O
at	O
an	O
activated	O
cryptic	O
5	O
splice	O
site	O
88	O
bp	O
upstream	O
from	O
the	O
3	O
end	O
of	O
exon	B-DRUG
6	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
C	O
to	O
A	O
mutation	O
at	O
the	B-DRUG
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
CYP27	O
gene	O
not	O
only	O
causes	B-DRUG
the	O
deficiency	B-D_ASE
in	I-D_ASE
the	I-D_ASE
sterol	I-D_ASE
27	I-D_ASE
-	I-D_ASE
hydroxylase	I-D_ASE
activity	I-D_ASE
,	O
but	O
also	O
partially	O
leads	O
to	O
alternative	O
pre	O
-	O
mRNA	O
splicing	O
of	O
the	O
gene	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
regarding	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
of	O
a	O
mutation	O
at	O
the	O
-	B-DRUG
2	O
position	O
of	O
a	O
5	B-DRUG
splice	O
site	O
.	O

ATM	O
germline	O
mutations	O
in	O
classical	O
ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
patients	O
in	O
the	O
Dutch	O
population	O
.	O

Germline	O
mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B-D_ASE
recessive	I-D_ASE
disorder	I-D_ASE
ataxia	B-D_ASE
-	I-D_ASE
telangiectasia	I-D_ASE
(	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
)	O
.	O

In	O
our	O
study	O
,	O
we	B-DRUG
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
19	O
classical	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
well	O
as	O
12	O
of	O
Dutch	O
ethnic	O
origin	O
.	O

Both	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	B-DRUG
and	O
the	O
restriction	O
endonuclease	B-DRUG
fingerprinting	O
(	O
REF	O
)	O
method	O
were	O
used	O
and	O
compared	O
for	O
their	O
detection	B-DRUG
efficiency	O
,	O
identifying	B-DRUG
76	O
%	O
and	O
60	O
%	O
of	O
the	O
mutations	O
,	O
respectively	B-DRUG
.	O

Most	O
patients	O
were	O
found	O
to	O
be	O
compound	O
heterozygote	O
.	O

Seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
10	O
were	O
not	O
reported	O
previously	O
.	O

Mutations	O
are	O
small	O
deletions	O
or	O
point	O
mutations	O
frequently	O
affecting	O
splice	O
sites	O
.	O

Moreover	O
,	O
a	O
16	B-DRUG
.	O

7	O
-	O
kb	O
genomic	O
deletion	O
of	O
the	O
3	O
end	O
of	O
the	O
gene	B-DRUG
,	O
most	O
likely	O
a	O
result	O
of	O
recombination	B-DRUG
between	O
two	O
LINE	B-DRUG
elements	O
,	O
was	O
identified	O
.	O

The	O
most	O
frequently	O
found	O
mutation	O
,	O
identified	O
in	O
three	O
unrelated	O
Turkish	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
individuals	O
,	O
was	O
previously	O
described	O
to	O
be	O
a	O
Turkish	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
founder	O
mutation	O
.	O

The	O
presence	O
of	B-DRUG
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	B-DRUG
population	O
groups	O
in	O
Western	O
Europe	O
could	O
indicate	O
a	O
high	O
carrier	O
frequency	O
in	O
such	O
communities	O
.	O

In	O
patients	O
of	O
Dutch	O
ethnic	O
origin	O
,	O
however	O
,	O
no	O
significant	O
founder	O
effect	O
could	O
be	O
identified	B-DRUG
.	O

The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	B-DRUG
relative	O
high	O
percentage	O
of	O
splice	O
-	O
site	O
mutations	O
had	O
no	O
reflection	B-DRUG
on	O
the	O
phenotype	O
.	O

All	O
patients	O
manifested	O
classical	O
A	B-D_ASE
-	I-D_ASE
T	I-D_ASE
and	O
increased	O
cellular	O
radioresistant	O
DNA	O
synthesis	O
.	O

Determination	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	B-D_ASE
recessive	I-D_ASE
Alport	I-D_ASE
syndrome	I-D_ASE
.	O

Autosomal	B-D_ASE
recessive	I-D_ASE
Alport	I-D_ASE
syndrome	I-D_ASE
is	O
a	O
progressive	O
hematuric	B-D_ASE
glomerulonephritis	I-D_ASE
characterized	O
by	O
glomerular	B-D_ASE
basement	I-D_ASE
membrane	I-D_ASE
abnormalities	I-D_ASE
and	O
associated	O
with	O
mutations	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
gene	O
,	O
which	O
encode	B-DRUG
the	O
alpha3	O
and	O
alpha4	O
type	O
IV	O
collagen	O
chains	O
,	O
respectively	O
.	O

To	O
date	O
,	O
mutation	O
screening	O
in	O
the	O
two	O
genes	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
information	O
.	O

We	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
gene	O
,	O
a	O
comprehensive	O
gene	O
screen	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B-D_ASE
recessive	I-D_ASE
Alport	I-D_ASE
syndrome	I-D_ASE
.	B-DRUG

Furthermore	O
,	O
we	O
identified	O
a	B-DRUG
glycine	O
to	O
alanine	O
substitution	O
in	O
the	O
collagenous	O
domain	O
that	O
is	O
apparently	O
silent	O
in	O
the	B-DRUG
heterozygous	O
carriers	O
,	O
in	O
11	O
.	O

5	O
%	O
of	O
all	B-DRUG
control	O
individuals	O
,	O
and	O
in	O
one	O
control	O
individual	O
homozygous	O
for	O
this	O
glycine	O
substitution	O
.	O

There	O
has	O
been	O
no	O
previous	O
finding	O
of	O
a	O
glycine	O
substitution	O
that	O
is	O
not	O
associated	O
with	O
any	O
obvious	O
phenotype	O
in	O
homozygous	O
individuals	O
.	O

Founder	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
breast	B-D_ASE
and	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
families	O
.	O

We	O
have	O
identified	O
four	O
mutations	B-DRUG
in	O
each	O
of	O
the	O
breast	B-D_ASE
cancer	I-D_ASE
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
French	O
Canadian	O
breast	B-D_ASE
cancer	I-D_ASE
and	O
breast	B-D_ASE
/	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
families	O
from	O
Quebec	O
.	O

To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	B-DRUG
independently	O
ascertained	O
French	O
Canadian	O
cancer	B-D_ASE
families	O
for	O
the	O
distribution	O
of	O
these	B-DRUG
eight	B-DRUG
mutations	O
.	O

Mutations	O
were	O
found	O
in	O
41	O
of	O
97	O
families	O
.	O

Six	O
of	O
eight	O
mutations	O
were	O
observed	O
at	O
least	O
twice	O
.	O

The	O
BRCA1	O
C4446T	O
mutation	O
was	B-DRUG
the	O
most	O
common	O
mutation	O
found	O
,	O
followed	O
by	O
the	O
BRCA2	O
8765delAG	O
mutation	O
.	O

Together	O
,	O
these	O
mutations	O
were	O
found	O
in	O
28	O
of	O
41	O
families	O
identified	O
to	O
have	O
a	O
mutation	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA1	B-DRUG
mutations	O
was	O
18	O
.	O

7x	B-DRUG
greater	O
if	O
one	O
or	O
more	O
cases	O
of	O
ovarian	B-D_ASE
cancer	I-D_ASE
were	O
also	O
present	O
in	O
the	O
family	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	B-DRUG
the	O
four	O
BRCA2	O
mutations	O
was	O
5	O
.	O

3x	O
greater	O
if	O
there	O
were	O
at	O
least	O
five	O
cases	O
of	O
breast	B-D_ASE
cancer	I-D_ASE
in	O
the	O
family	O
.	B-DRUG

Interestingly	O
,	O
the	O
presence	O
of	O
a	O
breast	B-D_ASE
cancer	I-D_ASE
case	O
<	O
36	O
years	O
of	O
age	O
was	O
strongly	O
predictive	O
of	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened	O
.	O

Carriers	O
of	O
the	O
same	O
mutation	O
,	O
from	O
different	O
families	O
,	O
shared	O
similar	O
haplotypes	O
,	O
indicating	O
that	O
the	O
mutant	O
alleles	O
were	O
likely	O
to	O
be	O
identical	O
by	O
descent	O
for	O
a	O
mutation	O
in	O
the	O
founder	O
population	O
.	O

The	O
identification	B-DRUG
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	B-DRUG
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	B-D_ASE
cancer	I-D_ASE
and	O
breast	B-D_ASE
/	I-D_ASE
ovarian	I-D_ASE
cancer	I-D_ASE
families	O
.	O

Are	O
Dp71	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B-D_ASE
impairment	I-D_ASE
in	O
Duchenne	B-D_ASE
muscular	I-D_ASE
dystrophy	I-D_ASE
?	O

Molecular	O
study	O
and	O
neuropsychological	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	B-D_ASE
muscular	I-D_ASE
dystrophy	I-D_ASE
(	B-DRUG
DMD	B-D_ASE
)	B-DRUG
in	O
order	O
to	B-DRUG
find	O
a	O
molecular	O
explanation	O
for	O
the	O
cognitive	B-D_ASE
impairment	I-D_ASE
observed	O
in	O
most	O
DMD	B-D_ASE
patients	O
.	O

Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
to	O
the	O
different	O
DMD	B-D_ASE
promoters	O
.	O

Qualitative	O
analysis	O
of	O
the	O
Dp71	O
transcript	O
and	O
testing	O
for	O
the	O
specific	O
first	O
exon	B-DRUG
of	O
Dp140	O
were	O
also	O
carried	O
out	O
.	O

Neuropsychological	O
analysis	O
assessed	O
verbal	O
and	O
visuospatial	O
intelligence	O
,	O
verbal	O
memory	O
,	O
and	O
reading	B-DRUG
skills	O
.	O

Comparison	O
of	O
molecular	O
and	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	B-DRUG
were	O
localized	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B-D_ASE
impairment	I-D_ASE
.	O

Two	O
altered	O
Dp71	O
transcripts	O
and	O
two	O
deleted	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B-D_ASE
dysfunction	I-D_ASE
.	B-DRUG

These	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	B-DRUG
part	O
of	O
the	O
gene	B-DRUG
and	O
,	O
in	O
particular	O
,	O
some	O
DMD	B-D_ASE
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	B-D_ASE
impairment	I-D_ASE
associated	O
with	O
DMD	B-D_ASE
.	O
.	O

I1307K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
non	O
-	O
Jewish	O
family	O
with	O
hereditary	B-D_ASE
non	I-D_ASE
-	I-D_ASE
polyposis	I-D_ASE
colorectal	I-D_ASE
cancer	I-D_ASE
.	O

We	O
describe	O
a	O
French	O
Canadian	O
hereditary	B-D_ASE
non	I-D_ASE
-	I-D_ASE
polyposis	I-D_ASE
colorectal	I-D_ASE
cancer	I-D_ASE
(	O
HNPCC	B-D_ASE
)	O
kindred	O
which	O
carries	O
a	O
novel	O
truncating	O
mutation	O
in	O
hMLH1	O
.	O

Interestingly	O
,	O
the	O
I1307K	B-DRUG
APC	O
polymorphism	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B-D_ASE
cancer	I-D_ASE
,	O
is	O
also	O
present	B-DRUG
in	O
this	O
family	B-DRUG
.	O

The	O
I1307K	O
polymorphism	O
has	O
previously	O
only	O
been	O
identified	O
in	B-DRUG
individuals	O
of	O
self	O
-	O
reported	O
Ashkenazi	O
Jewish	O
origins	O
.	O

In	O
addition	O
,	O
in	O
this	B-DRUG
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307K	O
polymorphism	O
and	O
the	O
presence	O
or	O
absence	O
of	O
cancer	B-D_ASE
.	O
.	O

Identification	O
of	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	O
hereditary	B-D_ASE
coproporphyria	I-D_ASE
family	O
.	O

Hereditary	B-D_ASE
coproporphyria	I-D_ASE
(	O
HCP	B-D_ASE
)	O
is	O
an	O
autosomal	B-D_ASE
dominant	I-D_ASE
disease	I-D_ASE
characterized	O
by	O
a	O
deficiency	B-D_ASE
of	I-D_ASE
coproporphyrinogen	I-D_ASE
oxidase	I-D_ASE
(	O
CPO	O
)	O
caused	O
by	O
a	O
mutation	B-DRUG
in	O
the	O
CPO	O
gene	O
.	O

Only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
in	O
HCP	B-D_ASE
patients	O
.	O

We	O
report	O
another	O
mutation	O
in	O
a	B-DRUG
Japanese	O
family	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
and	B-DRUG
direct	O
sequence	O
analyses	O
demonstrated	O
a	B-DRUG
C	O
to	O
T	O
substitution	O
in	O
exon	O
1	B-DRUG
of	O
the	O
CPO	O
gene	O
at	O
nucleotide	O
position	O
85	O
,	B-DRUG
which	O
lies	O
in	O
the	O
putative	O
presequence	O
for	O
targeting	O
to	O
mitochondria	B-DRUG
.	O

This	O
mutation	O
changes	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
termination	O
codon	O
at	O
amino	O
acid	O
position	O
29	O
.	O

MaeI	O
restriction	B-DRUG
analysis	O
showed	O
two	O
other	O
carriers	B-DRUG
in	O
the	O
family	O
.	O

The	O
C	O
-	O
T	O
mutation	O
is	O
located	O
within	O
a	B-DRUG
recently	O
proposed	O
putative	O
alternative	O
translation	O
initiation	O
codon	O
(	B-DRUG
TIC	O
-	O
1	O
)	O
,	O
supporting	O
that	O
TIC	O
-	O
1	O
is	O
the	O
real	O
TIC	O
rather	O
than	O
TIC	B-DRUG
-	O
2	O
.	O
.	O

Human	B-D_ASE
complement	I-D_ASE
factor	I-D_ASE
H	I-D_ASE
deficiency	I-D_ASE
associated	O
with	O
hemolytic	B-D_ASE
uremic	I-D_ASE
syndrome	I-D_ASE
.	O

This	O
study	O
reports	O
on	O
six	O
cases	O
of	O
deficiency	B-D_ASE
in	I-D_ASE
the	I-D_ASE
human	I-D_ASE
complement	I-D_ASE
regulatory	I-D_ASE
protein	I-D_ASE
Factor	I-D_ASE
H	I-D_ASE
(	O
FH	O
)	O
in	O
the	O
context	O
of	O
an	O
acute	B-D_ASE
renal	I-D_ASE
disease	I-D_ASE
.	O

Five	O
of	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	B-DRUG
hemolytic	B-D_ASE
uremic	I-D_ASE
syndrome	I-D_ASE
(	O
HUS	B-D_ASE
)	O
.	O

Two	O
of	O
the	O
children	O
exhibited	O
a	O
homozygous	B-DRUG
deficiency	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
150	O
-	O
kD	O
form	O
of	O
Factor	O
H	O
and	O
the	O
presence	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42	O
-	O
kD	O
Factor	O
H	O
-	O
like	O
protein	O
1	O
(	B-DRUG
FHL	O
-	O
1	O
)	O
and	O
other	O
FH	O
-	O
related	O
protein	O
(	O
FHR	O
)	O
bands	O
.	O

Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
deletion	O
of	B-DRUG
the	O
FH	O
gene	O
as	O
the	O
underlying	O
defect	O
for	O
the	O
deficiency	O
.	O

The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	B-DRUG
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
FH	O
family	O
.	O

Factor	B-D_ASE
H	I-D_ASE
deficiency	I-D_ASE
is	O
the	O
only	O
complement	B-D_ASE
deficiency	I-D_ASE
associated	B-DRUG
with	O
HUS	B-D_ASE
.	O

These	O
observations	O
suggest	O
a	O
role	O
for	O
FH	O
and	O
/	O
or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B-D_ASE
.	B-DRUG
.	B-DRUG

Further	O
evidence	O
for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B-D_ASE
dystrophy	I-D_ASE
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
Japanese	O
population	O
.	O

The	B-DRUG
myotonic	B-D_ASE
dystrophy	I-D_ASE
(	B-DRUG
DM	B-D_ASE
)	O
mutation	O
is	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
present	O
at	O
a	O
copy	B-DRUG
number	O
of	O
5	O
-	O
37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50	O
-	O
3000	O
copies	O
on	O
DM	B-D_ASE
chromosomes	O
.	O

Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	B-D_ASE
founder	O
chromosome	O
raise	O
a	O
question	O
about	B-DRUG
the	B-DRUG
molecular	O
events	O
involved	O
in	O
the	O
expansion	O
mutation	O
.	O

To	B-DRUG
investigate	O
whether	O
a	O
founder	O
chromosome	O
for	O
the	O
DM	B-D_ASE
mutation	O
exists	O
in	O
the	O
Japanese	O
population	O
,	O
we	O
genotyped	O
families	O
using	O
polymorphic	O
markers	O
near	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes	B-DRUG
.	O

Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	B-D_ASE
alleles	O
were	O
always	O
haplotype	O
A	O
.	O

To	O
find	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	B-DRUG
of	O
the	O
expansion	O
mutation	O
in	O
the	O
Japanese	O
population	O
we	O
have	O
studied	O
90	O
Japanese	O
DM	B-D_ASE
families	O
comprising	O
190	O
affected	O
and	O
130	O
unaffected	O
members	O
.	O

The	O
results	O
suggest	O
that	O
a	O
few	O
common	O
ancestral	O
mutations	O
in	B-DRUG
both	O
Caucasian	O
and	O
Japanese	O
populations	O
have	O
originated	O
by	O
expansion	O
of	O
an	O
ancestral	O
n	O
=	O
5	O
repeat	B-DRUG
to	O
n	O
=	O
19	O
-	B-DRUG
37	O
copies	O
.	O

These	O
data	B-DRUG
support	O
multistep	O
models	O
of	O
triplet	B-DRUG
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
DM	B-D_ASE
and	O
Friedreichs	B-D_ASE
ataxia	I-D_ASE
.	O
.	O

The	O
molecular	O
basis	O
of	O
C6	B-D_ASE
deficiency	I-D_ASE
in	B-DRUG
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	B-DRUG

Deficiency	B-D_ASE
of	I-D_ASE
the	I-D_ASE
sixth	I-D_ASE
component	I-D_ASE
of	I-D_ASE
human	I-D_ASE
complement	I-D_ASE
(	O
C6	O
)	O
has	O
been	O
reported	O
in	O
a	O
number	O
of	O
families	O
from	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

Meningococcal	B-D_ASE
disease	I-D_ASE
is	B-DRUG
endemic	O
in	O
the	O
Cape	O
and	O
almost	B-DRUG
all	O
pedigrees	O
of	O
total	O
C6	B-D_ASE
deficiency	I-D_ASE
(	O
C6Q0	O
)	O
have	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease	O
.	O

We	O
have	O
sequenced	O
the	O
expressed	O
exons	O
of	O
the	O
C6	O
gene	O
from	O
selected	O
cases	O
and	O
have	O
found	O
three	O
molecular	O
defects	O
leading	O
to	O
total	O
deficiency	O
879delG	O
,	O
which	O
is	O
the	B-DRUG
common	O
defect	O
in	O
the	O
Cape	O
and	O
hitherto	O
unreported	O
,	O
and	O
1195delC	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
previously	O
reported	O
in	O
African	O
-	O
Americans	O
.	O

We	B-DRUG
also	O
show	O
that	O
the	B-DRUG
879delG	O
and	O
1195delC	B-DRUG
defects	B-DRUG
are	O
associated	B-DRUG
with	O
characteristic	O
C6	O
/	O
C7	B-DRUG
region	O
DNA	O
marker	O
haplotypes	O
,	O
although	O
small	O
variations	O
were	O
observed	B-DRUG
.	O

The	O
1936delG	O
defect	O
was	O
observed	O
only	O
once	O
in	O
the	O
Cape	O
,	O
but	O
its	O
associated	O
haplotype	O
could	O
be	O
deduced	O
.	O

The	O
data	O
from	O
the	O
haplotypes	O
indicate	O
that	O
these	O
three	O
molecular	O
defects	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
38	B-DRUG
unrelated	O
C6Q0	O
individuals	O
we	O
have	O
studied	O
from	O
the	O
Cape	O
.	O

We	O
have	O
also	O
observed	O
the	O
879delG	O
defect	O
in	O
two	O
Dutch	O
C6	B-D_ASE
-	I-D_ASE
deficient	I-D_ASE
kindreds	O
,	O
but	O
the	O
879delG	O
defect	O
in	O
the	O
Cape	O
probably	O
did	O
not	O
come	O
from	O
The	O
Netherlands	O
.	O
.	O

Complement	B-D_ASE
C7	I-D_ASE
deficiency	I-D_ASE
:	B-DRUG
seven	B-DRUG
further	O
molecular	O
defects	O
and	B-DRUG
their	O
associated	O
marker	O
haplotypes	O
.	O

Seven	O
further	O
molecular	O
bases	O
of	O
C7	B-D_ASE
deficiency	I-D_ASE
are	O
described	O
.	B-DRUG

All	O
these	O
new	O
molecular	B-DRUG
defects	O
involve	O
single	O
-	O
nucleotide	O
events	O
,	O
deletions	O
and	B-DRUG
substitutions	O
,	O
some	O
of	O
which	O
alter	O
splice	O
sites	O
,	O
and	O
others	O
codons	O
.	O

They	O
are	O
distributed	O
along	B-DRUG
the	O
C7	O
gene	O
,	O
but	O
predominantly	O
towards	O
the	O
3	O
end	O
.	O

All	O
were	O
found	O
in	O
compound	O
heterozygous	O
individuals	O
.	O

The	O
C6	O
/	O
C7	O
marker	O
haplotypes	O
associated	O
with	B-DRUG
most	O
C7	B-D_ASE
defects	I-D_ASE
are	B-DRUG
tabulated	O
.	O
.	O

A	O
genome	O
-	O
wide	B-DRUG
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	B-DRUG
health	B-DRUG
wellness	O
in	O
relatives	O
at	O
high	B-DRUG
risk	O
for	O
bipolar	B-D_ASE
affective	I-D_ASE
disorder	I-D_ASE
among	O
the	O
Old	O
Order	O
Amish	O
.	B-DRUG

Bipolar	B-D_ASE
affective	I-D_ASE
disorder	I-D_ASE
(	O
BPAD	B-D_ASE
;	O
manic	B-D_ASE
-	I-D_ASE
depressive	I-D_ASE
illness	I-D_ASE
)	O
is	O
characterized	O
by	B-DRUG
episodes	O
of	O
mania	B-D_ASE
and	O
/	O
or	O
hypomania	B-D_ASE
interspersed	O
with	O
periods	O
of	O
depression	B-D_ASE
.	O

Compelling	O
evidence	O
supports	B-DRUG
a	O
significant	O
genetic	O
component	O
in	O
the	O
susceptibility	O
to	B-DRUG
develop	O
BPAD	B-D_ASE
.	O

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	B-DRUG
attempted	O
only	O
to	O
identify	B-DRUG
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
the	O
risk	O
of	O
developing	O
BPAD	B-D_ASE
.	O

To	O
determine	O
whether	O
there	O
could	O
be	O
protective	B-DRUG
alleles	O
that	O
prevent	O
or	O
reduce	O
the	O
risk	O
of	O
developing	O
BPAD	B-D_ASE
,	O
similar	O
to	O
what	O
is	O
observed	O
in	O
other	O
genetic	B-D_ASE
disorders	I-D_ASE
,	O
we	O
used	O
mental	O
health	O
wellness	O
(	O
absence	O
of	O
any	O
psychiatric	B-D_ASE
disorder	I-D_ASE
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
wide	O
linkage	O
scan	O
of	O
several	O
large	O
multigeneration	O
Old	O
Order	O
Amish	B-DRUG
pedigrees	O
exhibiting	O
an	O
extremely	O
high	O
incidence	O
of	O
BPAD	B-D_ASE
.	O

We	O
have	O
found	O
strong	O
evidence	O
for	B-DRUG
a	O
locus	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4	O
.	O
05	B-DRUG
,	O
P	O
=	O
5	O
.	O
22	O
x	O
10	O
(	O
-	O
4	O
)	O
;	B-DRUG
SIBPAL	O
Pempirical	O
value	O
<	O
3	O
x	O
10	O
(	O
-	O
5	O
)	O
)	O
and	O
suggestive	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	B-DRUG
4q	O
at	O
D4S397	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
3	O
.	O
29	O
,	B-DRUG
P	O
=	O
2	O
.	B-DRUG
57	O
x	O
10	O
(	O
-	O
3	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
1	O
x	O
10	O
(	B-DRUG
-	O
3	O
)	O
)	O
that	O
are	O
linked	O
to	O
mental	O
health	O
wellness	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	B-DRUG
clinical	O
manifestations	O
of	O
BPAD	B-D_ASE
and	O
perhaps	O
other	O
related	O
affective	B-D_ASE
disorders	I-D_ASE
.	O

Segregation	O
distortion	O
in	O
myotonic	B-D_ASE
dystrophy	I-D_ASE
.	O

Myotonic	B-D_ASE
dystrophy	I-D_ASE
(	O
DM	B-D_ASE
)	O
is	O
an	O
autosomal	B-D_ASE
dominant	I-D_ASE
disease	I-D_ASE
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
a	O
three	O
generation	O
anticipation	O
cascade	O
.	O

This	O
results	O
in	O
infertility	B-D_ASE
and	O
congenital	B-D_ASE
myotonic	I-D_ASE
dystrophy	I-D_ASE
(	O
CDM	B-D_ASE
)	O
with	B-DRUG
the	O
disappearance	O
of	O
DM	B-D_ASE
in	O
that	O
pedigree	O
.	O

The	O
concept	O
of	O
segregation	O
distortion	O
,	O
where	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
larger	B-DRUG
allele	O
at	O
the	O
DM	B-D_ASE
locus	O
,	O
has	O
been	O
put	O
forward	O
to	O
explain	O
partially	O
the	O
maintenance	O
of	O
DM	B-D_ASE
in	O
the	O
population	O
.	O

In	O
a	O
survey	O
of	O
DM	B-D_ASE
in	O
Northern	O
Ireland	B-DRUG
,	O
59	O
pedigrees	O
were	B-DRUG
ascertained	O
.	O

Sibships	O
where	O
the	O
status	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	B-DRUG
examined	O
to	O
determine	O
the	O
transmission	B-DRUG
of	B-DRUG
the	B-DRUG
DM	B-D_ASE
expansion	O
from	O
affected	O
parents	O
to	O
their	O
offspring	O
.	O

Where	O
the	O
transmitting	O
parent	O
was	O
male	O
,	O
58	O
.	O

3	O
%	O
of	O
the	O
offspring	O
were	O
affected	O
,	O
and	O
in	O
the	O
case	O
of	O
a	O
female	O
transmitting	O
parent	O
,	O
68	O
.	O

7	B-DRUG
%	O
were	O
affected	O
.	O

Studies	O
on	O
meiotic	O
drive	O
in	O
DM	B-D_ASE
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	B-DRUG
at	O
the	O
DM	B-D_ASE
locus	B-DRUG
in	O
non	O
-	O
DM	O
heterozygotes	O
for	O
CTGn	O
.	O

This	O
study	B-DRUG
provides	O
further	O
evidence	O
that	O
the	O
DM	B-D_ASE
expansion	O
tends	O
to	O
be	O
transmitted	O
preferentially	O
.	O

Diagnosis	O
of	O
hemochromatosis	B-D_ASE
.	O

If	O
untreated	O
,	O
hemochromatosis	B-D_ASE
can	O
cause	O
serious	O
illness	O
and	O
early	B-D_ASE
death	I-D_ASE
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
under	O
-	O
diagnosed	O
.	O

The	O
cornerstone	O
of	O
screening	O
and	O
case	O
detection	O
is	O
the	O
measurement	O
of	O
serum	O
transferrin	O
saturation	O
and	B-DRUG
the	O
serum	O
ferritin	O
level	O
.	O

Once	O
the	B-DRUG
diagnosis	O
is	O
suspected	O
,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	B-DRUG
of	O
iron	B-D_ASE
overload	I-D_ASE
.	O

Liver	O
biopsy	O
is	O
also	O
used	B-DRUG
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	B-D_ASE
,	O
which	O
can	O
affect	O
prognosis	O
and	O
management	O
.	O

A	O
DNA	O
-	O
based	O
test	O
for	O
the	O
HFE	O
gene	B-DRUG
is	O
commercially	O
available	O
,	O
but	O
its	O
place	O
in	O
the	O
diagnosis	O
of	O
hemochromatosis	B-D_ASE
is	O
still	O
being	O
evaluated	O
.	O

Currently	O
,	O
the	B-DRUG
most	O
useful	B-DRUG
role	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	O
hemochromatosis	B-D_ASE
in	O
the	O
family	O
members	O
of	O
patients	B-DRUG
with	O
a	O
proven	O
case	O
of	O
the	O
disease	O
.	O

It	O
is	O
crucial	O
to	O
diagnose	O
hemochromatosis	B-D_ASE
before	O
hepatic	B-D_ASE
cirrhosis	I-D_ASE
develops	O
because	O
phlebotomy	O
therapy	O
can	O
avert	O
serious	O
chronic	O
disease	O
and	O
can	O
even	O
lead	O
to	B-DRUG
normal	O
life	O
expectancy	O
.	O
.	O

Prevalence	O
of	O
the	O
I1307K	O
APC	B-D_ASE
gene	O
variant	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	B-DRUG
for	O
colorectal	B-D_ASE
cancer	I-D_ASE
.	O

BACKGROUND	O
&	O
AIMS	O
Israeli	O
Jews	O
of	O
European	O
birth	O
,	B-DRUG
i	O
.	O
e	O
.	O
,	O
Ashkenazim	O
,	O
have	O
the	O
highest	O
colorectal	B-D_ASE
cancer	I-D_ASE
incidence	O
of	O
any	O
Israeli	O
ethnic	O
group	O
.	O

The	O
I1307K	O
APC	B-D_ASE
gene	O
variant	O
was	O
found	O
in	O
6	O
.	O

1	O
%	O
of	O
American	O
Jews	O
,	O
28	O
%	O
of	O
their	O
familial	O
colorectal	B-D_ASE
cancer	I-D_ASE
cases	B-DRUG
,	O
but	O
not	O
in	O
non	O
-	O
Jews	O
.	O

We	O
assessed	O
the	O
I1307K	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	B-DRUG
risk	O
for	O
colorectal	B-D_ASE
cancer	I-D_ASE
.	O

METHODS	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
of	O
European	O
or	O
non	O
-	O
European	O
origin	O
,	O
with	O
or	O
without	O
a	O
personal	O
and	O
/	O
or	O
family	O
history	O
of	O
neoplasia	B-D_ASE
,	O
were	O
examined	O
for	O
the	O
I1307K	O
variant	O
by	O
the	O
allele	O
-	O
specific	O
oligonucleotide	O
(	O
ASO	O
)	O
method	O
.	O

RESULTS	O
In	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B-D_ASE
cancer	I-D_ASE
,	O
I1307K	O
was	B-DRUG
found	O
in	O
5	O
.	O

0	O
%	B-DRUG
of	O
120	O
European	O
and	O
1	O
.	O

6	O
%	O
of	B-DRUG
188	O
non	O
-	O
European	O
Jews	B-DRUG
(	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

It	O
occurred	O
in	O
15	O
.	O

4	O
%	O
of	O
52	O
Ashkenazi	O
Israelis	O
with	O
familial	O
cancer	B-D_ASE
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
was	O
not	O
detected	O
in	O
51	O
non	O
-	O
European	O
Jews	O
at	O
increased	O
cancer	B-D_ASE
risk	B-DRUG
.	O

Colorectal	B-D_ASE
neoplasia	I-D_ASE
occurred	O
personally	O
or	O
in	O
the	O
families	O
of	O
13	O
of	O
20	O
Ashkenazi	O
I1307K	B-DRUG
carriers	O
,	O
8	O
of	O
whom	O
also	O
had	O
a	O
personal	O
or	O
family	O
history	O
of	O
noncolonic	O
neoplasia	B-D_ASE
.	O

CONCLUSIONS	O
The	O
I1307K	O
APC	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	O
colorectal	B-D_ASE
,	I-D_ASE
or	I-D_ASE
other	I-D_ASE
,	I-D_ASE
cancers	I-D_ASE
in	O
Ashkenazi	O
Jews	O
,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	O
colorectal	B-D_ASE
cancer	I-D_ASE
in	O
European	O
Israelis	O
.	B-DRUG

Systematic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	B-D_ASE
coproporphyria	I-D_ASE
and	O
mutation	O
update	O
.	O

Hereditary	B-D_ASE
coproporphyria	I-D_ASE
(	O
HC	B-D_ASE
)	O
is	O
an	O
acute	O
hepatic	B-D_ASE
porphyria	I-D_ASE
with	O
autosomal	O
dominant	O
inheritance	O
caused	O
by	B-DRUG
deficient	B-D_ASE
activity	I-D_ASE
of	I-D_ASE
coproporphyrinogen	I-D_ASE
III	I-D_ASE
oxidase	I-D_ASE
(	O
CPO	O
)	B-DRUG
.	O

Clinical	O
manifestations	O
of	O
the	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B-D_ASE
dysfunction	I-D_ASE
often	O
precipitated	O
by	O
drugs	O
,	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	O
infectious	B-D_ASE
diseases	I-D_ASE
.	O

Skin	O
photosensitivity	O
may	O
also	O
be	O
present	O
.	O

The	O
seven	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
boundaries	O
and	O
part	O
of	O
3	O
noncoding	O
sequence	O
of	O
the	B-DRUG
CPO	B-DRUG
gene	O
were	B-DRUG
systematically	O
analyzed	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
strategy	O
followed	O
by	O
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	B-DRUG
HC	B-D_ASE
patients	O
from	O
France	O
,	O
Holland	O
,	O
and	O
Czech	O
Republic	B-DRUG
.	B-DRUG

Seven	O
novel	O
mutations	O
and	O
two	O
new	O
polymorphisms	O
were	O
detected	B-DRUG
.	O

Among	O
these	O
mutations	O
two	O
are	O
missense	O
(	O
G197W	O
,	O
W427R	O
)	O
,	O
two	O
are	O
nonsense	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
two	O
are	O
small	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
position	O
390	O
)	O
,	O
and	O
one	O
is	O
a	O
splicing	O
mutation	O
(	O
IVS1	O
-	B-DRUG
15c	O
-	O
-	O
>	O
g	B-DRUG
)	O
which	O
creates	O
a	O
new	O
acceptor	O
splice	O
site	O
.	O

The	O
pathological	O
significance	O
of	O
the	O
point	O
mutations	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
frame	O
deletion	O
390delGly	O
were	O
assessed	O
by	B-DRUG
their	O
respective	O
expression	O
in	O
a	O
prokaryotic	O
system	O
using	O
site	O
-	O
directed	O
mutagenesis	O
.	O

These	O
mutations	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
dramatic	O
decrease	B-DRUG
of	O
CPO	O
activity	O
.	O

The	O
two	O
polymorphisms	O
were	O
localized	O
in	O
noncoding	O
part	O
of	O
the	O
gene	O
1	O
)	O
a	O
C	O
/	O
G	O
polymorphism	O
in	O
the	O
promotor	O
region	O
,	O
142	O
bp	O
upstream	O
from	O
the	O
transcriptional	O
initiation	O
site	O
(	O
-	O
142C	O
/	O
G	O
)	O
,	O
and	O
2	O
)	O
a	O
6	B-DRUG
bp	O
deletion	O
polymorphism	O
in	O
the	O
3	O
noncoding	O
part	O
of	O
the	O
CPO	O
gene	O
,	O
574	O
bp	O
downstream	O
of	O
the	O
last	O
base	O
of	O
the	O
normal	O
termination	O
codon	O
(	O
+	O
574	O
delATTCTT	O
)	O
.	B-DRUG

Five	O
intragenic	O
dimorphisms	O
are	O
now	O
well	O
characterized	O
and	O
the	B-DRUG
high	O
degree	O
of	O
allelic	O
heterogeneity	O
in	O
HC	B-D_ASE
is	O
demonstrated	B-DRUG
with	O
seven	O
new	O
different	O
mutations	O
making	O
a	B-DRUG
total	O
of	O
nineteen	O
CPO	O
gene	B-D_ASE
defects	I-D_ASE
reported	O
so	O
far	O
.	O
.	O

Coincidence	O
of	O
two	O
novel	O
arylsulfatase	O
A	O
alleles	O
and	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
within	O
a	O
family	O
with	O
metachromatic	B-D_ASE
leukodystrophy	I-D_ASE
:	O
molecular	O
basis	O
of	O
phenotypic	O
heterogeneity	O
.	O

In	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	B-DRUG
developed	O
classical	O
late	O
infantile	O
metachromatic	B-D_ASE
leukodystrophy	I-D_ASE
(	O
MLD	B-D_ASE
)	O
,	O
fatal	B-DRUG
at	O
age	O
5	O
years	O
,	O
with	O
deficient	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
GS	O
)	O
excretion	O
.	O

The	O
two	O
other	O
siblings	O
,	O
apparently	O
healthy	O
at	O
12	O
(	B-DRUG
1	O
/	O
2	O
)	O
and	O
15	B-DRUG
years	O
,	O
respectively	O
,	O
and	O
their	O
father	O
,	O
apparently	O
healthy	O
as	O
well	O
,	O
presented	O
ARSA	O
and	O
GS	O
values	B-DRUG
within	O
the	O
range	O
of	O
MLD	B-D_ASE
patients	B-DRUG
.	O

Mutation	O
screening	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
involvement	O
of	O
three	O
different	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O

The	O
late	O
infantile	O
patient	O
inherited	O
from	O
his	B-DRUG
mother	O
the	O
frequent	O
0	O
-	O
type	B-DRUG
mutation	O
459	O
+	O
1G	O
>	O
A	O
,	B-DRUG
and	O
from	O
his	O
father	O
a	O
novel	O
,	O
single	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
nucleotide	O
7	O
in	O
exon	O
1	O
(	O
7delG	O
)	O
.	O

The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	B-DRUG
maternal	O
mutation	O
459	B-DRUG
+	O
1G	O
>	O
A	O
and	O
,	O
on	O
their	B-DRUG
paternal	O
allele	O
,	O
a	O
novel	O
cytosine	O
to	O
thymidine	O
transition	O
at	O
nucleotide	O
2435	O
in	O
exon	B-DRUG
8	O
,	O
resulting	O
in	O
substitution	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O

The	O
fathers	O
genotype	O
thus	O
was	O
7delG	O
/	O
A464V	O
.	O

Mutation	O
A464V	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
MLD	B-D_ASE
patients	O
and	O
50	O
controls	O
.	O

A464V	O
,	O
although	O
clearly	B-DRUG
modifying	O
ARSA	O
and	O
GS	O
levels	O
,	O
apparently	O
bears	O
little	O
significance	O
for	O
clinical	O
manifestation	O
of	O
MLD	B-D_ASE
,	O
mimicking	O
the	O
frequent	O
ARSA	B-DRUG
pseudodeficiency	O
allele	O
.	O

Our	B-DRUG
results	O
demonstrate	O
that	O
in	O
certain	O
genetic	O
conditions	B-DRUG
MLD	B-D_ASE
-	O
like	O
ARSA	O
and	B-DRUG
GS	O
values	O
need	B-DRUG
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
diagnostic	O
and	O
prognostic	O
implications	O
.	O

Moreover	O
,	O
further	O
ARSA	O
alleles	O
functionally	O
similar	O
to	O
A464V	O
might	O
exist	O
which	O
,	O
together	O
with	O
0	O
-	O
type	O
mutations	O
,	O
may	O
cause	O
pathological	O
ARSA	O
and	O
GS	O
levels	O
,	O
but	O
not	O
clinical	O
outbreak	O
of	O
the	O
disease	O
.	O
.	O

Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	B-D_ASE
malignancy	I-D_ASE
and	O
neurofibromatosis	B-D_ASE
type	I-D_ASE
1	I-D_ASE
.	O

Heterozygous	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	B-D_ASE
nonpolyposis	I-D_ASE
colorectal	I-D_ASE
cancer	I-D_ASE
.	O

The	O
disease	O
susceptibility	O
of	O
individuals	O
who	O
constitutionally	O
lack	O
both	O
wild	O
-	O
type	O
alleles	O
is	O
unknown	O
.	O

We	O
have	O
identified	O
three	B-DRUG
offspring	O
in	O
a	O
hereditary	B-D_ASE
nonpolyposis	I-D_ASE
colorectal	I-D_ASE
cancer	I-D_ASE
family	O
who	O
developed	B-DRUG
hematological	B-D_ASE
malignancy	I-D_ASE
at	O
a	O
very	O
early	O
age	B-DRUG
,	O
and	O
at	O
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B-D_ASE
type	I-D_ASE
1	I-D_ASE
(	O
NF1	B-D_ASE
)	O
.	O

DNA	O
sequence	O
analysis	O
and	O
allele	O
-	O
specific	O
amplification	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T	O
-	O
-	O
>	O
Arg226Stop	O
)	O
.	O

Thus	O
,	O
a	O
homozygous	O
germ	O
-	O
line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	B-DRUG
leukemia	B-D_ASE
and	O
/	B-DRUG
or	O
lymphoma	B-D_ASE
associated	B-DRUG
with	B-DRUG
neurofibromatosis	B-D_ASE
type	I-D_ASE
1	I-D_ASE
.	O
.	O

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	B-DRUG
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B-D_ASE
eye	I-D_ASE
malformations	I-D_ASE
.	O

Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	B-D_ASE
(	O
congenital	B-D_ASE
absence	I-D_ASE
of	I-D_ASE
the	I-D_ASE
iris	I-D_ASE
)	O
,	O
a	B-DRUG
rare	O
dominant	O
malformation	B-D_ASE
of	I-D_ASE
the	I-D_ASE
eye	I-D_ASE
.	O

The	O
spectrum	O
of	O
PAX6	B-DRUG
mutations	O
in	O
aniridia	B-D_ASE
patients	O
is	O
highly	O
biased	O
,	O
with	O
92	O
%	O
of	O
all	O
reported	O
mutations	B-DRUG
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
deletions	O
)	O
and	O
just	O
2	O
%	O
leading	O
to	O
substitution	B-DRUG
of	O
one	O
amino	O
acid	O
by	O
another	O
(	O
missense	O
)	O
.	O

The	O
extraordinary	O
conservation	O
of	O
the	O
PAX6	O
protein	O
at	O
the	O
amino	O
acid	O
level	O
amongst	O
vertebrates	O
predicts	O
that	B-DRUG
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
common	O
even	O
though	O
they	O
are	O
hardly	O
ever	O
seen	O
in	O
aniridia	B-D_ASE
patients	O
.	O

This	O
indicates	O
that	O
there	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
PAX6	O
missense	B-DRUG
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	B-D_ASE
.	O

Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
mutations	B-DRUG
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	B-DRUG
ectopia	B-D_ASE
pupillae	I-D_ASE
(	O
displaced	B-D_ASE
pupils	I-D_ASE
)	B-DRUG
and	O
congenital	B-D_ASE
nystagmus	I-D_ASE
(	O
searching	B-D_ASE
gaze	I-D_ASE
)	O
,	B-DRUG
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
aniridia	B-D_ASE
phenotypes	O
.	O

Strikingly	O
,	O
all	O
four	O
mutations	O
are	O
located	O
within	O
the	O
PAX6	O
paired	O
domain	O
and	O
affect	O
amino	O
acids	O
which	O
are	O
highly	O
conserved	O
in	O
all	O
known	O
paired	O
domain	O
proteins	O
.	O

Our	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
under	O
-	O
representation	O
of	O
missense	O
mutations	O
is	O
caused	O
by	O
ascertainment	B-DRUG
bias	O
and	O
suggest	O
that	O
a	O
substantial	O
burden	O
of	O
PAX6	B-D_ASE
-	I-D_ASE
related	I-D_ASE
disease	I-D_ASE
remains	O
to	O
be	O
uncovered	O
.	O
.	O

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
factor	O
B	O
,	B-DRUG
and	O
deficiency	B-D_ASE
of	I-D_ASE
the	I-D_ASE
second	I-D_ASE
component	I-D_ASE
of	I-D_ASE
complement	I-D_ASE
.	O

The	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
allotypes	O
and	O
for	O
deficiency	B-D_ASE
of	I-D_ASE
the	I-D_ASE
second	I-D_ASE
component	I-D_ASE
of	I-D_ASE
complement	I-D_ASE
(	O
C2	O
)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
connective	O
tissue	O
disorders	O
.	O

Patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
C2	B-D_ASE
deficiency	I-D_ASE
.	O

12	O
families	O
with	O
15	O
matings	O
informative	O
for	O
C2	B-D_ASE
deficiency	I-D_ASE
were	O
found	O
.	O

Of	O
57	O
informative	O
meioses	O
,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B-D_ASE
deficiency	I-D_ASE
gene	O
and	O
the	O
HLA	O
-	O
B	O
gene	O
,	O
with	O
a	O
recombinant	B-DRUG
fraction	O
of	B-DRUG
0	O
.	O

035	O
.	B-DRUG

A	O
lod	O
score	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	B-D_ASE
deficiency	I-D_ASE
and	O
HLA	O
-	O
B	O
at	O
a	O
maximum	O
likelihood	B-DRUG
value	O
of	O
the	B-DRUG
recombinant	O
fraction	O
of	O
0	O
.	O

04	O
.	O

18	O
families	O
with	B-DRUG
21	O
informative	O
matings	O
for	O
both	O
properdin	O
Factor	O
B	O
allotype	O
and	O
HLA	O
-	O
B	B-DRUG
were	O
found	O
.	O

Of	O
72	O
informative	O
meioses	O
,	B-DRUG
three	O
recombinants	O
were	O
found	O
,	B-DRUG
giving	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O

042	O
.	O

A	O
lod	O
score	O
of	O
16	O
between	O
HLA	O
-	O
B	O
and	O
Factor	O
B	O
allotypes	O
was	O
calculated	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	B-DRUG
fraction	O
of	O
0	O
.	O

04	O
.	O

A	O
crossover	O
was	O
shown	O
to	O
have	O
occurred	O
between	O
genes	O
for	B-DRUG
Factor	O
B	O
and	O
HLA	O
-	O
D	O
,	O
in	O
which	O
HLA	O
-	O
D	O
segregared	B-DRUG
with	O
HLA	O
-	O
A	O
and	O
B	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
genes	O
for	O
Factor	O
B	O
and	O
C2	B-D_ASE
deficiency	I-D_ASE
are	O
located	O
outside	O
those	O
for	O
HLA	O
,	O
that	B-DRUG
the	O
order	O
of	O
genese	O
is	O
HLA	O
-	O
A	O
,	O
-	O
B	O
,	O
-	O
D	O
,	O
Factor	O
B	O
allotype	O
,	O
C2	B-D_ASE
deficiency	I-D_ASE
,	O
that	O
the	O
genes	O
coding	O
for	O
C2	B-D_ASE
deficiency	I-D_ASE
and	O
Factor	O
B	O
allotypes	O
are	O
approximately	B-DRUG
3	O
-	B-DRUG
-	O
5	O
centimorgans	O
from	O
the	O
HLA	O
-	O
A	O
and	O
HLA	O
-	O
B	O
loci	O
,	O
and	O
that	O
the	O
apparent	O
lack	O
of	O
recombinants	O
between	O
the	O
Factor	O
B	O
gene	O
and	O
C2	B-D_ASE
deficiency	I-D_ASE
gene	O
suggests	O
that	O
these	O
two	O
genes	O
lie	O
in	O
close	O
proximity	O
to	O
one	O
another	O
.	O

Distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	O
Emery	B-D_ASE
-	I-D_ASE
Dreifuss	I-D_ASE
muscular	I-D_ASE
dystrophy	I-D_ASE
.	O

Emerin	O
is	O
a	B-DRUG
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery	B-D_ASE
-	I-D_ASE
Dreifuss	I-D_ASE
muscular	I-D_ASE
dystrophy	I-D_ASE
(	O
EDMD	B-D_ASE
)	O
.	O

It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
associated	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
lamin	O
B	O
receptor	O
(	O
LBR	O
)	O
.	O

A	O
panel	O
of	B-DRUG
16	O
monoclonal	O
antibodies	O
(	B-DRUG
mAbs	O
)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
sites	B-DRUG
throughout	O
the	O
emerin	O
molecule	O
using	O
phage	O
-	O
displayed	O
peptide	O
libraries	O
and	O
has	O
been	O
used	O
to	O
localize	O
emerin	O
in	O
human	O
and	O
rabbit	O
heart	O
.	O

Several	O
mAbs	O
against	O
different	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	B-DRUG
the	O
heart	O
,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
strongly	O
,	O
both	O
at	O
the	O
rim	O
and	B-DRUG
in	O
intranuclear	O
spots	O
or	O
channels	O
.	O

A	O
polyclonal	O
rabbit	O
antiserum	O
against	O
emerin	O
did	O
recognize	O
both	O
nuclear	O
membrane	O
and	O
intercalated	O
discs	O
but	O
,	O
after	O
affinity	O
purification	O
against	O
a	O
pure	O
-	O
emerin	O
band	O
on	O
a	O
western	O
blot	O
,	O
it	O
stained	O
only	O
the	O
nuclear	O
membrane	O
.	O

These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
a	O
product	O
of	O
the	O
emerin	O
gene	O
and	O
,	O
therefore	O
,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	B-DRUG
cardiac	B-D_ASE
defects	I-D_ASE
in	O
EDMD	B-D_ASE
are	B-DRUG
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O
.	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
absent	O
from	O
many	O
non	O
-	O
myocyte	O
cells	O
in	O
the	O
heart	O
.	O

This	O
distribution	O
of	O
emerin	O
was	O
similar	O
to	O
that	O
of	O
lamin	O
A	O
,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
form	O
of	O
EDMD	B-D_ASE
.	O

In	O
contrast	O
,	O
lamin	O
B1	O
was	O
absent	O
from	O
cardiomyocyte	O
nuclei	B-DRUG
,	O
showing	O
that	O
lamin	O
B1	O
is	O
not	O
essential	O
for	O
localization	O
of	O
emerin	O
to	O
the	B-DRUG
nuclear	O
lamina	O
.	O

Lamin	O
B1	O
is	O
also	O
almost	O
completely	B-DRUG
absent	O
from	O
skeletal	O
muscle	O
nuclei	O
.	O

In	O
EDMD	B-D_ASE
,	O
the	O
additional	O
absence	B-DRUG
of	O
lamin	O
B1	O
from	O
heart	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
lack	B-DRUG
emerin	O
may	O
offer	B-DRUG
an	O
alternative	O
explanation	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
affected	O
.	O
.	O

Genetic	O
mapping	O
of	O
the	O
copper	B-D_ASE
toxicosis	I-D_ASE
locus	O
in	O
Bedlington	O
terriers	O
to	B-DRUG
dog	O
chromosome	O
10	O
,	O
in	O
a	O
region	O
syntenic	O
to	O
human	O
chromosome	B-DRUG
region	O
2p13	O
-	O
p16	O
.	O

Abnormal	O
hepatic	B-D_ASE
copper	I-D_ASE
accumulation	I-D_ASE
is	O
recognized	O
as	O
an	O
inherited	B-D_ASE
disorder	I-D_ASE
in	O
man	O
,	O
mouse	O
,	O
rat	O
and	O
dog	O
.	O

The	O
major	O
cause	O
of	O
hepatic	B-D_ASE
copper	I-D_ASE
accumulation	I-D_ASE
in	O
man	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene	O
,	O
causing	O
Wilson	B-D_ASE
disease	I-D_ASE
(	O
WD	B-D_ASE
)	O
.	O

Mutations	B-DRUG
in	O
the	O
ATP7B	O
genes	O
have	O
also	O
been	O
demonstrated	O
in	O
mouse	O
and	O
rat	O
.	O

The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B-D_ASE
overload	I-D_ASE
disease	O
non	B-D_ASE
-	I-D_ASE
Indian	I-D_ASE
childhood	I-D_ASE
cirrhosis	I-D_ASE
,	O
indicating	O
genetic	O
heterogeneity	O
.	O

By	O
investigating	O
the	O
common	O
autosomal	O
recessive	O
copper	B-D_ASE
toxicosis	I-D_ASE
(	O
CT	B-D_ASE
)	O
in	O
Bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
a	B-DRUG
new	O
locus	O
involved	O
in	O
progressive	B-DRUG
liver	B-D_ASE
disease	I-D_ASE
.	O

We	O
examined	O
whether	O
the	O
WD	B-D_ASE
gene	O
ATP7B	O
was	O
also	B-DRUG
causative	O
for	O
CT	B-D_ASE
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
ATP7B	O
and	O
C04107	O
,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	B-DRUG
FISH	O
)	O
.	O

C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
closely	O
linked	O
to	O
CT	B-D_ASE
.	O

However	O
,	O
BAC	O
clones	O
containing	O
ATP7B	O
and	O
C04107	O
mapped	O
to	B-DRUG
the	O
canine	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
respectively	O
,	O
demonstrating	O
that	B-DRUG
WD	B-D_ASE
cannot	O
be	O
homologous	O
to	O
CT	B-D_ASE
.	O

The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	B-DRUG
excluded	O
as	O
candidate	O
genes	O
for	O
CT	B-D_ASE
since	O
they	O
both	O
mapped	O
to	O
canine	O
chromosome	O
region	O
CFA11q22	O
.	O

2	O
-	O
22	O
.	O

5	O
.	O

A	O
transcribed	O
sequence	O
identified	O
from	O
the	O
C04107	O
-	O
containing	O
BAC	O
was	O
found	O
to	O
be	O
homologous	O
to	O
a	O
gene	O
expressed	O
from	O
human	O
chromosome	O
2p13	O
-	O
p16	B-DRUG
,	O
a	O
region	O
devoid	O
of	O
any	O
positional	O
candidate	O
genes	O
.	O

Molecular	O
analysis	O
of	O
the	O
APC	B-D_ASE
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
FAP	B-D_ASE
and	O
evidence	O
for	O
the	O
role	O
of	O
APC	B-D_ASE
amino	O
acid	O
changes	B-DRUG
in	O
colorectal	B-D_ASE
cancer	I-D_ASE
predisposition	O
.	O

BACKGROUND	O
/	O
AIMS	O
The	O
development	O
of	O
colorectal	B-D_ASE
cancer	I-D_ASE
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	B-D_ASE
adenomatous	I-D_ASE
polyposis	I-D_ASE
(	O
FAP	B-D_ASE
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B-D_ASE
polyposis	I-D_ASE
coli	I-D_ASE
(	O
APC	B-D_ASE
)	O
gene	O
mutations	O
.	O

In	O
this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
APC	B-D_ASE
gene	O
was	O
performed	O
to	O
determine	O
genotype	B-DRUG
-	O
phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	B-DRUG
to	O
investigate	O
the	O
incidence	O
of	O
APC	B-D_ASE
mutations	O
in	O
non	O
-	O
FAP	O
colorectal	B-D_ASE
cancer	I-D_ASE
.	O

METHODS	O
The	O
APC	B-D_ASE
gene	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	B-D_ASE
and	O
15	O
non	O
-	O
FAP	O
colorectal	B-D_ASE
cancer	I-D_ASE
patients	B-DRUG
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
truncation	O
test	O
,	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
Chain	O
terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	B-D_ASE
group	O
(	O
105	O
patients	O
)	O
.	O

Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
FAP	O
group	O
of	O
colorectal	B-D_ASE
cancer	I-D_ASE
patients	O
.	O

Genotype	O
-	O
phenotype	O
correlations	B-DRUG
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
FAP	B-D_ASE
patients	O
belonging	O
to	O
three	O
mutation	O
subgroups	O
.	O

CONCLUSIONS	O
Extended	O
genotype	O
-	O
phenotype	O
correlations	O
made	O
in	O
this	O
study	O
may	O
have	O
the	O
potential	O
to	O
determine	B-DRUG
the	O
most	O
appropriate	O
surveillance	O
and	O
prophylactic	O
treatment	O
regimens	O
for	O
those	O
patients	O
with	O
mutations	O
associated	O
with	O
life	O
threatening	O
conditions	O
.	O

This	O
study	O
also	O
provided	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
APC	O
associated	O
with	O
both	O
FAP	B-D_ASE
and	O
non	O
-	O
FAP	O
colorectal	B-D_ASE
cancer	I-D_ASE
patients	O
.	B-DRUG
.	O

Inherited	B-D_ASE
colorectal	I-D_ASE
polyposis	I-D_ASE
and	O
cancer	B-D_ASE
risk	O
of	O
the	O
APC	O
I1307K	O
polymorphism	O
.	O

Germ	O
-	O
line	O
and	O
somatic	O
truncating	O
mutations	O
of	O
the	O
APC	B-D_ASE
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	B-D_ASE
tumor	I-D_ASE
formation	O
in	O
familial	B-D_ASE
adenomatous	I-D_ASE
polyposis	I-D_ASE
syndrome	I-D_ASE
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
.	O

Recently	O
,	O
an	O
isoleucine	O
-	O
-	O
>	O
lysine	O
polymorphism	O
at	O
codon	O
1307	O
(	O
I1307K	O
)	O
of	O
the	O
APC	B-D_ASE
gene	O
has	O
been	O
identified	O
in	O
6	O
%	O
-	O
7	O
%	O
of	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O

To	O
assess	O
the	O
risk	O
of	O
this	O
common	O
APC	B-D_ASE
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	B-DRUG
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
Ashkenazi	O
Jewish	O
subjects	O
with	O
adenomatous	B-D_ASE
polyps	I-D_ASE
and	O
.	O
or	O
colorectal	B-D_ASE
cancer	I-D_ASE
,	I-D_ASE
for	B-DRUG
the	B-DRUG
APC	O
I1307K	O
polymorphism	O
.	O

The	O
APC	O
I1307K	O
allele	O
was	O
identified	O
in	O
48	O
(	O
10	O
.	O
1	O
%	O
)	O
of	O
476	B-DRUG
patients	O
.	O

Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
,	O
the	O
APC	O
I1307K	O
allele	O
is	O
associated	O
with	O
an	O
estimated	O
relative	O
risk	O
of	O
1	O
.	O

5	O
-	O
1	O
.	O

7	O
for	O
colorectal	B-D_ASE
neoplasia	I-D_ASE
(	O
both	O
P	O
=	O
.	O
01	O
)	O
.	O

Furthermore	O
,	O
compared	O
with	O
noncarriers	O
,	O
APC	B-DRUG
I1307K	O
carriers	O
had	O
increased	O
numbers	O
of	O
adenomas	B-D_ASE
and	O
colorectal	B-D_ASE
cancers	I-D_ASE
per	O
patient	O
(	O
P	O
=	O
.	O
03	O
)	O
,	O
as	O
well	O
as	O
a	O
younger	O
age	O
at	O
diagnosis	O
.	O

We	O
conclude	O
that	O
the	O
APC	O
I1307K	O
variant	O
leads	O
to	O
increased	O
adenoma	B-D_ASE
formation	B-DRUG
and	O
directly	O
contributes	O
to	O
3	O
%	O
-	O
4	O
%	O
of	O
all	O
Ashkenazi	B-DRUG
Jewish	O
colorectal	B-D_ASE
cancer	I-D_ASE
.	O

The	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360	O
,	O
000	O
Americans	O
expected	O
to	O
harbor	O
this	O
allele	O
,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
-	O
outcome	O
studies	O
may	O
impact	O
significantly	O
on	O
colorectal	B-D_ASE
cancer	I-D_ASE
prevention	O
in	O
this	O
population	O
.	O

Localization	O
of	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
high	O
-	O
grade	O
,	B-DRUG
non	B-D_ASE
-	I-D_ASE
inherited	I-D_ASE
